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Abstract 
 
 
Chronic lymphocytic leukaemia (CLL) is a mono-clonal B-cell malignancy characterised by 
heterogeneous clinical course and response to treatment. Recent studies with whole 
genome or whole exome sequencing have identified novel recurrent genomic lesions, and 
associated them with adverse clinical outcome of this disease. Owing to their limited 
sensitivity, the true incidence of these mutations, subclonal complexity and evolution and 
their roles in disease progression and treatment resistance are still not quite clear. To gain 
insight into these issues, I developed a highly sensitive (with an average coverage depth 
being 2250x and the lowest limit of detection 1%) and robust next generation sequencing 
(NGS) test using HaloPlex and Ion Torrent PGM to target exons of 15 recurrently mutated 
genes including TP53, ATM, SF3B1, PCLO, NOTCH1, LRP1B, SAMHD1, FBXW7, BIRC3, 
HISTIH1E, XPO1, CHD2, MYD88, POT1 and ZFPM2 in CLL. 
  
In the initial study using this technique, samples from a cohort of 32 cases with progressive 
and/or therapy resistant CLL before (n = 10) or after chemotherapy (n = 22) were screened. 
87.5% of the patients were found to carry at least one somatic non-synonymous mutation in 
the first 12 targeted genes (VAF: 2-98%). The most commonly mutated genes were SF3B1, 
ATM, TP53 and PCLO identified in 11, 10, 9 and 8 cases, respectively. Mutations in TP53 and 
its upstream regulator ATM appeared to be dominant over other concurrent gene mutations 
compared to other genes (P = 0.011). Combining NGS and global SNP array analyses revealed 
a significant association between genomic aberrations in the ATM-p53 pathway and genomic 
instability. Moreover, prior exposure to DNA-damaging chemotherapy was associated with 
the bigger numbers of mutation events and mutated genes, although the increases were 
borderline significant. These results suggest that ATM-p53 pathway defects contribute to the 
acquisition of additional genomic aberrations and that treatment with DNA-damaging 
chemotherapy may play a role in the induction or selection of mutations. 
 
In the subsequent longitudinal study of 33 additional samples of 23 mutated cases from the 
same cohort, I showed the existence of different mutational processes operative in CLL 
including mutations related to AID, ageing and other factors. I confirmed the significant 
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contribution of AID-related mutations to CLL clonal evolution, implying on-going activity of 
this enzyme in off-target genes. In addition, I demonstrated the predominance of a linear 
path of clonal evolution in this cohort. Thus, 89.3% of the mutated clones/subclones 
identified at advanced disease stages were detectable at time of diagnosis or prior to 
treatment. Hence, the early detection of these mutations may potentially serve as predictive 
biomarkers to inform on therapeutic decisions. I also documented convergent clonal 
evolution with priori-selection of clones carrying deleterious mutations in 2 target genes 
including ATM and TP53. This observation suggests that not all the mutations in the same 
gene play an equal role in disease progression and/or treatment resistance. Analysis of 
mutation doubling time revealed that driver mutations, including those in TP53, BIRC3, 
NOTCH1 and SF3B1, were significantly correlated with faster evolution as indicated by the 
shorter doubling time of variant allele frequency. Importantly, I found that increased 
subclonal sizes were strongly associated with shorter treatment-free survival in patients with 
driver mutations. 
 
Taken together, the results from this thesis have provided strong evidence emphasising the 
importance and usefulness of applying the ultra-sensitive NGS test in the early detection and 
subsequent monitoring of these recurrent somatic mutations in CLL. A translational study 
based on findings in this thesis is now ongoing, with an aim to convert this test into a 
regional clinical service. 
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1.1. Chronic lymphocytic leukaemia 
 
Chronic Lymphocytic Leukaemia (CLL) is a malignant disorder of mature B-lymphocytes. 
These monoclonal B-cells accumulate in the blood, bone marrow and lymphoid tissues. 
 
1.1.1. Epidemiology  
CLL is the most common leukaemia in adults in the Western countries. It accounts for 38% of 
all leukaemia in the United Kingdom (UK ) [1]. It is estimated that 4 - 6 cases are diagnosed in 
every 100 000 individuals each year. The disease is more common in men than women with 
a male to female ratio of 1.7:1 [2]. It more likely affects the elderly, with the median age at 
diagnosis being over 70 years [3]. Conversely, only about 1 in 10  CLL patients are reported 
to be younger than 55 years [4] and it is very rare in children. Having a family history of CLL 
in first degree relatives is considered to be a risk factor for developing CLL and  this risk is 
two to four folds higher compared to general population [5].  
 
1.1.2. B-lymphocyte maturation and differentiation 
Progenitor B-lymphocytes (pro-B cells) originate from haematopoietic stem cells.  In bone 
marrow they initially undergo multistage development to acquire genomic and protein 
markers for differentiation with the support of micro-environment, including bone marrow 
stromal cells. Functional re-arrangement of immunoglobulin (Ig) loci occur in an error-prone 
process which involves combinatorial rearrangement of heavy (H) chain gene segments V 
(variable) D (diversity) and J (joining) and the light (L) chain segments V and J [6]. This is 
followed by combination with a constant region μ gene. After translation of the rearranged 
Ig genes, combination between the surrogate L chain and μ-H chain of IgM forms a B-cell 
receptor (BCR) in the more mature pre-B cell (pre-BCR) [7]. Expression of the recombined 
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pre-BCR is important for B-cell survival and further development, since any defective 
recombination serves as a control point that renders the cells vulnerable to loss through 
negative selection aided by bone marrow macrophages. Although the capacity of pre-BCR 
for induction of proliferation signals by binding with ligands is still not fully understood, the 
surviving pre-B cells are  capable to migrate from bone marrow to secondary lymphoid 
tissues/organs, e.g. lymph nodes and spleen, for further maturation and differentiation [8].  
Once migrating to the lymphoid tissues, these so called naïve B-cells, express IgM and IgD (δ-
heavy chain) BCR and stay in resting G0 phase. Upon encountering antigen, the B-cells are 
activated to undergo proliferation and diversity generation in a process called somatic 
hypermutation of the V regions (SHM). This process generates a  wide range of diverse 
antibodies with high affinity binding sites to various antigenic epitopes [9]. It is mediated by 
antigen presenting cells and T-helper lymphocytes [10]. It is also in these B-cells in the 
secondary lymph tissues/organs that class switch recombination (CSR) occur. The CRS is a 
process mediated by intra-chromosomal recombination event in which alternative heavy 
chain constant region genes such as α, γ or ε is selected to form IgA, IgG or IgE, respectively. 
Both SHM and CSR processes are mediated by Activation Induced Cytidine De-aminase (AID) 
enzymes [11]. 
Further differentiation of these antigen exposed mature B-cells that are primed for high 
affinity, results in the production of memory B-cells. They harbour surface immunoglobulins 
and await specific antigen re-exposure (secondary immune response). In addition, other B- 
cells secrete their antibodies and terminally differentiate into plasma cells in the bone 
marrow [12]. 
 
1.1.3. CLL cell origin 
The definitive cellular origin of CLL is not clear [13, 14], although there are several 
suggestions based on surface markers and genomic profiles. Initially, it was proposed that 
CLL arise from naïve CD5+ B-cells. However, later evidence of existence of some similarities 
between splenic marginal zone (SMZ) B-cells and CLL cells, suggested that SMZ B-cells are 
the cells from which CLL develops [15]. More recently, following the discovery that clones of 
CLL have either mutated or unmutated Immunoglobulin Variable Heavy Chain (IGHV) genes 
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[16], it was postulated that CLL cells can arise from two models of cells which are different in 
their stage of differentiation and history of encountering antigen. 
IGHV mutated CLL group are CD5+and CD27+ and their CLL cells represent the mature post 
germinal centre cells. IGHV unmutated CLL originate from mature CD5+ and CD27- pre 
germinal centre B-cells which have retained the capacity to proliferate through competent 
BCR which enhances tumour cell growth and survival [17]. This biological feature possibly 
explains the clinical aggressiveness of the disease among this group of patients [18]. 
Furthermore, the abundance of poly reactive or auto reactive BCR among IGHV unmutated 
cases has been reported. For example, a more intense auto-antigen reactivity was profiled in 
patients with unmutated IGHV and Richter transformation compared to mutated IGHV 
patients who have less aggressive disease [19]. Moreover, the preponderance of ZAP-70 and 
CD38 which are markers of B-cell activation through BCR signalling in this group of patients 
provided further support to this view [20]. 
 
1.1.4. Diagnosis  
Diagnosis of CLL is usually made by blood lymphocyte count, morphology and 
immunophenotype as described in the International Workshop on Chronic Lymphocytic 
Leukaemia (IWCLL) 2008 guideline [21]. The typical CLL cells in a blood smear are small in 
size. They have a narrow cytoplasmic rim and a dense nucleus with indistinguishable 
nucleoli. Minimum 5 x 109 clonal B-lymphocytes per litre of blood confirmed by flow 
cytometry are required to diagnose the disease. Flow cytometry is also used to identify the 
surface protein markers of CLL cells, which is characterised by co expression of a T-cell 
antigen CD5 and B-cell antigens CD19, CD23, and low level of surface immunoglobulin (sIg), 
CD20 and CD79b [21].  
 
1.1.5. Clinical staging  
For the purpose of clinical management of this disease, two clinical staging systems were 
developed over thirty five years ago by Rai and Binet. The recently modified Rai staging 
system defines three risk categories. Low risk disease is characterised by lymphocytosis. If 
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lymphocytosis and lymph node enlargement or organomegaly coexist, then the disease is 
classified as intermediate risk. If features of bone marrow failure such as anaemia or 
thrombocytopenia develop, then a highly risky disease is defined [21]. 
Binet staging system uses similar parameters; the number of involved anatomical lymph 
node areas is taken into account. Stage A is defined when ≤ 2 lymph node areas involved 
without anaemia or thrombocytopenia. If > 2 lymph node areas involved, then the disease is 
classified as stage B. If anaemia and /or thrombocytopenia develop, then the disease will be 
defined as stage C, irrespective of the presence of organomegaly [21]. 
These staging systems are still simple and useful for guidance for initiation of therapy in CLL. 
This is because they evaluate disease stages by both physical examination and routine 
laboratory tests without the need for any expensive or invasive procedure [22]. However, on 
the other hand, these systems may be not able to sensitively and specifically predict disease 
progression and relapse due to the lack of information about cellular and molecular 
pathology of CLL. Therefore, they are not helpful in tailoring patient specific therapy [23]. 
 
1.1.6. Clinical course  
1.1.6.1. Heterogeneity of disease outcome 
Clinical presentation, course and outcome of the disease are very variable among patients. 
Thus, some patients have an indolent disease which may even be asymptomatic at time of 
diagnosis, while others may have features of advanced disease such as anaemia, infection, 
lymph node enlargement and organomegaly [24]. Accordingly, patients with indolent 
disease have a life span similar to age and sex matched controls, while others suffer from 
aggressive, therapy resistant disease or transform to a more aggressive disease (Richter 
transformation) and die within few years of diagnosis [22]. 
1.1.6.2. Definitions of disease progression and resistance to therapies 
As this project is planned to study CLL patients with progressive and /or therapy-resistant 
disease, it is important to mention the criteria for defining these disease entities according 
to the updated guidelines in 2008 for diagnosis and treatment of CLL by the IWCLL [21].  
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Progressive disease before therapy is defined when one or more of the following criteria are 
met: 
1. progressive increase in the number of circulating lymphocytes of more than 50% 
within a period of two months or lymphocyte doubling in less than six months 
2. development of features of marrow failure  
3. symptomatic progressive splenomegaly ≥ 6 cm below the costal margin or 
lymphadenopathy ≥ 10 cm in longest diameter 
4. auto immune cytopenias that is resistant to standard therapy  
5. appearance of constitutional symptoms attributable to CLL such as unexplained 
weight loss of 10% within six months or easy fatigability that renders the patient 
unable to perform usual daily activities or unexplained fever (body temperature > 38 
◦C) for two weeks or nocturnal sweating for longer than one month without infection 
[21]. 
Two types of resistance are described at 2008 IWCLL; refractory disease and relapse. The 
former is defined as failure to achieve either complete or partial remission after treatment, 
or disease progression within 6 months of treatment. The latter is defined when disease 
progression occurred within or after six months of achieved initial response to treatment 
(complete or partial remission) [21]. 
Disease progression during or after treatment is characterised by development of at least 
one of the followings: 
1. new lymph node or organ infiltration or an increase by 50% or more in largest 
diameter of any previously determined site 
2.  increase in blood lymphocyte count by 50% or more with at least 5000 B- 
lymphocytes/µl 
3. transformation to a more aggressive histology established by lymph node biopsy 
4. occurrence of disease related cytopenias after exclusion of drug related cytopenias 
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1.1.7. Treatment  
As mentioned earlier, starting therapy depends on clinical stage and status of disease 
progression. Patients at early stage or with an asymptomatic and non-progressive disease 
should usually be monitored without therapy. This is largely because the disease is incurable 
and there is no evidence to support that early treatment can prolong survival in such 
patients [25]. In addition, the side effects of unnecessary chemotherapy can increase risks to 
patients including secondary tumours [21]. For these reasons, treatment is usually confined 
to progressive or symptomatic disease, for example those at intermediate or high risk group 
in Rai system or at Binet Stage B and C. 
 
 
1.1.7.1. Front-line therapies 
Before the invention of purine analogues, alkylating agents such as cyclophosphamide and 
chlorambucil were used to treat the patients. Other alkylating agents, such as bendamustine 
has also recently been incorporated into first line therapy regimens. Although each drug in 
this group has its own mechanism of action, they all alkylate DNA, RNA and protein of 
tumour cells. The primary cytotoxic effect is considered to be caused by formation of DNA 
cross links and activation of apoptosis [26]. These agents have been studied in clinical trials 
both as mono-agent and as combination therapy with the goal of improving survival and 
maximising the attainment of complete response. For example, in the UK CLL 4 trial, 
responses to treatment in groups of patients randomly assigned to different therapeutic 
regimens such as fludarabine plus cyclophosphamide or fludarabine alone were compared. A 
significant improvement in complete response rate  was achieved for fludarabine plus 
cyclophosphamide than for fludarabine alone [27]. Moreover, in German CLL 11 trial, it has 
been shown that the combination of an anti-CD20 antibody with chlorambucil prolongs 
remission and improves the overall survival in previously untreated patients with CLL 
compared to chlorambucil alone [28]. Despite this improvement in treatment response 
offered by multi-agent therapy and achievement of initial complete response, majority of 
patients eventually develop resistance. 
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General mechanisms of chemotherapy resistance including changes in drug transport and 
metabolism, as well as alteration in apoptotic and DNA repair activity of the tumour cells 
have been proposed [26]. In CLL, it has been suggested that the first two mechanisms are 
the least likely causes of resistance to alkylating agents. This suggestion is based on results 
that found similar pattern of drug uptake between B-cells taken from untreated and 
resistant CLL patients. Moreover, there are  conflicting  reports about drug metabolism and 
detoxification mechanisms being predominant in the cause of resistance to these agents 
[26]. The main pathway that has been implicated in CLL drug resistance is alteration of DNA 
repair and apoptotic pathways [29, 30]. 
 
Following the alkylating agents, purine analogues such as fludarabine, cladribine and 
pentostatin have been used in CLL treatment. However, it has been shown that their 
mechanism of action is different between resting and proliferating cells. Combination of 
these drugs with the alkylating agents has synergistic action and is associated with longer 
overall survival in CLL, but with increased toxic side effects [27, 31].  
 
Both the alkylating agents and purine analogues initiate killing of CLL cell by DNA damage 
[32]. This induces apoptosis via activation of p53 [33]. Therefore defects in either p53 or its 
upstream activator ATM are associated with resistance to those chemotherapies [32]. 
 
More recently, monoclonal antibodies targeting B-cell specific antigen CD20 are introduced 
in the treatment of CLL. These antibodies include initially used rituximab and more recently 
available ofatumumab [34] and obinutuzumab (GA-101) [35]. The latter two antibodies have 
different orientation and more stable binding to their targets.  
 
Unlike chemotherapeutic agents, these antibodies act by complement-dependent cell 
cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). In a trial conducted 
by Laurent et al. for relapsed/refractory CLL, the efficacy of ofatumumab in treatment of 
patients with or without TP53 mutations was similar [36].    
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1.1.7.2. Second line therapies  
For those high-risk patients, second line treatment has been developed to overcome drug 
resistance in CLL. For example, alemtuzumab is an anti CD52 antibody that induces cell death 
through pathways that is p53 independent. Therefore, a combination of high dose steroids 
and alemtuzumab had been preferably used in patients with fludarabine resistance and 
defective p53 function [25, 37]. Since alemtuzumab has been discontinued from the market, 
a later study used Lenalidomide which is a thalidomide analogue that acts through immune 
modulation by blocking the induction of cancer cell-induced T-cell tolerance and by 
inhibition of angiogenesis. In that study, patients who had been treated with alemtuzumab 
and dexamethasone were randomly assigned to no maintenance therapy or maintenance 
therapy using lenalidomide. The latter regimen resulted in longer progression-free survival  
and therefore enhanced efficacy of alemtuzumab and dexamethasone [38]. However, there 
is controversy regarding the use of this agent as a frontline therapy owing to the suboptimal 
response rate it achieved [25]. 
 
Moreover, pathway specific therapies are in continuous development. Idelalisib (CAL101) is 
an inhibitor of PI3K signalling. This signalling pathway offers protective function for the CLL 
cells with the support of micro-environment through CD40 ligand [29]. PI3K is expressed at 
high levels in CLL cells. CAL101 is a high affinity binder of PI3K-α, its cytotoxic activity is 
partially dependent on caspase activation, but largely independent on p53 [39]. It has been 
shown that combination of idelalisib and rituximab in relapsed/refractory CLL patients with 
unfavourable genetic features such as 17p deletion or TP53 mutations or unmutated IGHV, 
was strongly associated with longer progression-free survival compared to rituximab 
monotherapy [40]. 
 
Another example is ibrutinib, which irreversibly inhibits bruton a gamma-globulinemia 
tyrosine kinase (BTK). It inhibits BCR signalling which is responsible for B-cell proliferation 
and it also inhibits cellular adhesion and signals for proliferation from the supportive micro- 
environment. It has been used in clinical trials for treatment of therapy-naive or relapsed CLL 
patients with aberrant p53 function [29]. The superior efficacy of ibrutinib as a mono-agent 
therapy has been shown compared to ofatumumab in unfit patients with relapsed or 
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refractory CLL [41]. Resistance to this agent has recently been shown to be associated with 
acquired mutations in BTK and in a gene downstream to BTK that is phospholipase Cγ2 
(PLCG2) detected by NGS [42, 43]. 
 
In addition, a selective anti-apoptotic protein BCL2 inhibitor ABT-199 (Venetoclax) has been 
tested in clinical trials. Its effectivity is mediated by mimicking pro-apoptotic BH3-family 
members against the over expressed anti-apoptotic proteins in the BCL2 family. This 
inhibitor is particularly useful for patients with aberrant p53 (upstream negative regulator of 
BCL2) and with chemoresistance [44]. It has achieved promising results in the treatment of 
patients with relapse and refractory disease [45].  
 
More recently, selinexor which is a selective inhibitor of exportin1 (XPO1) has been 
developed. XPO1 is recurrently mutated in CLL (it is one of the target genes in this thesis) 
and XPO1 protein is overexpressed in primary CLL cells compared to normal control B-cells 
[46]. It has been demonstrated that inhibition of XPO1 by selective inhibitors of nuclear 
export can induce killing of CLL cells in vitro [46]. 
 
1.2. General mutational landscape and concepts of carcinogenesis 
 
In the initial attempts to understand the causes of cancer, hereditary influences were 
identified. This is due to the fact that higher incidence of cancer is reported among patients 
with hereditary genetic diseases for example ataxia telangiectasia and high incidence of 
lymphoproliferative disorders [322]. For instance tumour viruses are involved in the 
causation of malignant disorders such as Kaposi sarcoma and association with human 
immune-deficiency viruses. These and other acquired mutagenic factors such as irradiation, 
chemotherapy or any mutation that occur during the lifetime of an individual form the basis 
of somatic mutation evolution at cellular level. A small proportion of these mutations that 
confer cell growth and survival advantages will expand clonally to form a tumour. A wide 
variety of gene families have been extensively studied in different types of cancer for 
example lung, breast and colorectal cancers. Substantial variation in the number of mutated 
genes per tumour has been identified. Moreover, within the tumour subtypes, few 
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commonly mutated genes were found. This observation re-enforced the idea of random 
evolution and heterogeneity within a tumour subtype. For example, MAPK pathway in lung 
cancer is most commonly affected pathway, however the incidence of individual gene 
mutations within this pathway is less than 1% [323]. Similarly in CLL, mutations in various 
signalling pathways have been implicated in disease heterogeneity which was originally 
considered as a homogenous disease. Therefore, prognostic biomarkers are continuously 
developed.   
For a long time, conventional clinical and laboratory findings including that by physical 
examination, patterns of marrow infiltration, lymphocyte doubling time and serum levels of 
lactate dehydrogenase (LDH) and β2-Microglobulin (β2-M) [47], and the clinical staging 
systems were used to predict the outcome. For example, LDH and serum deoxy-thymidine 
kinase (STK) are metabolic enzymes released from proliferating tumour cells. Elevated levels 
of these enzymes were found in the serum taken from CLL patients. It is widely believed that 
they reflect the tumour burden and their potential as an  independent prognostic marker 
has been shown [48]. For example, a positive correlation between levels of serum β2-M and 
clinical stage was also established. Patients with bulky disease as well as those with diffuse 
marrow infiltration had remarkably higher levels of β2-M compared to others [49]. Other 
biomarkers such as adhesion molecules and inflammatory mediators such as interleukins 
and soluble CD23 [50] have been considered and linked with bulky disease as well [51].   
However these conventional markers do not fully explain biological causes of the clinical 
heterogeneity in CLL. Decades passed with no breakthrough achieved. Later, cytogenetic 
studies revealed chromosomal aberrations and their associations with each subtype 
(detailed in section 1.2.3). Thereafter, in the late 1990s two biologically distinct subtypes of 
CLL were discovered based on IGHV mutational status [18, 52]. Subsequently, larger studies 
were performed to study gene expression profile of each subtype either with mutated IGHV 
or with unmutated IGHV. This led to the discovery of genes that were differentially 
expressed between the two subgroups such as ZAP70 and CD38 that overexpressed in the 
IGHV unmutated subtype. These new prognostic parameters have obviously improved the 
risk stratification for disease progression and response to therapy.  
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Recently, particular attention has been paid not only to heterogeneity in clinical course, but 
also to response to treatment. Heterogeneous treatment response has been linked to the 
existence of underlying biological factors, for example chromosomal aberrations and gene 
mutational status [53]. Some of these factors have been extensively studied and are now 
routinely used as established biomarkers for predicting prognosis. Considering the choice of 
therapy, adjustment of therapeutic decision is made if TP53 mutations or chromosome 17p 
deletion exist, so that DNA damaging agents are avoided [54].  
 
As more biomarkers are available, they have been categorised in to three main types: 
molecular, immune-phenotypic and genomic markers [47]. The most commonly used 
biomarkers and their roles in biological and clinical stratification of CLL are presented in the 
following sections. 
 
1.2.1. IGHV mutational status as molecular markers 
Two different biological subtypes characterising diverse clinical courses have been 
categorised based on stages of differentiation of the original B-cells. As a marker of 
differentiation, somatic hypermutation of immuno-globulin variable region is delineated. 
This process occurs in the germinal centre, thus pre-germinal centre B-cells are less mature 
and they express unmutated IGHV. 
 
Sequence homology of the heavy chain variable region gene to the appropriate germ-line 
sequences of 98% or more is accounted as unmutated. This cut off was selected to make 
clinically relevant distinction between the two subtypes as up to 2% disparity can exist due 
to occurrences of common polymorphisms in this region [55]. The somatic hyper-mutations 
can occur in the light chains variable region, but at lower rates [56]. Usually they carry two to 
three times less mutation load compared to mutation load of the variable heavy chain [57]. 
However, initially the sequence of the light chain was proposed to be used for assessment of 
the mutation status [18], but later studies revealed that only IGHV mutation status at 
diagnosis is  independent prognostic marker [58]. 
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It has been documented that up to 50% of CLL patients are IGHV unmutated [16]. As it 
arises from naive B-cells, it tends to represent a more aggressive disease [18]. Associations 
between this subtype and a typical CLL cell morphology, trisomy 12 [59], higher percentage 
of CD38 and higher expression of ZAP-70 [60] have been documented. These patients  
commonly suffer from rapid disease progression, poor response to multi-regimen 
chemotherapy and shorter survival [52]. A significant tendency for V1 family gene usage 
was found, especially biased usage of V1-69 among this group and this is also associated 
with an unfavourable outcome [61, 62].  
 
IGHV mutated CLL arises from memory B-cells. It has a relatively indolent course and  better 
prognosis compared to patients with unmutated IGHV [18]. Moreover, association of this 
subtype with del 13q14 has also been found [52]. Notably, preferential usage of V3-21 
repertoire among this subtype was associated with p53 dysfunction [63, 64] and shorter 
overall survival than other mutated IGV repertoires [65]. 
 
 
1.2.2. Immuno- phenotypic features  
1.2.2.1. CD38 
CD38 is a trans-membrane glycoprotein, its expression occurs at times during B-cell 
maturation when interactions between the cells are necessary for development [66]. Surface 
expression of CD38 is based on a cut-off value of 30% determined by flow cytometry [67]. 
CD38 expression is considered as a robust biomarker to predict clinical outcome in the 
majority of patients owing to its stability over time of disease progression or upon treatment 
with chemotherapy [68]. It has been suggested that two subsets of CLL can be distinguished 
based on CD38 expression [17].  
  
CD38 negative patients are characterised by longer treatment-free time and prolonged 
survival [67]. In contrast, CD38 positivity is associated with unfavourable clinical course 
including a more advanced disease stage [69]. Although initially a strong association with 
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unmutated IGHV was found [70], but later studies found that the association was not 
absolute and CD38 should rather be used as an independent prognostic indicator [71].   
 
1.2.2.2. ZAP-70 
             ZAP-70 is a CD3 associated protein kinase of T cells. ZAP-70 activation triggers its 
downstream signalling pathways including the Ras/mitogen activated protein kinase (MAPK) 
pathway which is important for T-cell survival and proliferation [72]. Typically B-cells lack 
ZAP-70. They utilize a different protein kinase which is Syk to mediate signal transduction of 
the BCR complex. Thus, ZAP-70 and Syk are alike in their roles in membrane antigen-receptor 
signalling pathways [73].   
 
In CLL, cells with unmutated IGHV genes commonly express high levels of ZAP-70 protein 
while  CLL cells with mutated IGHV frequently associate with undetectable levels of ZAP-70 
protein [73, 74]. Moreover, it has been shown that high-level expression of CD38 is 
correlated with elevated ZAP-70 expression [73]. 
 
In addition of protein expression, later studies have suggested that ZAP-70 mRNA expression 
might serve as a surrogate marker for identifying the Ig-mutated and Ig-unmutated CLL 
subtypes and prognostic subgroups. For example, patients whose CLL cells express a high 
level of ZAP-70 usually have progressive disease with shorter overall survival compared to 
cases with low level of ZAP-70 mRNA expression [60].  
 
1.2.3. Genomic aberrations 
Genomic aberrations in CLL vary considerably from patient to patient. Initially, by using 
conventional G banding, 40 - 50% of the patients had been reported to have chromosomal 
abnormalities. However, the low mitotic activity of the CLL cells in vitro hampered such 
analysis. Later, with the invention of fluorescence in situ hybridisation (FISH), the frequency 
of detected clonal chromosomal abnormalities was found to be higher and reached up to 
80%. This was due to its capability to detect such genetic lesions (copy number changes) in 
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interphase nuclei [75]. The most common recurrent aberrations in CLL are deletion (del) 13q, 
del 11q, trisomy 12q and del 17p [75]. 
 
Copy number neutral loss of heterozygosity (CNN- LOH) or uni-parental disomy (UPD) 
(imbalance of specific allele without net change in its copy number) occurs because of 
mitotic recombination or gene conversion and this is not uncommon in CLL [76]. Such 
abnormalities can be detected by high density single nucleotide polymorphism array (SNP 
array) [77]. The use of genome arrays has led to the identification of additional genetic 
lesions which were otherwise undetected with FISH, for example; trisomy 19 [78], gain of 2p 
[79] and identification of anatomical subtypes of del 13q14 in CLL [80].  
 
All in all, these changes have been used as prognostic indicators. Some of them are linked 
with indolent disease while others are associated with rapid disease progression and 
chemoresistance. The most common and intensively investigated chromosomal 
abnormalities are discussed individually in subsequent sections. 
 
1.2.3.1. Structural chromosomal abnormalities 
1.2.3.1.1. Del.13q 
Deletion of the long arm of chromosome 13 involving 13q14 is the most frequent 
chromosomal abnormality observed in CLL. Incidence approaching 55% has been reported in 
unselected CLL cohorts [81]. It can either occur as a single genetic abnormality or in 
association with other abnormalities. The size of the deletion varies from the entire loss of 
the long arm to a few megabases which can be detected by FISH. The majority of the 
deletions are monoallelic, but biallelic deletions do occur [82]. 
Initially, it was proposed that existence of variation in clinical outcome in patients with this 
lesion as a solitary abnormality may be due to presence of differences either in the number 
of lost alleles or the sum of interphase nuclei that carry the lesion. For example, it has been 
documented that patients with monoallelic loss carry a better prognosis than those with 
biallelic loss [82]. However, subsequent studies found that the nuclear percentage carrying 
the abnormality affects the prognosis rather than the number of affected alleles [83]. Later, 
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the size and anatomical location of the affected regions were also identified to cause this 
variation. The minimal deleted region (MDR) which contains target genes has been defined. 
In 13q deletion, this region encompasses sequences encoding deleted in leukaemia (DLEU-2) 
and (DLEU-1) [84, 85]. There are also two micro RNAs (small non- coding RNAs that are 21-22 
nucleotide long and contribute to regulation of coding genes’ expression) miR-15a and miR-
16-1 which are located in the MDR [86]. These micro RNAs are found to share tumour 
suppression activity by their interaction with pathways controlling apoptosis. An example is 
direct negative regulation of p53 [87]. This is further supported by a finding that loss of miR-
15a and miR16-1 is associated with de-repression of BCL2 oncogene and an adverse 
outcome in CLL [88]. 
It is still unclear why not all the patients with deletion 13q14 have unfavourable prognosis. 
To refine the prognostic influence of this genetic lesion, it has been proposed to classify 
del13q into two groups; group I, where the deletion involves a narrower region, it is 
confined to MDR and is associated with a relatively indolent disease [89]; whereas in group 
II, deletions involve a larger area that include the tumour suppressor retinoblastoma-1 (RB1) 
gene. This group is more commonly associated with aggressive clinical course and 
transformation to diffuse large B- cell lymphoma (DLBCL) [80, 90].  
More recently, other genes outside the region of the MDR were found to be involved and 
correlated with adverse prognostic outcome [91]. In addition, a study has found an 
association of 13q deletion with MYD88 mutation [92] that is a driver event in CLL [93]. 
 
1.2.3.1.2. Del.11q 
Initially, the frequency of this abnormality in CLL was underestimated when detected by 
conventional chromosomal banding. Later studies using FISH for screening of CLL cases 
revealed the true prevalence of this chromosomal aberration. By far, this genetic aberration 
is ranked as the second most common chromosomal lesion which occurs in up to 10% of CLL 
patients at time of diagnosis [94, 95].  
 
The ataxia-telangiectasia mutated (ATM) gene maps to chromosome 11q22-23 [96]. It is one 
of the candidate genes within the MDR affected by this karyotypic abnormality in CLL [97]. 
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This gene is a member of the phosphatidylinositol-3 kinase (PI3K) family [95]. Its down 
regulation has been observed in patients with deletion of long arm of chromosome 11 
carried by > 20% of the nuclei as detected by FISH [95]. Similarly, sub-chromosomal 
alterations were found to have the same consequences [98].  
 
Del11q can be associated with mutation of the remaining ATM allele in 36% of CLL cases. In 
this respect, two subgroups based on the integrity of the residual ATM allele have been 
identified; firstly, patients with monoallelic ATM loss and; secondly, patients with biallelic 
ATM defects and complete loss of ATM function. The latter group  were characterised by 
impaired responses to cytotoxic agent in vitro and worse prognosis [99]. It has been 
suggested that subclones carrying deleted and/or mutant ATM can develop during disease 
progression and lead to selection and further expansion of these subclones [99]. 
Furthermore, 11q deletion is considered to be the most common karyotypic abnormality to 
undergo clonal expansion with disease progression [100]. Correlation study revealed that 
del11q is  significantly associated with poor prognostic features including extensive nodal 
involvement and more rapid disease progression in CLL [94].  
 
Another gene that is affected by this deletion is BIRC3. 87% of 11q deleted cases harboured 
allelic loss of this gene, with only a small percentage of patients having a mutation on the 
residual allele (< 5%) [101]. However, a later study found a more frequent co-occurrence of 
BIRC3 mutation and loss of the other allele which occurred in a higher percentage than 
originally thought [102]. Deletion or mutation of this gene was found to be associated with 
drug resistance in TP53 unmutated cases [102]. However, a more recent study showed that 
larger 11q deletion that involves BIRC3 does not differ from 11q deletions not involving 
BIRC3  in terms of impact on survival [103]. The same study also reported higher association 
of patients with BIRC3 mutation and/or deletion with other poor prognostic factors 
compared to patients without these abnormalities [103]. 
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1.2.3.1.3. Del.17p 
Deletion of the short arm of chromosome 17  including the TP53 locus at 17p13.1 are found 
to occur in up to 7% of treatment naïve patients [104] and in up to 50% of relapsed or 
refractory cases [105]. This deletion usually associates with TP53 mutation on the other 
allele in up to 80% of patients [106]. Del17p therefore results in loss of the tumour 
suppressor TP53 gene and renders CLL cells resistant to spontaneous apoptosis and DNA 
damaging therapy-induced apoptosis [107]. 
More recently, TP53 mutation as a solitary abnormality has been shown to have the same 
biological and clinical consequences as 17p deletion [108]. 17p deletion with or without 
mutation in the remaining TP53 allele has been associated with poor prognostic features 
[102] such as faster disease progression and poor response to chemotherapy [109]. For that 
reason, chromosome 17p13 deletion is regarded as the first (hitherto) biological marker to 
affect decision of choosing the first-line treatment [110]. Patients with this abnormality are 
offered alternative therapies that are independent of p53 pathway such as monoclonal 
antibodies directed against epitopes expressed on the surface of tumour cells [111].  
1.2.3.2. Numerical chromosomal aberrations 
1.2.3.2.1. Trisomy 12  
Similar to other chromosomal abnormalities, the conventional G banding analysis 
underestimated the frequency of this genomic abnormality in CLL. Trisomy 12 is the third 
most common karyotypic abnormality and the most frequent numerical chromosomal 
abnormality in CLL. It has been found in 10 - 20% of CLL cases at time of diagnosis [98]. For 
risk stratification, it has been more commonly recognised as a marker of intermediate risk 
disease [75]. However, recent studies have considered this aberration as an indicator of low 
risk disease [112]. This difference is assumed to be due to a combination of associated 
genetic abnormalities that are located outside chromosome 12 such as recurrent mutations 
of NOTCH1 on chromosome 9 which may confer other pathogenic mechanisms [113, 114]. 
However, the precise pathogenic mechanisms of how trisomy 12 can cause tumorigenic 
transformation are still unclear because multiple genes are distributed throughout the entire 
length of the chromosome. Gene expression profiling showed differential expression of 
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various genes located on this chromosome. One of the most important genes is murine 
double minute 2 (MDM2) which is involved in the repression of tumour protein p53 [115].  
Overexpression of this gene results in de-regulation of cell cycle [116]. More importantly, 
this genetic lesion is primarily considered as a clonal driver that occurs early in CLL evolution 
and facilitates the acquisition of subsequent chromosomal aberrations or mutations in genes 
such as TP53, NOTCH1 and FBXW7 [117]. Correlations with atypical cellular morphology, 
high CD38 and ZAP-70 expression as well as unmutated IGHV gene have also been reported 
[118].  
 
1.2.3.2.2. Trisomy 2P 
Recently, by application of high density SNP array and high-resolution genomic profiling of a 
large cohort of unselected CLL cases, this lesion was found in up to 7% of patients with CLL 
[76]. It was found that the minimally gained region sized approximately 2 Mb and was 
located at  2p16.1-2p15 which includes multiple genes including BCLIIA and XPO1 [119]. 
Patients with this karyotypic lesion carried high-risk genomic changes. 
1.2.3.3. Complex karyotype   
Karyotype complexity is defined by the existence of three or more cytogenetic abnormalities 
in a single case. It has been found in up to 16% of CLL cases [120]. Carrying this abnormality 
has been stratified among high risk disease as it predicts rapid disease progression, short 
duration of remission and shorter overall survival [121]. The mechanism underlying this 
complexity is thought to be due to genomic instability and has been linked to ATM/p53 
aberrations [122]. 
1.2.3.4. Chromosomal translocations 
Unlike the other neoplasms, the presence of specific chromosomal translocations is not a 
characteristic cytogenetic feature of CLL. However, an incidence of 32 - 42% has been 
reported in various studies of CLL [123]. It has been found that these chromosomal 
rearrangements have significant prognostic potential. Unbalanced translocations have been 
linked to poor outcome regardless of the sum of the rearrangements [124]. Translocations 
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involving IGH locus on chromosome 14 are not common in CLL, although a disease subset 
with poor outcome was identified in association with this translocation [125]. 
In subsequent studies, it has been revealed that the outcome of the translocation (t) is 
determined by the recipient chromosome involved in the partnership. Thus, t (14; 19) which 
involves the BCL3 locus is linked to complex cytogenetics, germ-line IGHV, atypical cellular 
morphology and inferior survival, whereas patients harbouring t (14; 18) that involve BCL2 
locus were not marked by aggressive prognostic features [125].  
 
Other  recurrent translocations have been reported, for example translocation involving 
chromosome 13q which occurs in 10% of patients carrying chromosome 13q loss [126]. Such 
abnormality is found to be associated with larger 13q deletion that involve the RB1 locus and 
hence, can cause poor prognosis [127]. However, being a balanced translocation in most of 
the cases, such abnormality has not been implicated in causation of poor prognostic features 
[128].    
 
1.2.3.5. Chromothripsis 
A unique pattern of clustered rearrangements typically involving only a single chromosome 
and presenting at least 10 switches between 2 or 3 copy number states is defined as 
chromothripsis. It is thought that this chromosomal aberration results from a single cellular 
catastrophe. This event is not common in CLL and found only in <5% of previously untreated 
patients [119]. However, higher frequencies have also been found especially in patients with 
p53 aberrations [129]. Such abnormality is associated with unmutated IGHV, rapid disease 
progression and shorter overall survival [119]. 
 
1.2.4. Recurrent gene mutations  
As mentioned earlier in this chapter, clinical staging systems do not provide biological 
reasons for the clinical variability and are not reliably predict disease progression and drug 
resistance in CLL. Obviously, biomarkers developed on knowledge about pathogenesis of CLL 
especially that about genomic alterations, are required. To stratify high-risk disease, 
Chapter 1. General introduction 
45 
 
cytogenetic studies have correlated del17p and del11q with TP53 and ATM mutations, 
respectively [99, 105].  
 
1.2.4.1. TP53 
The TP53 gene is mapped on the short arm of chromosome 17 (17p13.1). It composed of 11 
exons of which exon 1 is non-coding. The gene encodes transcription factor p53 protein 
which is composed of 393 amino-acid residues. Structurally, p53 protein has 3 main 
domains. Firstly, the N- terminally located transcription activation domain which spans from 
amino acid 1 - 91 residues; secondly, a middle sequence specific domain that binds to target 
DNA, the so called DNA binding domain which extends from amino acid 95 to 288;  and 
thirdly, the C- terminally located nuclear localisation/tetramerisation and basic domain 
which extends from amino acid 316 to 393 [130].  
 
The activities of p53 including activation of apoptosis and cell cycle arrest, are determined by 
folding, tetramerisation and nuclear localisation functions which indirectly affect the DNA 
binding capacity of the protein. As evidenced by various experimental studies, the activation 
domain induces pro-apoptotic genes or inhibits anti-apoptotic genes. On the other hand, 
maintenance of the activation domain’s trans-activation or trans-repression functions is the 
duty of the C- terminal domain [130]. 
 
In normal cellular state, p53 is present at trace amounts due to its short half-life. Under 
certain conditions, for example, DNA damage, the protein becomes activated to adapt its 
shape to interact with the damaged DNA. This is mediated by kinases which induce 
conformational changes and tetramerisations of p53 to become large enough to be trapped 
inside the nucleus [130].   
 
P53 defects, either due to allelic loss or mutations, can occur in various solid tumours as well 
as other haematological malignancies [131]. As mentioned above, the defect is usually 
caused by its deletion from one allele and mutation in the remaining allele [132]. The 
mutations are distributed throughout the coding sequences of the gene. However, the 
functional characteristics of the mutations vary according to the tumour type. Most of the 
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mutations are missense, so that the full length of the protein can be produced but the 
change in amino acid hampers its DNA binding ability [133]. The same findings are common 
in CLL,  in that 89.9% of mutations are localised to the DNA binding domain in exons 5 - 8 
while the remaining occur in other exons [134]. 
 
TP53 mutations are found in 5 - 10% of previously untreated CLL patients [135]. The 
frequency of mutations tends to increase over disease progression. Thus, the mutations are 
more likely detected in patients with a history of therapy, with an incidence of 25% has been 
reported among chemotherapy-resistant patients [106, 136]. Regarding the nucleotide 
changes caused by the mutation, transitions are common, but incidence of CpG transition 
compared to other cancers is significantly low. Classical p53 mutation hot spots for CLL are 
found at codons 175, 179, 220, 248, 273, 281 and 209 [134].  
 
Owing to the TP53 mutation profile and residual function similarity in patients without and 
with treatment, it was suggested that the post-treatment mutations are selected, rather 
than being caused by chemotherapy [134]. This hypothesis was supported later in 
longitudinal studies using highly sensitive NGS methods. It has been suggested that CLL 
subclones with TP53 mutation exist before and expand after treatment induced selection 
[137]. To further support this, a recent NGS study for 309 CLL patients at early stages has 
found that up to 9% harboured small subclones with TP53 mutations. Importantly, these 
patients shared the same aggressive clinical phenotype and poor survival as those harboured 
clonal TP53 aberrations [138].  
 
Although TP53 mutations are more common in patients with unmutated IGHV, they are 
independently associated with poor disease outcome in CLL, predominantly by reducing 
apoptosis and inducing resistance to DNA damaging agents [139]. Of notes, the clinical 
consequence may vary depending on location of mutations and their effects on p53 
functions. For example, It has been documented that mutations in DNA binding motif and 
gain of function mutations are associated with extremely poor survival in CLL [139].  
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1.2.4.2. ATM 
This gene is mapped on chromosome 11 (11q22.3), it composed of 63 exons of which exon 1 
is non-coding. It encodes the phospho-protein ATM which is composed of 3065 amino-acid 
residues. It has multiple domains including the C- terminal domain which shares homology 
with phosphatidylinositol 3-4 kinase (PI3K), phosphokinase like domain, and ARM-TF domain 
[140]. This phospho-protein acts upstream to p53 in controlling the cell cycle and apoptosis 
through mediation of p53 phosphorylation at multiple sites in response to DNA damage 
[141]. 
 
Mutations of this gene can occur in up to 12% of unselected CLL patients [142], while 
monoallelic loss through 11q abnormality occurs in 20%. Moreover, up to 36% of 11q 
deleted patients harbour mutated ATM gene in the remaining allele [99]. A small proportion 
of ATM mutations can occur without loss of ATM allele [95]. ATM mutation and/or 11q 
deletion occurs in 25% of cases at time of diagnosis [95]. Mutations are distributed across 
the entire gene sequence. Although no hot spots have been identified, more frequently the 
C- terminus of the protein (PI3K domain) which is critical for phosphorylation activity of the 
protein is affected. Regarding mutation types, those with truncating features accounts for 
55% of all the mutations while others are missense mutations [143].  
Consequently, biallelic ATM loss due to ATM deletion and mutations and/or mutations alone 
diminishes ATM expression [144]. This reduces phosphorylation of target genes and lowers 
auto-phosphorylation in response to radiation in CLL [33, 99, 145]. Therefore, defects in ATM 
gene can produce effects similar to p53 loss [33].  
 
In a clinical context, ATM defects were associated with chemoresistance, advanced disease 
stages and shorter overall survival [146]. Mutations can occur in both IGHV mutated and 
unmutated groups, but are more commonly associated with germ-line IGHV. Occasionally, it 
can also co-exist with TP53 mutations [142].  
 
1.2.4.3. Novel recurrent gene mutations 
Despite the earlier biomarkers for CLL mentioned above, there have been continuous efforts 
to identify new biomarkers. This is due to the fact that the available biomarkers failed to 
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predict the outcome for all the CLL patients. The initial effort using whole genome 
sequencing (WGS) for 7 cases led to identification of new recurrent gene mutations with 
unknown clinical significance in CLL. Later, studies using whole exome sequencing (WES) for 
a substantial number of CLL cases identified somatic mutations in around 75 novel genes. It 
is estimated that a CLL genome can carry somatic mutations ranging from 2 to 76 mutations. 
As revealed by the WES studies, most of these mutations were detected in less than 5% of 
cases. 
For those recently identified gene mutations, the exact functional consequences and their 
role in CLL progression are still not very clear [147]. However, some of these genes have 
been evaluated in the context of a larger series of patients, in addition of a correlation 
between higher number of somatic mutated genes and unmutated IGHV [147]. 
Interestingly, the incidences of various gene mutations were different between CLL 
subtypes. For example, in IGHV-unmutated cases, mutations of NOTCH1, SF3B1, XPO1 and 
POT1 were commonly found [148, 149]. In contrast, IGHV-mutated patients had enriched 
mutations of KLHL6, MYD88 and CHD2 [148]. A number of important signalling pathways 
relevant to CLL pathology have been identified through functional clustering analysis of the 
commonly mutated genes, they include NOTCH1 signalling, mRNA splicing, DNA damage – 
cell cycle- control and inflammatory response pathways [150]. All of those suggested that 
such mutations play roles in CLL development.  
 
 
1.2.4.3.1. NOTCH1 
This gene is mapped on chromosome 9q34.3. It composed of 34 coding exons. It encodes a 
transmembrane protein (receptor) which is composed of two main domains; namely an 
extracellular N-terminal domain and an intracellular C-terminal domain. The latter composed 
of ankyrin (ANK), transactivation (TAD) and proline-glutamate-serine and threonine (PEST) 
domains. The protein acts as a ligand activated transcription factor in controlling cellular 
proliferation and apoptosis [151]. 
In quiescent cells, the two domains are joined together. Upon ligand binding to the 
extracellular domain, the intracellular domain releases through proteolytic activity of gamma 
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secretase. The detached intracellular domain moves to the nucleus to trigger signals upon 
which active transcription complexes are accumulated. It is the PEST domain part of C- 
terminal of the protein that is responsible for the limitation of this activity. This function is 
accomplished through phosphorylation of the PEST domain by which proteasomal 
degradation via the FBXW7 complex is enhanced [147]. 
In CLL, almost all of the mutations detected are located in the exon 34, which encodes the 
TAD and PEST domains. Among the mutations, p.F2482Ffs*2 is the most common alteration, 
making up more than 85% of mutations in this gene. Usually, as a result of these mutations, 
a truncated highly stable protein is generated that is then overexpressed in the CLL cells 
[152]. Clinically, NOTCH1 mutations characterise patients with more aggressive disease. In 
addition, this aberration is enriched in patients with unmutated IGHV and trisomy 12 [153]. 
Although the mutations can be detected at time of diagnosis and in non-progressive CLL, few 
cases showed acquisition or loss of NOTCH1 mutations over time of disease progression or 
after receiving treatment [153]. Thus, the incidence of NOTCH1 mutation varies from 4% in 
unselected CLL cohorts [154] to 20% in chemo-refractory CLL. An even higher incidence up to 
30% was found among CLL patients with Richter transformation [155]. 
 
1.2.4.3.2. SF3B1 
SF3B1 gene is located on chromosome 2q33.1. It composed of 25 coding exons. It encodes 
SF3B1 protein that is composed of two regions, the N-terminal hydrophilic region which 
contains a number of protein binding motifs (encoded by codons 1 - 450) and the C-terminal 
region, which consists of 22 non identical HEAT repeats (codons 453 - 1298). It is a 
component of the spliceosomal complex, which also contains five small nuclear ribonucleic-
proteins (snRNP) [156]. This complex becomes assembled on premature RNA to efficiently 
splice introns with fidelity. Mutations affecting splicing recognition sites may result in the 
abnormal splicing of various genes in the form of retained introns, skipped exons, abnormal 
elongation or truncation of proteins and altered gene expression [156]. A recent study in CLL 
has  documented that mutated SF3B1 is associated with defective ATM/p53 transcriptional 
and apoptotic responses to DNA-damaging agents even in samples with intact ATM and 
TP53 genes [157].  
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Somatic alterations of SF3B1 occur in 10 - 15% of CLL patients at time of diagnosis [158] and 
up to 30% of chemo-refractory cases [159]. 90% of the identified mutations are clustered in 
exons 14 - 16 that encodes the HEAT 5 - 8 domains. The four most common hot spots at 
codon 700, 742 ( reported for the first time during this study), 662 and 666 together 
comprise 80% of all the SF3B1 mutations in CLL [158].  
Considering their clinical effects, these mutations more frequently occur in patients with 
advanced disease who showed shorter time to progression and poorer response to 
treatment. Furthermore, associations with adverse biological features such as unmutated 
IGHV and 11q abnormality have also been documented [159]. 
 
1.2.4.3.3. BIRC3 
BIRC3 is localised on 11q22.2. Structurally, it consists of 9 exons of which the 1st exon is non- 
coding. BIRC3 protein has multiple domains including BIR1-3, ubiquitin associated domain 
(UBA), caspase recruitment (CARD) and Ring finger (RING) domains. Codons 529-604 encode 
the RING domain which is the key player of unbiqutination activity to regulate NFB 
signalling. This gene is a negative regulator of NFB. Target genes of NFB are involved in 
inhibition of apoptosis, signal transduction and chemotaxis. These targets have significantly 
higher expression in lymph node derived CLL cells compared to CLL cells in the peripheral 
blood  [160], suggesting the existence of specific interactions between protective micro-
environmental niches and CLL cells. Since activation of NFB signalling results in pro-survival 
signals to the leukaemic clones through the up-regulation of those anti-apoptotic genes 
[160], such activation through different mechanisms including micro- environmental 
interactions is an important contributor to disease progression and chemotherapy resistance 
in CLL [161].  
At molecular level,  gene alterations along the NFB pathway also play a role in pathogenesis 
of CLL through the activation of this pathway [162]. This is true for other B-cell malignancies 
such as splenic marginal zone lymphoma [163] and diffuse large B-cell lymphoma [164]. 
BIRC3 monoallelic loss associated with 11q deletion can result in activation of NFB 
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pathway. Moreover, truncating mutations (nonsense and frame shift alterations mostly 
affecting RING domain) and monoallelic loss can have similar effects.  
The incidence of BIRC3 mutations is 4% at time of diagnosis, 10% at time of disease 
progression and is up to 24% in fludarabine refractory CLL [162]. It characterises high risk 
genetic and phenotypic features such as unmutated IGHV, fludarabine refractoriness and 
poor survival in CLL [162]. However, independent significance of BIRC3 alterations in patients 
with 11q deletion is uncertain. 
 
1.2.4.3.4. MYD88 
MYD88 is located on chromosome 3p22.2. It composed of 5 coding exons which encode a 
protein of 317 amino-acids. This protein molecule is composed of 2 main domains including 
death domain (DD) (amino-acids 1-150) and toll/interleukin receptor domain (amino-acids 
151-317) that is encoded by exon 3, 4 and 5. It is found to be recurrently mutated at a low 
incidence (2% - 10%) in CLL. It encodes a critical adaptor molecule of the interleukin-1 
receptor/toll-like receptor (TLR) signalling pathway. Consistent with this functional feature, 
MYD88 mutated CLL show secretion of significantly higher amounts of the interleukin-1 
receptor antagonist, interleukin 6, and chemokine ligands upon TLR stimulation compared to 
wild type group [165]. Activation of TLR leads to induction of NFB signalling [166]. In 
addition, the excessive production of these cytokines recruits more macrophages and nurse- 
like cells by CLL cells, forming a favourable niche to escape apoptosis and death [167]. 
The activating mutations in this gene have been identified in 3% of unselected CLL cases. 
Their prognostic significance in CLL is still not clear. An early report demonstrated that those 
mutations were more common in patients  50 years old, with mutated IGHV, low CD38 and 
ZAP-70 expression and favourable outcome [168]. However evidence from a recent study on 
a bigger CLL cohort (published in 2015) suggested that such mutations are associated with 
advanced disease stages (Binet stages B and C) and a shorter time to first time treatment 
(TTFT) [169]. 
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1.2.4.3.5. POT1 
The gene is localised on chromosome 7q31.33. It consists of 19 exons of which 15 are coding 
(exons 5 - 19). In the N- terminal portion of the protein, there are two important domains 
OB1 and OB2 which are essential for DNA binding activity and protection of telomere (POT) 
function. In normal cell division process, DNA initially needs to undergo replication. With 
each round of cell division, the length of telomere that is composed of protein bound 
sequence of GT rich repeats is lost. If the telomere loss is profound, the cell can no longer 
undergo DNA replication to divide and therefore loses the capacity to survive [170]. To 
counteract this DNA loss, the enzyme telomerase adds telomeric DNA sequences only to the 
linear structure of 3’ GT rich sequence overhang. Hence, the telomere length is restored and 
the cell can undergo further cell cycles [170]. 
POT1 encodes a member of a protein complex that is called shelterin, which binds to the 
telomeric sequence of DNA. This binding forms a bridge between single strand DNA (the 
overhang) and the double strand DNA. The bridging results in folding of the telomere to 
render it inaccessible to the telomerase enzyme. This process is called end capping [171].  
The efficiency of this capping is not only dependent on proper binding of the protein 
complex to DNA, but also depends on the length of the telomere. The shorter the telomere, 
the less efficient binding is resulted [171]. Therefore, reduction or loss of the capping 
capacity indicates higher replicative capacity induced by telomerase due to unprotected 
chromosomal ends as seen in CLL [172]. Furthermore, it is postulated that loss of this DNA 
capping ability initiates erroneous DNA damage response culminating with inappropriate 
end repair through end joining (fusion) of sister chromatids and chromosomal aberrations. 
In CLL, POT1 mutations are found in 3.5 - 5% of unselected cases and up to 9% of IGHV un-
mutated cases [173]. It has been found that these mutations mainly affect the N- terminal 
OB1 and OB2 domains. The mutations were heterozygous and more commonly resulted in 
truncated protein. Dominant negative role of mutations has been confirmed by defective 
DNA binding in a heterozygous POT1 mutated cell line. However, POT1 mutated protein 
could form the complex with the other member of the family [173]. Molecular analysis of 
POT1 mutations in CLL showed increased incidence of telomere attrition and chromosomal 
end fusion with more advanced disease while the incidence was lower in patients prior to 
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disease progression. Specifically patients with dysfunctional telomeres were found to have 
large-scale genomic rearrangements enriched at the ends of the chromosomes. Moreover, 
the recent discovery of frequent POT1 mutations and associated telomeric and 
chromosomal abnormalities in CLL strongly supports the model that telomere shortening 
and fusion contribute to the progression of CLL [174]. Consistently, the significantly higher 
rates of chromosomal fusions and complex karyotype [173] have been found to be 
associated with shorter survival in CLL [120].  
 
1.2.4.3.6. SAMHD1 
This gene which is located on chromosome 20q11.23, encodes a protein that has two 
important domains, the first is sterile alpha motif (SAM) and the second is histidine-aspartic 
domain (HD). Normally the gene reduces the intracellular dNTP pool by decomposing this 
molecule through resection of its three phosphate atoms. Depletion of this element which is 
required for DNA synthesis can result in reduced cellular proliferation through cell cycle 
inhibition and apoptosis [175].  
Whole genome or whole exome sequencing studies of CLL have recently indicated that this 
gene is recurrently mutated in CLL. Mutations can occur at a frequency ranging from 3% in 
untreated CLL to 11% of relapsed and refractory cases [175]. The mutations are distributed 
throughout the exons and are found to occupy the entire clones reflected by high variant 
allele frequency. Genome wide array has revealed that 80% of SAMHD1 mutations were 
associated with monoallelic loss or copy number loss of heterozygosity. This finding 
suggested that disruption events of this gene can be a founder to early stage 
leukemogenesis [176].  
SAMHD1 mutated CLL cells invariably had reduced mRNA expression compared to normal B- 
cells. Furthermore, exposure of cell lines carrying recombinant mutated HD domain to 
escalated doses of DNA damaging agents, showed resistance to cell death [175]. This study 
highlighted the possible role of HD domain of this gene in the regulation of cell survival and 
response to DNA damaging agents [176]. From the clinical perspectives, mutations were 
found to be associated with enhanced resistance to DNA damaging chemotherapy evidenced 
by enrichment of these mutations in the relapsed/refractory patients [175]. Still no 
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significant associations for mutations are found with overall survival rate and transformation 
to Richter syndrome due to small size of the studied samples. 
 
1.2.4.3.7. CHD2 
CHD2 is situated on chromosome 15q26.1. It is composed of 38 coding exons which encode 
a complex protein that has multiple domains including N-terminal chromatin organisation 
modifier domain, dead-like helicase superfamily domain, a putative DNA binding domain and 
a C-terminal domain of unknown function. CHD2 is a regulator of transcription and 
chromatin remodelling [177, 178]. 
Somatic mutations in CHD2 have been identified in 5 % of CLL [117]. Notably, 50% of 
the mutations are predicted to result in deleterious biological effects through truncation of 
protein structure either by frame-shift alterations, splice site changes and premature stop 
codons. The mutations were commonly detected in the functional domains particularly the 
DNA binding domain (codons 480 - 946), accounting for 33% of all the mutations [177].  
Transcriptome analysis has identified significant enrichment for genes belonging to the 
phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) pathway. Since this pathway plays a 
remarkable role in the BCR signalling which contributes to survival and proliferation of CLL 
cells [179, 180], a possible role of this gene in CLL development has been suggested.  
Biological parameters of CLL patients with CHD2 mutations showed frequent IGHV 
mutations, however a statistically significant association between these two biological 
variables could not be identified. Moreover, there were no difference in the clinical 
parameters of IGHV mutated patients with or without CHD2 mutations [177]. Detailed 
clinical description of CHD2 mutations in CLL is still unknown. 
 
1.2.4.3.8. XPO1 
This gene is located on chromosome 2p15 and composed of 24 coding exons. It encodes 
XPO1 (exportin-1) protein which functions in nucleo-cytoplasmic export of numerous 
proteins including anti-apoptotic and tumour suppressor proteins. In fact, the nuclear export 
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of the tumour suppressor p53 requires both MDM2 and XPO1. Through E3 ubiquitin ligase 
activity, MDM2 initiates the nuclear export signal (NES) in p53, resulting in a conformational 
change in p53 that lead to exposure of its NES domain. Following this conformational change 
in p53, XPO1 recognises the NES signal of p53 and transfer the protein from the nucleus to 
the cytoplasm. In this way, XPO1 negatively regulates transcriptional activities of p53 [181]. 
However, an influence of XPO1 mutations on p53 regulation function is still unknown. 
In CLL, this gene is found to be recurrently mutated, with a frequency approaching 3 - 5% of 
patients using whole genome and whole exome and targeted deep sequencing in unselected 
cases or untreated patients. Harbouring XPO1 mutations was considered as a predictor of 
poor outcome, however due to small sample size there was lack of reliable statistical 
evidence to prove this [13, 92].  
 
1.2.4.3.9. FBXW7 
This gene is localised on chromosome 4q31.3 and composed of 11 coding exons. The protein 
encoded by F-box and WD40 repeat domain-containing 7 (FBXW7) is an ubiquitin ligase. It 
has three domains including the dimerisation domain, the F-box domain that is responsible 
for recruitment of the other constituents of the ubiquitin ligase complex, and the WD40 
(codons 400 - 700) repeats that attaches to substrates [182]. FBXW7 has central roles in cell 
division, growth, and differentiation by down regulating several target proteins, including c-
Myc, Notch family proteins and cyclin E [183]. 
Mutations of this gene can have a dominant negative effect, particularly the hot spot codon 
465 (located inside the WD domain) which is important for recognition of the target onco-
proteins [184]. Accordingly, dysfunctional FBXW7 can be an alternative pathway for 
activation of NOTCH signalling and consequent MYC transcription [185]. Notably, like p53 
disruption, NOTCH signalling and MYC activation are frequently enriched in CLL cases with 
Richter transformation [186]. 
Mutations of FBXW7 were found in 8% of CLL cases with trisomy 12 [13]. In a study that 
recruited a large number of untreated CLL cases, 2.5% of the patients carried FBXW7 
mutations. The mutations were found to affect the WD40 domain; moreover, alterations in 
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codon 465 comprised 30% of the mutations. Heterozygous missense mutations were the 
most frequent alteration accounting for 91% of the mutations. Variant allele frequencies of 
one third of the detected mutations were below 10% [92].   
  
1.2.4.3.10. PCLO 
The gene is located on chromosome 7q11.23-21.3. It constitutes of 25 coding exons that 
encode a giant protein of 5142 amino-acids. The piccolo presynaptic cyto-matrix protein 
(PCLO) is involved in the organisation of the cytoskeleton and extracellular matrix as well as 
cell adhesion through calcium sensing [187]. For instance, increased intracellular Ca2+ 
concentration has been shown to be important in cell migration. In human lymphoid tissues, 
extracellular calcium sensing stimulates B-cell activation and function through activation of 
various pathways such as PI3K, NFB and Toll like receptor pathways [188].  
In CLL, a role of PCLO mutations in augmented calcium responsiveness has been suggested. 
Yet, few studies have addressed the functional consequences of mutated PCLO gene 
generally in cancer and specifically in CLL. However, increased calcium responsiveness is 
found to be associated with shorter lymphocyte doubling times (LDT) and shorter time to 
treatment [189]. Mutations in PCLO have been found in up to 9% of representative CLL 
cohort included 11 untreated and 34 relapsed/refractory CLL cases [190] and up to 11% of 
CLL cases with Richter transformation using NGS techniques [191]. Moreover, very common 
mutations in this gene were observed in up to 35% of patients with denovo DLBCL [192].  
 
1.2.4.3.11. LRP1B 
This gene located on chromosome 2q21.2. It composed of 91 coding exons. It encodes a 
member of low density lipoprotein cell surface receptor family of 4599 amino-acids which 
possesses four ligand binding domains in the N terminal part. Through interaction with 
multiple ligands, the gene exhibits a diverse biological role in lipoprotein catabolism, cell 
development, cell adhesion and migration. Furthermore, it is a putative tumour suppressor 
gene and one of the most commonly mutated genes in a number of human cancers [193]. 
Mutations in this gene have been found to be associated with disease progression and 
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metastasis in hepatocellular carcinoma [194], lung cancer [195] and with drug resistance in 
ovarian cancer [196]. Whole exome study of CLL found mutations in LRP1B in 5% of patients 
[149]. The functional significance of this gene and the consequences of its alteration in CLL 
are still unclear. 
 
1.2.4.3.12. HIST1H1E 
This intron-less gene is located on chromosome 6p22.2. It encodes a histone linker protein 
named H1e, which with other histone linker subtypes namely H1a, H1c and H1d play a 
fundamental role in the regulation of gene expression at the chromatin level. Conjoining of 
the histones (fundamental nuclear proteins on which DNA is wrapped around) leads to 
compaction of chromatin. It is the degree of this compressed chromatin structure that 
controls the DNA-binding transcription factors to access their cognate binding sites [197].  
HIST1H1E mutations occurred in 4% of CLL patients using a WGS approach in 145 unselected 
CLL patients [198]. The functional significance or consequences of its mutations in CLL is still 
unclear. However, it is among the putative driver gene mutations identified recently in a 
comprehensive analysis of WES data from 538 CLL cases of three trials [93].  
1.2.4.3.13. ZFPM2 
This gene is positioned on chromosome 8q23. It has 8 coding exons encoding zinc finger 
protein (1151 amino-acids) which is a member of the FOG family of transcription factors. It 
plays a pivotal role in modulating the activity of GATA family proteins (important regulators 
of haematopoiesis) [199]. Alterations in this gene have been found to affect 5% of CLL 
patients [190]. 
 
1.2.4.3.14. Other novel recurrently mutated genes 
Numerous other recurrently mutated genes have been identified in CLL. The frequency of 
these mutations is generally below 4% for each. Some of the most important genes that are 
involved in pathways implicated in CLL pathogenesis are shown in Table 1.1. 
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1.2.5. Clonal evolution in CLL 
1.2.5.1. ATM-P53 pathway in clonal evolution 
The ATM-p53 pathway constitutes a meshwork of genes that are targeted to respond to a 
variety of intrinsic and extrinsic cellular stress signals that affect homeostatic mechanisms to 
monitor DNA replication, chromosome segregation and cell division [319]. Briefly, in 
response to a stress signal such as irradiation subsequent DNA double strand breaks emerge. 
This damage brings about phosphorylation of ATM which then activates p53 protein in a 
specific manner by post-translational modifications, including phosphorylation.  The 
activation of p53 leads to initiation of DNA damage repair, arrest in cell cycle, a program that 
induces cell senescence and/or cellular apoptosis [320]. In cancer cells with defective ATM-
p53 pathway, various intrinsic or extrinsic stresses may result in abnormal DNA replication, 
genome instability and cell cycle progression which favour survival and proliferation of these 
cells and consequently result in clonal evolution of the cancer and deterioration of clinical 
status of the affected individuals. Figure 1.1. shows a summary of ATM-p53 pathway in 
response to DNA damage. 
 
Figure 1.1.   A summary of ATM-P53 pathway.  –p: phosphorylated proteins; 
G1>S>G2>M:  4 phases of cell cycle; Chk1: Checkpoint kinase 1; Chk2: Checkpoint kinase 
2;  
 
Cellular consequences: 
Senescence 
Apoptosis 
DNA repair 
Growth arrest 
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1.2.5.2. Concepts: models of clonal evolutions based on mutation profiles 
Clonal evolution is one of the enabling characteristics of CLL, in which the acquisition of 
successive multiple mutations result in alterations in its genetic composition (make up) 
overtime. This depends on positive selection of additional somatic mutation(s) that are able 
to compete and adapt to external pressure such as chemotherapy. Therefore, the 
phenotypic change of CLL (disease progression and relapse) must stem from underlying 
genetic evolution. This concept has indeed been confirmed in the past by FISH or other 
cytogenetic techniques; For example, clonal evolution was identified in a considerable 
number of patients (up to 43%) using  FISH or other cytogenetic techniques (of low 
sensitivity), with frequent acquisition of the poor prognostic markers such as del (11q) and 
del (17p) over time of progression and relapse [200].  
More recently, while the current study was ongoing, models of CLL clonal evolution have 
been proposed through application of high throughput sequencing techniques (mainly WES) 
for longitudinal samples. Firstly, linear evolution is characterised by increase in mutant clone 
population with preservation of the initial genetic composition with or without maintenance 
of clonal equilibrium.  Secondly, branching evolution in which the genetic composition is 
altered in the progeny such that the new developing clones carry mutations diverse from the 
ancestor clones [198]. Based on mutation profile, the founder of a clonal mutation (exist in ≥ 
95% of the tumour cells) should have occurred before or during the latest selective step, 
while subclonal ones should have occurred after the most recent selective step [198].  
Chapter 1. General introduction 
60 
 
Table 1.1. Summary of some other recurrently mutated genes with low incidences  
Pathways involved Gene symbol Chr. location (Ensembl) % of cases CLL cohort type and 
No. of patients 
Method Ref. 
MAPK-ERK pathway/BCR signalling MAP2K1 
BRAF 
NRAS 
KRAS 
PLEKHG5 
15q22.31 
7q34 
1p13.2 
12p12.1 
1p36.31 
2% 
3.7% 
2% 
2.6% 
3% 
Unselected (n=287) 
Unselected (n=160) 
 
Unselected (n=48) 
WGS 
WES 
 
WES/n=5 
Targeted 
NGS/n=48 
[93] 
[198] 
 
[155] 
RNA processing DDX3X Xp11.4 2-3% 
 
 
Unselected (n=81) 
Unselected (n=160) 
 
Untreated and 
relapsed (n=45) 
WGS + WES 
WES 
 
Targeted 
NGS 
[150, 
198] 
 
[190] 
Toll like receptor/inflammatory IRF4 
MAPK1 
6p25.3 
2q11.21 
1.5% 
3% 
Wnt/MYC signalling MED12 
FUBP1 
 
MGA 
Xq13.1 
1p31.1 
 
15q15.1 
2-5% 
1.7% 
 
3.2% 
Unselected (n=160) 
 
Unselected (n=287) 
 
WES 
 
WGS 
 
[198] 
 
[93] 
 
Chromatin modification ASXL1 
ZMYM3 
 
IKZF3 
 
20q11.21 
Xq13.1 
 
17q21.1 
2% 
2% 
 
2% 
Unselected (n=287) 
 
Unselected (n=287) 
 
WGS 
 
WGS 
 
[190] 
 
[93] 
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1.2.5.3. Existence of subclones prior to CLL progression or drug resistance and the 
importance of their identification as early as possible 
Subclonal mutations are expected to occur at early stages of CLL. These subclonal mutations 
more commonly follow a complex branched pattern of evolution rather than a traditional 
linear model of evolution. This is proposed to be due to complex interaction among highly 
diverse population which by itself fuels clonal evolution. Importantly, it is the evolution of 
mutant subclones that is responsible for disease development in CLL. Therefore, diverse 
subclonal composition can predict poor prognostic outcome such as disease progression and 
treatment unresponsiveness [198]. As found in recent studies, subclonal mutations in TP53 
gene have similar effects of clonal mutations in terms of disease progression and response 
to treatment [138]. Recurrent subclonal mutations in other genes including ATM, NOTCH1 
and SF3B1 have been also found to be associated with disease progression and/or 
chemoresistance in CLL [137, 201]. 
 
1.2.5.4. A need of sensitive methods to detect small subclones with driver 
mutations 
It is important to note that to date majority of the published data in CLL have been limited to 
the detection of gross clonal heterogeneity (clone size > 10% of the entire cell population) 
[198]. This is because only clones that existed in a substantial proportion of the CLL cells or 
clones that become dominant at the time of study were traceable using the less sensitive 
methodologies [137]. So that, achieving deeper sequencing depth is important to enable 
identification of smaller subclones and thus maximising the ability to decipher the true 
extent of genomic heterogeneity and to provide early prediction for disease progression 
and/or resistance to therapies in this disease.  
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1.3. Methods for identification of genomic aberrations in CLL 
 
1.3.1. Identification of chromosomal abnormalities and copy number changes 
In the early 1950s, chromosome banding following the discovery of hypotonic solution 
heralded the recognition of exact chromosomal number in human cells. Abnormal numbers 
or structures of chromosomes were noticed in various human diseases including cancers 
with high mitotic activity [202]. In the 1970s, further refinement of this method followed 
upon the discovery of mitogens. This discovery was particularly useful to study the CLL 
genome which is characterised by low mitotic activity. Although chromosomal abnormalities 
could be detected in this disease,  the incidence and complexity of these aberrations was 
underestimated in this tumour [202]. 
 
Subsequently, in-situ hybridisation was developed in which specific emission probes of 
thymidine were used to detect DNA fragments. However, this was a complicated and time-
consuming test which required experienced hands and storage of the fixed slides in light 
proof boxes for 2 months to obtain results. It was therefore not an ideal test for clinical 
diagnosis. Eventually, a successive development of florescent probes for FISH has 
circumvented this problem [202]. 
 
 
1.3.1.1. FISH 
 
FISH was developed in 1980s. It uses florescent probes to detect complementary DNA or 
RNA sequences, and is therefore more specific, sensitive and time-saving compared to other 
conventional cytogenetic techniques. With its ability to identify chromosome 
rearrangements in non-dividing cells and further refinement for using multi-colour probe 
painting, it  has become a particularly useful tool  to identify prognostic subgroups in 
haematological malignancies [203]. In CLL, interphase FISH has been successfully used to 
detect recurrent chromosomal aberrations (e.g. del 17p, del 11q, del 13q and trisomy 12) 
which remarkably help in identifying high-risk disease.  However, chromosomal aberrations 
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detected by FISH are incomplete as limited chromosome regions being targeted and often 
difficult to be quantified.   
 
 
1.3.1.2. Array based karyotyping methods 
 
Comparative genomic hybridisation was the earliest array method used for karyotyping 
studies. The patient DNA and a normal control DNA are differentially labelled with florescent 
dyes which are then subjected to competitive hybridisation with a normal chromosomal 
preparation. Colour deviation of the test sample from the control is then used to 
computationally analyse the results. 
 
Although initially the method produced a picture of chromosomal abnormalities across the 
genome without the need for metaphase spread, only large gain or losses were detectable 
owing to its low resolution. Application of oligonucleotide or bacterial artificial chromosome 
potentiated the detection of smaller deletion or amplification spanning in Kilobases. It is also 
possible to study the entire genome or to target specific locations within the genome. Its 
main drawback is inability to detect balanced translocations [204] . 
 
SNP array is the latest developed method for detecting genome-wide CNA. Various SNP 
array methods with different resolution have been developed depending on the number of 
probes specific to common single nucleotide polymorphisms spanning a particular 
chromosomal region. This technique allows detection of copy neutral loss of heterozygocity 
(LOH) or uniparental disomy (CNN-LOH) that is loss of one homologue of a chromosomal 
region and replacement of this loss by doubling of identical segment of the other 
homologue. An example of high resolution SNP array is Infinium CytoSNP-850K BeadChip 
which utilises single-base extension. Bead bound DNA probes are attached to the array 
surface (each bead is attached by identical copies of the same probe). Amplified fragments 
of genomic DNA are hybridised to the probes. Biotin-labelled ddCTP and ddGTP, and 2, 4-
dinitrophenol (DNP)-labelled ddATP and ddUTP are incorporated into the probe sequence 
depending upon the genotype at that base. The hybridised DNA is then detached and 
washed out to leave the fluorescent labelled probes. Probes then receive a fluorescent label; 
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streptavidin labels biotin green and anti-DNP antibody labels DNP red. After completion of 
the assay, the chip is scanned by a laser and the intensity of the fluorescence is measured. 
The relative intensity of red and green fluorescence is dependent upon the genotype [204, 
205]. 
In CLL, copy number changes are commonly used as prognostic indicators. For example, for 
patients with 17p deletion, a different regimen or a more intensive treatment might be 
selected. Conversely, for patients with isolated 13q14 deletion or normal karyotype, “watch 
and wait” approach might be used in management plan. As mentioned earlier, array-based 
karyotyping is superior to FISH and CGH in performance. This is because it has higher 
resolution and greater coverage of genomic regions. It has been found that 50% of patients 
who had been assigned as normal karyotype for regions covered by FISH probes, had 
subclonal population of genomic lesion with prognostic significance outside the detection 
limit of FISH. Furthermore, SNP array methods detect both copy number abnormalities and 
copy neutral events, such as uni-parental disomy (UPD) and genomic complexity that cannot 
be identified by FISH and CGH. Moreover, acquisition of additional genetic lesions is a sign of 
clonal evolution which has been shown to shorten overall survival of a median of only 22 
months [206]. 
UPD has been reported in CLL patients with TP53 mutations, thus 2 mutated copies have 
been produced which has the same clinical significance of 17p del in CLL risk assessment. 
Moreover, the q arm of chromosome 13 has been reported to be affected by UPD which 
changed the original heterozygous deletion at 13q14 to a homozygous deletion with 
identical break points on both alleles [206, 207]. More recently, the utility of whole genome 
and whole exome NGS data has been extended to detect copy number changes, thereby 
they can serve as substitutes for identification of SNVs and CNAs [208]. 
 
1.3.2. Identification of point mutations, small insertions and deletions 
 
There are various methods for detection of point mutations and small indels. The choice of a 
method depends on the status of mutation (whether it is known or unknown), number of 
the mutations, and size of DNA regions where the mutations exist and reliability of the 
method. 
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1.3.2.1. Single strand conformational polymorphism (SSCP) 
Various tests can be used to detect unknown point mutations using the physical property of 
denatured DNA. For example, SSCP uses the concept that DNA variations cause alterations in 
the conformation of denatured DNA fragments. It compares the altered migration of 
denatured wild-type and mutant DNA fragments during the electrophoresis [209]. In this 
technique, DNA fragments up to 200 bp can be screened. It has the capacity to detect up to 
80% of potential point mutations or any sequence change (synonymous or non-synonymous 
single nucleotide variation as well as short indels) [210].  
 
1.3.2.2. Heteroduplex formation 
Likewise, heteroduplex formation by mutant DNA and its differential mobility as compared 
to homoduplex forming wild type DNA is the basic concept of using denaturing high 
performance liquid chromatography (DHPLC) to detect point mutations [211]. Similarly, 
based on differences in the melting behaviour of DNA even with single base substitution, 
denaturing gradient gel electrophoresis (DGGE) has been used. This technique is beneficial 
because DNA fragments up to 1Kbp can be screened; moreover, over 95% of point 
mutations can be reliably detected by this method. Although this method is considered to be 
labour intensive [211].   
 
1.3.2.3. Property of mutant proteins 
For some genes, the mutated proteins can be used for unknown mutation screening if their 
properties are predictable. The well-known example is to use mutant p53 to identify samples 
harbouring TP53 mutations in human cancers including CLL. 
1.3.2.3.1. Mutant p53 protein expression 
In contrast to wild type p53 protein which stays too short to be readily detected in 
unstimulated normal cells, the mutant p53 has a prolonged half-life [212]. Therefore, the 
high baseline level and lack of activation of p53 protein as measured with either 
immunohistochemistry or flow cytometry suggest TP53 mutation in CLL [213]. Nevertheless, 
its clinical utility is compromised due to false negative and false positive from stop codons 
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and destabilising mutations. Additionally, result variability from technical aspects such as the 
use of different antibodies and scoring criteria were frequently encountered [212].  
 
1.3.2.3.2. Loss of transcriptional activity 
Due to the disadvantages of the above method, a technique was established to detect any 
unknown mutations affecting the transcription activity of p53 which is called functional 
analysis of separated allele in yeast (FASAY). The basic principal of this assay is that p53 
functions in gap repair by homologous recombination and its transcription activity can be 
detected in the yeast report system. In this test, TP53 cDNA (exon 4 - exon 9) is inserted into 
a linearised vector followed by co-transformation in to yeast cells. Identification of 
functional p53 protein depends on the yeasts’ minimal promoter gene expression upon 
which white colonies are produced. While red colonies are produced if mutated p53 are 
inserted because of lack of the promoter gene expression [214]. 
 
This method has been used as an initial screening test for CLL cases to identify TP53 
mutations followed by Sanger sequencing of the colonies to determine the location and type 
of nucleotide change because of its cost effectiveness. The main advantages of this method 
are; firstly, the ability to analyse both alleles separately; secondly, a substantial part of the 
gene can be quantitatively analysed with a high sensitivity; thirdly, fully inactivating 
mutations can be distinguished from partially inactivating ones; and lastly, the colonies can 
be sequenced for confirmation [214]. On the other hand, the method is technically 
demanding and time consuming. Moreover, it cannot detect mutations causing alternative 
splicing or mutations that are transcription independent. Besides, only the coding sequences 
between codons 42- 374 of the gene are examined [214]. 
 
All the above methods described are designed for screening unknown mutations. The 
following methods are used to detect known mutations. 
 
Chapter 1. General introduction 
67 
 
1.3.2.4. Allele-specific PCR 
A type of polymerase chain reaction (PCR) called allele specific (AS) PCR can be used to 
detect known point mutations or small indels. In this method, two PCR reactions are 
performed using respective primers specific for mutant and wild-type sequences.  
 
The method is valuable because in addition to identifying the genomic state (wild type or 
mutant), the carrier status (heterozygous or homozygous) of a sample can also be 
determined. The method is sensitive to detect mutation with allelic frequency as low as 1% 
[215]. However, its utility is hampered as it is restricted to known mutations and there is a 
frequent occurrence of non-specific amplifications, which require use of known control 
samples and optimisations [216]. 
 
1.3.2.5. Restriction fragment length polymorphism (RFLP) 
RFLP uses the concept that some point mutations can change restriction sites in DNA causing 
alteration in cleavage by restriction endonuclease enzymes which produce fragments with 
various sizes. Therefore its use is limited to detecting mutations that occur in restriction sites 
[210]. 
1.3.2.6. Sanger sequencing 
Sanger sequencing is the first generation DNA sequencing technique. It was developed by 
Frederick Sanger and colleagues in 1977 and is still a gold standard of sequencing technology 
as served in the 1000 Human Genomes Project [217]. 
 
This technique depends on chain termination. Radioactively or fluorescently labelled single 
nucleotides are added by DNA polymerase. Although the radioactive labelling and 
autoradiography were initially used for visualising DNA sequence, the fluorescent dye-
terminator sequencing is now the mainstay in automated sequencing owing to its greater 
expediency and speed.  In this modified method, the emitted lights are excited by laser in 
the DNA sequencer while passing through the detection region. The DNA sequence is 
revealed from the order of the fluorescent fragments [218]. Subsequently, base-calling and 
error probability assignments applications are used to call the DNA sequence and evaluate 
Chapter 1. General introduction 
68 
 
the accuracy of the base calling which is scaled by Phred score. Any base that achieves the 
standard Phred 20 (Q20) is a high quality base as its error probability is equivalent to 1% 
[218]. Through this and other further improvements, sequencing reads of up to 900 bp can 
be now obtained with high (99.999%) accuracy [219]. Conversely, because the sequencing is 
performed on four individual amplicons, each of which contains only one of the four 
dideoxynucleotides (ddATP, ddCTP, ddGTP or ddTTP), variation in intensity of fluorescent 
emission can result in less precise signal recognition. This appears as misleading small 
background peaks. Therefore its sensitivity is limited to identification of mutations with 
allele frequency greater than 10% [218]. 
 
Sanger sequencing bears technical limitation for sequencing large number of targets as it is 
not time or cost efficient. It requires PCR amplification for DNA template (library) 
preparation which usually involves either DNA cloning or gel purification. The estimated cost 
for an 800 bp sequencing reaction is £3. Another big challenge for this method is that it can 
directly sequence only relatively short (300 - 1000 nucleotides) DNA fragments in a single 
reaction. All of the above limitations hamper its further application and justify  development 
of new techniques with a higher capacity and efficiency to sequence a big size of DNA region 
in a large number of samples concurrently [217]. 
 
1.3.2.7. Next generation DNA sequencing 
 
Next generation sequencing (NGS) is a new technique developed only a decade ago.  It is 
characterised by massively parallel sequencing in which up to millions of DNA fragments 
from a single sample or multiple samples are sequenced simultaneously. Unlike Sanger 
sequencing, this technology has witnessed improvement in mutation detection at higher 
sensitivity based on the large order of sequencing magnitudes each target nucleic acid can 
achieve through deep sequencing approaches [220]. Various NGS platforms are 
commercially available and newly emerging platforms are continuing to be developed. These 
platforms have different throughput capacity. Large scale machines such as Illumina Hiseq 
can generate Gigabases (Gbp) of sequences per run which allow an entire genome to be 
sequenced in less than 4 days. More recently, Illumina HiSeq X10 is underway which 
produces 1.8 Terabases (Tbp) of sequence [221]. This tremendous increase in throughput 
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allows the whole human genome to be sequenced at reduced cost; however the system 
itself is very expensive which limits its availability only to large institutes performing 
population-scale genome sequencing [221]. 
 
Lower throughput bench top sequencing machines such Roche 454, Illumina Miseq and Ion 
Torrent (more recent) are also available. They can generate Megabases (Mbp) of sequencing 
output at relatively low cost. This has made sequencing facilities accessible to more labs and 
highlighted an interest for their use  in a clinical setting which require cheaper, faster, and 
easier-to-use sequencer [222]. Various platforms capacity and sequencing mechanisms are 
summarised in (Table 1.2). 
 
Table 1.2. Comparison of the most widely used NGS platforms [223, 224] 
Platforms 
parameters 
Roche 454 GS 
 
SOLiD 5500 xl Illumina 
HiSeq 2000 
Illumina 
MiSeq v1 
Ion 
Torrent 
PGM 
PacBio RS 
Amplification Emulsion PCR Emulsion PCR Bridge 
amplification 
Bridge 
amplification 
Emulsion 
PCR 
No PCR 
Sequencing 
mechanism 
Pyrosequencing Oligonucleotide 
ligation 
Sequencing 
by synthesis 
Sequencing 
by synthesis 
Sequencing 
by 
synthesis 
Single 
molecule 
real time 
sequencing 
Detection 
method 
Light detection Light detection Light 
detection 
Light 
detection 
H+ ion 
detection 
Light 
detection 
Output/run 50 Mbp 150 Gbp 600 Gbp 2 Gbp 20 Mb-1 
Gbp 
100 Mbp 
Turnaround 
time 
10 hr 8 days 3 days 26 hr 2-5 hr 2 hr 
Av. Read 
length 
400 bp 75 bp 100 bp 150bp 100-200 bp 900 bp 
Approximate 
sequencing 
cost/Mbp 
£6 £0.05 £0.03 £0.05 £0.06 £0.12 
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Although different platforms use different techniques, they commonly share a similar order 
of workflow (Figure 1.2), including DNA library and sequencing template preparation, data 
production and data analysis. Among these stages, data processing and analysis are 
generally most difficult owing to the vast amount of data generated, limitation of informatics 
infrastructures and time requirement to produce comprehensive analysis [200].  
 
            
       
 
Figure 1.2. Main stages of next generation sequencing 
The targeted NGS consist of 5 major steps, named genomic DNA extraction, target DNA 
enrichment, sequencing template preparation, sequencing data production and data 
analysis.  
 
 
1.4. Next generation sequencing approaches 
The use of next generation sequencing (NGS) has expanded the knowledge of the genomic 
alterations in CLL as it has led to discovery of new recurrently mutated genes which were 
previously unknown in CLL. Functional and clinical studies of these novel gene mutations 
have discovered new mechanisms implicated in the pathogenesis of the disease, revealed 
new insights into CLL molecular evolution that could ultimately translate into improvements 
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in the clinical management of patients. There are three NGS approaches, each suiting a 
specific purpose. A brief description of each approach is outlined in the following sections. 
 
1.4.1. Whole genome sequencing (WGS) 
In this approach, the whole human genome is sequenced. Human genome is composed of 
approximately 3.2 Gbp of nucleotides. It has been feasible to study the genome at 
population scale grounded by the advancements of NGS in throughput and reduction in cost. 
The most widely used platforms are Illumina HiSeq 2000 (100 Gbp), Illumina HiSeq 2500 
(1000 Gbp) and the most recent platform Illmina HiSeq X Ten (10000 Gbp) marketed in 2014 
[225, 226]. The average coverage sequence depth is usually 30 - 50 x. 
Since the accomplishment of the first large-scale human genetic variation study namely the 
1000 Genomes Project in 2004, larger unprecedented projects have been launched. These 
projects include the sequencing of thousands of genomes which are disease specific. Whole 
genome sequences enable understanding of the relationship between genomic variation and 
phenotype. Moreover, it serves as  comprehensive testing in clinical diagnosis of various 
types of genetic disorders including identification of novel genetic factors particularly in 
inherited diseases [227]. However, this approach is still unpractical because of many facts; 
the cost remains relatively high,  the turnaround time from the sequencing itself and data 
analysis is still pronounced and data storage is a challenging issue [221]. Moreover, its 
limited coverage depth (range 30 x - 100 x) and low sensitivity render the method 
inappropriate for identification of somatic alterations carried by small population of cells.  
 
1.4.2. Whole exome sequencing (WES) 
          This approach has emerged to study defined regions of human genome in which only the 
coding regions of the genome are sequenced. The protein coding regions comprise nearly 
1% of the entire human genome or ~30 Mbp which split across ~180,000 exons [228]. 
However, this part of human genome contains approximately 85% of known disease- related 
variants [221]. For this reason, sequencing of whole exome has been more extensively used 
compared to  whole genome sequencing for clinical studies in the recent years [221]. 
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In this approach, only the coding regions are sequenced and therefore the genomic 
alterations detected reflect sequence changes that result in functional alteration of proteins. 
Thus the smaller genomic regions targeted result in higher coverage depth usually of 100 x-
160 x and therefore increasing sensitivity of identification of somatic changes. In CLL, this 
approach has been implemented by various groups to study CLL genomic landscape as well 
as monitoring recurrent gene mutant clonal evolution in different selected and unselected 
cohorts [149, 150, 229].    
 
1.4.3. Targeted DNA sequencing 
In addition of the cost inefficiency and time apprehension in data production and 
management, the two earlier approaches suffer from lower coverage depth. Therefore, 
some important disease related variants may be missed through the bio-informatics 
algorithms applied to call high quality variants. Higher quality variants are achieved through 
increasing the read depth by focusing on disease specific variants or genes. For many 
diseases, there are a limited number of variants or genes which can be targeted with better 
coverage [230]. Not surprisingly, targeted NGS has recently been applied in more and more 
clinical diagnostics for various tumours including CLL [231]. 
The key step in targeted NGS is to enrich DNA sequence of interest through library 
preparation. Target capturing is accomplished by fusing randomly fragmented pieces of DNA 
molecule to platform specific adaptors. This is followed by PCR to amplify the adapter bound 
DNA. Later, by the help of the adaptors’ immobilisation site and sequencing primer site, the 
DNA libraries are amplified and sequenced. The adaptors also contain barcodes which are 
used for indexing multiple samples. Several systems for target enrichment have been 
developed. Their performances are measured by a number of parameters including 
sensitivity, specificity, reproducibility and uniformity of coverage. Moreover, cost, ease of 
use and the amount of DNA consumed are the other important factors specifically for 
handling clinical samples [232]. 
 
Sensitivity of enrichment is equivalent to the percentage of the targeted bases represented 
by at least a single sequencing read, while specificity denotes the percentage of sequence 
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reads that map to the target regions. Uniformity is the degree of evenness in sequence 
coverage across the target regions. Reproducibility is consistency of obtained results from 
replicated experiments [232]. Here we describe the most widely used target enrichment 
approaches and summarise the performance of each system. 
 
1.4.3.1. Target enrichment systems for next generation sequencing 
PCR based systems depend on primer pairs to amplify the target regions in the genome. To 
increase the throughput particularly for large target regions, a large number of amplicons 
must be generated. This is difficult to be achieved by uniplex PCR. Despite multiplexing of 
PCR through concurrent use of numerous primer pairs for amplification, the occurrence of 
multiple amplifications often cause interactions between primers which result in a limited 
number of amplicons successfully work simultaneously. To overcome those difficulties, other 
methods have been developed for target enrichment. 
 
Emulsion PCR has proven to be useful to overcome the nonspecific amplifications as each 
emulsion droplet which is occupied by a single template and the primers. However, emulsion 
PCR fails to produce long amplicons due to the restricted size of the droplets [233]. To 
overcome this problem, overlapping PCR for adjacent regions has been suggested. However, 
it is time consuming as individual PCR reactions need to be as efficient as possible to reduce 
the total amount of consumed DNA. Moreover, after recovery of the PCR products, 
normalisation is required to circumvent sequencing one dominant product over the others 
[232]. Altogether, PCR based methods are expensive, difficult to use and require high 
amounts of DNA which is estimated to be 8 µg for 1 Mbp of target region. Moreover, it loses 
specificity when targets of large sizes are amplified [232]. 
 
Molecular inversion probe (MIP) system works through circularising target DNA regions. The 
probes are single stranded oligonucleotide sequences. The central portion of the probe is 
composed of a common sequence so called linker while its two ends are complementary to 
specific sequences of target DNA. Upon annealing and ligation of the probes with the target, 
circularisation of the region of interest occurs. The reaction then subjected to enzymatic 
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digestion to break down un-circularised DNA. The circular DNA segments are then amplified 
by PCR. 
 
Compared to PCR based systems, this system is less expensive if large numbers of samples 
are processed. It is not cumbersome, as little as 200 ng of DNA is required and it offers more 
specificity with large target regions [232, 234].  
 
Hybrid capture systems are available in 2 forms either through array surface capture or in 
solution capture. In the array system, the target specific oligonucleotide probes are fixed on 
an array plate. After hybridisation of targeted DNA, the non-specific DNA hybrids are washed 
out. Various arrays with different capacities have been developed. Unlike PCR based 
methods, this approach is quicker and less laborious; however it is more expensive and 
consumes higher amounts of DNA irrespective of the size of the target region [232]. 
 
In solution hybrid capture uses DNA probes designed to target region of interest. In addition 
to the advantage of sample multiplexing and a greater capacity to capture large target 
regions, it is found to be superior to all the above mentioned systems. This is because it 
requires less DNA as it uses excess probes over DNA. Moreover, it is easy to use and yields 
more specific and uniform coverage than array based methods [232]. Examples are the 
SureSelect hybrid capture method and HaloPlex target enrichment systems. The latter is the 
newest version of in solution hybrid capture developed by Agilent Technologies in 2012 
[235]. It is the enrichment system that has been used in this study. It is more advantageous 
than SureSelect in that it requires less starting DNA; it is highly specific and provides more 
even genome coverage. On the other hand, a maximum of 5 Mbp of custom designed 
regions can be enriched, which is much less compared to 24 Mbp for SureSelect hybrid 
capture [234]. However, this limitation does not affect this project since the total size of DNA 
targets is much smaller than the maximum. Therefore, HaloPlex was selected for the current 
study shortly after it became available.   
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1.4.3.2. Next generation sequencing data analysis 
Analysis of huge amount of sequence data is still the bottle neck in NGS studies. This 
requires support by bioinformatics, which generally includes a data analysis pipeline, a 
database for annotation and reporting processes. NGS data analysis is usually composed of a 
three step computational framework, namely primary, secondary and tertiary stages. 
 
In the primary stage, sequencing signals are processed to produce raw sequence data. This is 
followed by identification of variants by mapping of the sequence reads to a reference 
genome. Finally, annotation and filtering of variants is executed. At each stage, an 
opportunity for quality control is provided to minimise the chance of false variant calls. In-
house or platform specific pipelines and external tools are required to process the data 
[236]. The output data from the primary stage of analysis is in a file of sequence information 
and quality score (FASTQ). The presence of the quality score helps trimming or filtering of 
poor quality reads.  
 
In the secondary stage, different mapping algorithms are integrated with flexibility in order 
to identify the best candidate mapping region and position of sequence variations. The 
output data file from this process is a Sequence Alignment Map (SAM) which can be 
compressed to a Binary Alignment Map (BAM) file using specific tools. These file formats can 
be uploaded to a freely available source called Integrative Genomic Viewer (IGV) to visualize 
the coverage and sequence of the aligned reads [237]. The output of the variant calling 
process is used to generate Variant Call Format (VCF) file that includes information on the 
variant’s chromosomal location and its quality metrics.  
 
In the last stage, VCF files are exported to external software for identification of common 
germline polymorphisms. This identification is possible because all the external software 
have integrated genomic mutation databases such as dbSNP and 1000 Genomes Project. 
Some software also have incorporated prediction tools to identify the potential significance 
of each variant [236]. The comparison to known databases helps to classify variants 
identified by NGS into different types, e.g. germline or somatic, biologically tolerated or 
deleterious, and clinically benign or damaging alterations. 
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1.5. Outline of targeted NGS using HaloPlex and Ion Torrent PGM 
Since HaloPlex is used to enrich target DNA and Ion Torrent PGM for the sequencing in this 
study, the details of these techniques are introduced in the following sections.  
  
1.5.1. Steps in target enrichment with HaloPlex 
There are five major steps in this system as presented in Figure 1.3. Firstly, genomic DNA is 
digested by sixteen restriction enzymes to form DNA fragments with a size ranging from 150 
- 550 bp. Secondly, the fragmented DNA molecules are circularised and hybridised to 
biotinylated probes which at both ends, are complementary to the target DNA. Thirdly, 
through ligation and multiple steps of washing the on-target DNA is retrieved by streptavidin 
coated magnetic beads while the off-target DNA fragments are removed. Fourthly, PCR is 
performed to amplify the captured DNA using universal primer complimentary to a sequence 
in the probes’ linker region. Lastly, size selection of the PCR product is performed using solid-
phase immobilisation AMPure XP beads which is carboxyl-coated magnetic particles. These 
particles can reversibly bind to negatively charged DNA in the presence of polyethylene 
glycol (PEG) and sodium chloride. This allows the free adapter, PCR primer dimers, as well as 
short PCR products (e.g. < 100 bp) to be removed from the library [238]. 
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Figure 1.3. Target DNA enrichment by HaloPlex system 
This system utelizes 8 sets of restriction digestion enzymes to fragment the genomic 
DNA. The fragments are then circularised by hybridisation to biotinylated probes which 
contain sequences complimentary to target DNA at both ends, barcodes, PCR primers 
and sequence primers. The target DNA is captured by streptavidin beads and the ends 
are then ligated. Only the properly ligated DNA is kept after multiple washing steps, 
which is subjected to PCR amplification. Following the PCR, size selection is performed 
to clean up the amplicons from free adaptors and primers. 
 
 
 
 
Following these major steps, quality of the enriched DNA library is verified using Bioanalyser 
or tape station. The quantified DNA libraries are then pooled if barcoded before being 
sequenced on a specific platform. 
 
1.5.2. Sequencing using Ion Torrent PGM 
Ion Torrent PGM became available in the market at the end of 2010, shortly before the start 
of this study. As introduced in section 1.3.2.7, it is a small bench top machine which uses 
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semiconductor sequencing technology instead of optical light detection. So far, it is the 
fastest and cheapest NGS platform.  
1.5.2.1. Versions of Ion Chip and their capacities 
Three different pH sensitive chips were available at time of this study; version 1 of Ion 314, 
316 and 318 Chips were replaced by version 2 for corresponding chips with improved total 
output. These chips have different output depending on the number of micro-wells on the 
surface of the chip (Figure 1.4) [239]. The higher the number of micro-wells, the higher the 
number of reads generated. Although the sequence output is also dependent on the 
sequence read length, the read length is largely dependent on the sequencing template 
preparation kit rather than the type of chips [240].  
 
 
Figure 1.4. Capacity scales of various Ion Torrent chips available at time of this 
study 
The number of micro-wells on the surface of the elliptical shaped area is shown for each 
chip. The sequence output depends on the type of chip used as well as on the type of the 
sequencing template preparation kit. 
 
 
Gb 
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1.5.2.2. Sequencing template preparation 
Initially, unique DNA library molecules are attached to the surface of beads (Ion Sphere 
Particles (ISP)). The DNA library molecules on the beads are then clonally amplified in 
emulsion PCR reaction. The emulsion droplet sequesters clonally amplified libraries on the 
surface of the beads. This process is performed using automated One Touch systems.  
 
1.5.2.3. Chip loading and signal generation 
Following the above steps, the ISPs with amplified DNA library are loaded on the Ion Chips. 
Through centrifugation, one ISP particle is deposited into each micro-well in the chip. Cyclical 
flooding of the wells with nucleotides automatically occurs. As presented in Figure 1.5, in 
each cycle, the incorporation of a nucleotide to the DNA molecules by the polymerase 
results in release of a hydrogen ion (H+) and reduction of pH [239]. Through detecting the 
difference in pH by the underlying pH sensor, the machine recognises whether the 
nucleotide is complemented or not. The pH shifts are then changed to electrical voltages. 
Therefore, no voltage will be found if no nucleotide is added while if 2 nucleotides are 
added, double voltage peaks are detected. However, adherence to this rule is diminished in 
the presence of long homo-polymeric sequences [219].  
 
 
Figure 1.5. Sequencing template preparation by emulsion PCR for Ion Torrent PGM 
In optimal emulsion PCR conditions, each ISP is attached by one DNA library fragment 
which then encircled by an emulsion droplet to clonally amplify the library on the 
surface of ISP. The ISP then loaded into the micro-well which is underlined by a pH 
sensitive layer. Upon nucleotide incorporation with cyclic flooding of the micro-wells, an 
H+ ion is released which can be detected and converted to electrical voltage and 
sequencing signals by the machine.  
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1.5.3. Ion Torrent sequence data analysis   
The most commonly used pipeline is Torrent Suite Pipeline which has been developed and 
optimised by the manufacturer for Torrent sequence data analysis (Figure 1.6). At the start 
of this project version (v3.2) was available. Later, a newer version (v4.2) was released which 
differed from the earlier version in that more stringent parameters were introduced to more 
accurately process signals, align reads and improve variant calling accuracy. The raw signal 
on the Ion Torrent Server is algorithmically converted in to linear sequence data in FASTQ 
format by Torrent Base Caller. This file can be exported to various external pipelines for 
downstream analysis. 
 
Alignment of the sequence reads to a reference genome yields BAM file format by Torrent 
Mapping Alignment Programme (TMAP). This programme uses a combination of Burrow 
Wheeler Aligners (BWA) and Sequence Search and Alignment by Hashing Algorithm (SSAHA) 
to refine the created mapping locations. The run summary contains chip loading, total 
output, sequence quality, mapping quality metrics and read length is displayed in the 
Torrent Browser Report summery page. By using the Torrent Variant Calling (TVC) plugin, 
custom specific algorithms can be applied to precondition variant recognition and calling. 
The output file generated after this process is Variant Call Format (VCF). This file contains the 
list of the called variants, their chromosomal location and quality metrics.  
 
The VCF file can be exported to various open access variant effect predictor software or to 
Ion ReporterTM Software either manually or automatically using Ion ReporterTM Uploader 
plugin. The automatic uploading operates from the initial step of BAM file processing.  
 
The advantages of using Ion ReporterTM Software are; firstly, time effectiveness as it needs 
less bioinformatics work to figure out the effects of the identified variants; secondly, the 
software integrated comprehensive public annotations which enable germline variant 
filtration; thirdly, it provides an organised workflow for comparing multiple samples. 
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Figure 1.6. Torrent Suite pipeline work flow 
The processors, quality control and output files in each stage of data processing are 
shown. The process starts from raw sequence data generation from conversion of 
electrical voltage signals and ends with variant calling which produce VCF file. 
 
 
1.6. Sources of error in NGS data 
NGS data like any other sequencing technology might harbour false positive or false negative 
variants. The sources for false positive calls might be PCR duplicates which tend to occur in 
the same position of unified PCR amplicons or at around the indels. The former is usually 
filtered out by filtering PCR duplicates, while the latter is usually prevented by specific [322]  
tools that locally realign the reads around the indels to the reference sequence for example 
genome analysis tool kit (GATK). More importantly, having accurate and proper reference 
sequence is important to correctly identify mismatched bases, in addition to the need of 
germline sequence information to distinguish somatic mutations. On the other hand, false 
negative results might be encountered if shallow coverage or no coverage of target genes 
were achieved. Details for avoiding false negative calls will be shown in subsequent chapters 
of this thesis. 
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1.7. The study hypothesis and aims  
As mentioned earlier, through application of massively parallel sequencing, novel genes have 
been found to be recurrently mutated in CLL. Some of these genes have been associated 
with disease course and response to treatment. It has been found that mutations occur at 
early disease stages and can expand either at the time of disease progression or after 
chemotherapy through selection of fitter and more resistant clones. However, it is still not 
fully understood whether and what interrelationships exist among these mutant clones/and 
or subclones to affect the evolutionary process and contribute to chemo refractoriness.    
 
It is therefore important to identify minor mutant subclones to guide treatment choice and 
predict prognosis at earlier stages. A sensitive, fast and affordable next generation 
sequencing technique is needed to meet this clinical demand. This prompted us to conduct 
this study with aims firstly to develop a deep sequencing method to detect known genomic 
alterations in targeted multiple genes relevant to biology and clinical outcome of CLL; and 
secondly to apply it to study evolution of those mutant subclones and their 
interrelationships in disease progression and resistance to treatment. Ultimately, we hope to 
develop novel molecular biomarkers for this disease. 
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Chapter 2. Development of ultra-deep targeted next generation 
sequencing based on combined HaloPlex target enrichment and Ion 
Torrent PGM techniques 
 
Chapter 2. Development of ultra-deep targeted NGS  
2.1. Introduction and aim 
Shortly before the beginning of this study, a number of novel gene mutations had been 
identified in heterogeneous cohorts of CLL cases with high throughput next generation 
sequencing (NGS), including whole genome (WGS) and whole exome (WES) sequencing 
techniques [241]. Their frequencies in CLL had been revealed and an association with 
advanced disease and drug resistance had been also implied. In subsequent studies, clonal 
evolution of chromosomal aberrations and its association with disease progression and 
outcome were described [117]. Evidence suggested that diverse CLL subclonal populations 
arising from a common ancestor can exist before and be selected by therapies. Thus highly 
fit or resistant subclones survive and eventually dominate [242]. These findings highlighted 
the need for a more sensitive targeted sequencing technique to identify the low level of 
these identified mutations in order to monitor clonal evolution and to predict disease 
outcome as early as possible. However, no such technique was available before this study. 
We were therefore prompted to firstly establish an in-house deep next generation 
sequencing approach.  
 
For this purpose, HaloPlex was selected for enrichment of target DNA and Ion Torrent PGM 
as the sequencing platform. HaloPlex target enrichment system was an in-solution 
hybridisation target capture method launched by Agilent shortly before this study. Given 
that it requires the least amount of g. DNA, provides scalable target size capture and enables 
sample multiplexing, it is an ideal candidate method for intended clinical application in the 
future. Ion Torrent PGM was among the most recently commercialised bench top next 
generation sequencing platforms. Owing to its scalability in throughput as well as its time 
and cost effectiveness as described in Chapter 1 (Section 1.3.2.7), it would be the best 
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nominee to be used for clinical service. Besides, this platform was in-house accessible and 
provided a software package for automatic data analysis. 
The aim of work presented in this chapter, was to step by step optimise conditions and 
validate results of a NGS deep sequencing method to test for mutations in a CLL gene panel 
designed for clinical diagnostic service in the future. 
 
2.2. Materials and methods 
 
2.2.1. CLL sample selection, processing and storage 
All CLL cell samples used for this study were cryopreserved in the Liverpool Leukaemia Bio-
bank with informed consent of patients and the approval of the Liverpool Research Ethics 
Committee. Diagnosis for all patients met the criteria recommended by 2008 IWCLL [21]. For 
the purpose of this chapter, we used 12 CLL samples to develop the highly sensitive NGS 
method. Five of these samples had previous archived DNA sequence information for TP53. 
These included a CLL case with wild-type TP53 and 4 cases with 4 distinct point mutations in 
TP53 as detected by functional analysis of separated alleles in yeast (FASAY) and Sanger 
sequencing. These mutated samples were used to test the sensitivity of the method by serial 
dilution of the point mutations with the TP53 wild type DNA sample. 3 of these TP53 
mutated samples as well as the wild-type DNA sample were also re-screened with the NGS 
method prior to performing the sensitivity test. Furthermore, 2 CLL cases with wild-type 
ATM and 5 cases with a total of 8 distinct mutations in ATM detected by the Ion Torrent 
PGM were sent to another centre for confirmation. Details of mutations in those samples 
are shown in Table 2.1.  
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Table 2.1. Clinical and genetic information of the CLL samples used in this chapter  
CLL-ID Gene 
mutation  
status 
Gene ploidy 
by FISH 
 
Chr. locations and 
N. changes (hg19) 
VAF % In-house methods 
applied 
CLL-A Mu TP53 Del 97% 17:7577539G>A 96 FASAY+Sanger 
CLL-1 Mu TP53 N 17:7576891T>A 
17:7577079 
24 
5 
FASAY+Sanger+PGM 
PGM 
CLL-4 Mu TP53 N 17:7577100T>C 74 FASAY+Sanger+PGM 
 
CLL-6 Mu TP53 N 17:7578394T>C 98 FASAY+Sanger+PGM 
 
CLL-11 Mu ATM N 11:108121763G>A 
11:108213973G>A 
37 
38 
PGM 
CLL-12 Mu ATM N 11:108186598T>C 98 PGM 
CLL-15 Mu ATM Del 64% 11:108143528T>G 
11:108168106-7InsC 
14.7 
14.4 
PGM 
CLL-17 Mu ATM N 
 
11:108186599A>G 
11:108216582-
86Del5Nt 
47 
48 
PGM 
CLL-18 Mu ATM Del 58%  11:108198445-
54Del10Nt 
 PGM 
CLL-22 Wt ATM N   PGM 
CLL-24 Wt TP53 N 
 
  FASAY+Sanger+PGM 
CLL-32 Wt ATM  N 
 
  PGM 
 
 
Mononuclear cells were prepared from patients’ peripheral blood according to a standard 
operating procedure (SOP) of the Bio-bank. Briefly, the heparinised whole blood was loaded 
on Lymphoprep TM (Axis-Shield PoC AS, Norway, d = 1.077) and centrifuged at 800 xg for 30 
minutes to collect the mononuclear cells. This was followed by washing and re-suspending 
the cells in ice cold RPMI-1640 supplemented with 10% fetal calf serum (both from Sigma-
Aldrich, UK). These cells were then mixed slowly on ice with the same volume of chilled 
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RPMI-1640 containing 20% Dimethyl sulphoxide (DMSO) (Sigma-Aldrich, UK) so that the 
concentration of cells was at 2 x 107/ml. Immediately, each 1-ml aliquot of this cell 
suspension was transferred to a labelled cryo-vial and left at -80 oC overnight before being 
stored in -150 oC freezers. With this procedure, purity of CD19+ lymphocytes (approximately 
equal to CLL cells) were > 90% [243]. Additionally, DNA from 5 CLL cases was received from 
the University of ULM, Germany to be screened for identification of TP53 mutations in a 
multicentre double blinded study organised by the European Research Initiative on CLL 
(ERIC).   
 
2.2.2. Genomic DNA extraction from CLL cells 
After thawing from -150 oC, the CLL cells were transferred to a clean 1.5-ml Eppendorf tube 
and centrifuged at 800 rpm in a bench-top micro-centrifuge for 1 minute. The pelleted cells 
were washed in 1 ml phosphate buffered saline (PBS) under the same centrifugation 
conditions before the culture media was removed. For genomic DNA (g. DNA) extraction, 
Qiagen AllPrepDNA/RNA Mini Kit (Qiagen, UK) was used following the manufacturer’s 
instructions. Briefly,  0.5 – 10 x 106 of washed and loosen CLL cells were disrupted 
completely by slowly adding and mixing by pipetting of appropriate volume (350 - 600 µl) of 
Buffer RLT (contained 1% of 14.3 M β-Mercaptoethanol (BME)) (Sigma-Aldrich, UK). 
 
The disrupted cells were homogenised by transferring them into a QIAshredder spin column 
(Qiagen, UK) and centrifuging at 13000 rpm in the micro-centrifuge for 2 minutes. Then, the 
homogenised lysate was transferred to an AllPrep DNA spin column and centrifuged again at 
10000 rpm for 30 seconds. The column bounded DNA was transferred to a new 2-ml 
collection tube and washed with 500 µl of the provided washing buffer AW1 (diluted with 
ethanol before use) by spinning at 10000 rpm for 15 seconds. This was followed by the 
second wash with 500 µl of buffer AW2 (diluted with ethanol before use) and spinning at 
10000 rpm for 2 minutes. After one more minute of centrifugation at 14000 rpm for 
complete dryness, the AllPrep DNA spin column was transferred to a new 1.5-ml collection 
tube. 
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At the DNA elution step, 50 µl elution buffer (EB) was added to the column.  Following 
incubation for 1 minute at room temperature, the DNA was spun from the column down to 
the collection tube at 10000 rpm for a minute. The DNA elution step was repeated again to 
maximize the yield if necessary. The isolated g. DNA was immediately stored at -20 oC 
following the assessment of purity and quantity. 
 
2.2.3. DNA quality assessment 
Determining the DNA quality and quantity is essential for downstream molecular biology 
work. Purity of the isolated DNA from Section 2.2.2 was assessed using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, UK). The isolated DNA was considered to be pure if 
the ratio of UV light absorbance at 260 nm to 280 nm fell within the range of 1.8 - 2.0. A 
value below 1.8 indicates protein contamination while a value above 2 indicates RNA carry 
over.  
 
2.2.4. Fluorometric DNA concentration measurements 
The DNA concentration was measured using Qubit® 2.0 Fluorometer and Qubit® dsDNA HS 
Assay Kit (both from Thermo Fisher Scientific, UK). This method is superior to Nanodrop for 
measuring DNA concentration as the high selectivity to double-stranded DNA (dsDNA) 
provides more accurate measurement of DNA concentration. According to the 
manufacturer’s manual, the Qubit® working solution was prepared by combining 1 µl of 
Qubit® dsDNA HS reagent and 199 µl of Qubit® dsDNA HS buffer. In order to produce a 
standard concentration curve for each batch of experiment, measurement of both the high 
or low concentration standards provided were performed. The standards were equilibrated 
to room temperature and then diluted in 190 µl of the prepared working solution using a 
Qubit® Assay Tube (Thermo Fisher Scientific, UK). For sample DNA measurement, 1 - 4 µl of 
the sample DNA were diluted in 199 -196 µl of the prepared working solution in each tube.  
Then each tube was measured on the Qubit® 2.0 Fluorometer. DNA concentration   4.5 
ng/µl was considered appropriate for downstream application. For samples with high 
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concentrations, therefore, a dilution was required to make the DNA concentration 5 ng/µl 
(range 4.5 - 6.5 ng/µl) with nuclease free water (Thermo Fisher Scientific, UK).  
 
 
2.2.5. DNA size measurement 
DNA size was measured at different steps of this study. This is because firstly the integrity of 
starting g. DNA is essential for the success of the test, as degraded DNA not only affects 
efficiency of the test but also the target coverage, and secondly, DNA size reflects outcome 
of DNA fragmentation, PCR amplification and target DNA purification. The following two 
approaches were used to measure DNA size. 
 
2.2.5.1. Agarose gel electrophoresis  
This technique was repeatedly used in this study to assess results of separation, 
quantification and purification of DNA fragments based on differential migration for DNA 
fragments with different number of base pairs (bp). An electrical field separates the 
fragments where high percentage gels are used for isolating small and low percentage gels 
for large DNA fragments. The size of separated bands of DNA is determined by comparison 
to DNA ladders with known molecular weight. 
 
Desired amounts of agarose powder (Sigma-Aldrich, UK) were weighed, then 100 ml of 
either 0.5 x Tris-borate- Ethyene-diaminen-tetra-acetic acid (EDTA) (TBE) buffer or 1x of Tris-
Acetate- EDTA (TAE) buffer was added in a clean autoclaved flask. By using a microwave, the 
dissolved powder was heated initially for 1 minute, and then for short times until the 
agarose was completely melted. A few minutes were allowed for the agarose to cool down 
before pouring it in to a gel tray. With the desired well comb in place, the gel was allowed to 
set at room temperature for at least 1 hour.   
 
After removal of the comb, the gel was placed in an electrophoretic tank (the loading slots 
were close to the negative electrode). Then the gel was covered with the same TBE buffer 
used in gel preparation. After mixing at a ratio of 5:1 with 6 x loading buffer (NEW ENGLAND 
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BioLabs, UK), separate g. DNA samples and a DNA standard ladder were loaded into the 
corresponding slots. Following electrode connection to a power pack, the electrophoresis 
was applied under 100 V constant voltages until sufficient displacement of the tracking dye 
(bromophenol blue) was observed (for up to 1 hour for that in TBE buffer or up to 16 hours 
for that in TAE buffer). Then the gel was stained in 200 ml of the corresponding buffer mixed 
with either 20 µl Ethidium Bromide (EtBr) (10 mg/ ml) (Sigma-Aldrich, UK) or 15 µl of Midori 
Green Advance DNA stain (GENEFLOW, UK) with continuous shaking for 20 - 40 minutes. 
DNA bands on the gel were visualised and recorded using an INGenius UV image system 
(SYNGENE, UK). 
 
2.2.5.2. On chip microfluidic electrophoresis 
For a more accurate measurement for DNA digest products and DNA libraries for next 
generation sequencing, this method was preferable because it is faster, produces a high-
quality real-time digital data without necessity of adjustment of electrophoresis time and 
consumes the least amount of DNA. It was performed using an Agilent 2100 Bioanalyser 
system and Agilent High Sensitivity DNA Assay Kit (both from Agilent Technologies, UK).  
The Bioanalyser system works depending on the passage of separate voltage through 16 
micro-channels. Of them, 4 are specified for loading gel dye mixture, 11 for DNA samples 
mixed with internal DNA upper and lower markers, and the remaining one for DNA size 
ladder. In this system, smaller DNA fragments migrate faster than the large ones. The signals 
of fluorescent dyes intercalated into DNA, are then detected and translated into separated 
DNA band images on gel and DNA peaks and positions in electrophoreogram. 
 
Following the manufacturer’s recommendation, the High Sensitivity DNA Dye and the High 
Sensitivity DNA Gel matrix were allowed to equilibrate from 4 oC to room temperature for 30 
minutes before use. 15 µl of the above dye was added to one vial of the gel matrix provided 
with the kit and properly mixed using a vortex. This mixture was then transferred to the spin 
filter and centrifuged at 6000 rpm in a bench-top micro-centrifuge for 15 minutes and stored 
away from light at 4 oC for later use. 
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The High Sensitivity DNA chip was loaded after placing it in to the chip priming station. 
Initially, 9 µl of the gel-dye mix was loaded into the specified gel loading well using a non-
filtered tip and by vertically directing the pipette tip until it touched the bottom of the well. 
The syringe plunger attached to the prime station was then positioned at the 1-ml mark. 
With the priming station closed, the plunger was pushed down to the 0-ml mark and clipped 
by the prime station for 60 seconds to allow the gel to distribute through the interconnected 
micro-channels of the chip. Then the plunger was released for 5 seconds to allow 
spontaneous air returning. Next, the plunger was slowly pulled back to the 1-ml mark before 
the prime station was opened. The same amount of the gel-dye mix was then loaded to each 
of the other three gel loading wells without creating any pressure. Then, 5 µl of the sample-
internal DNA marker were loaded in each of the other 12 sample wells including the ladder 
well. Following this, 1 µl of the kit provided DNA ladder or 1 µl of DNA samples was loaded 
into each corresponding well. The loaded chip was vortexed for 1 minute at 2400 rpm on a 
chip-adapted vortex mixer before placed in the Bioanalyser system. Finally, the Agilent 2100 
High Sensitivity assay was performed and results were visualised and analysed using the 
Agilent 2100 Software. 
 
 
2.2.6. Gene panel selection  
Based on information on CLL recurrent mutations found in WGS and WES studies by others 
before this study [149, 162, 163, 165], 15 genes were included in the targeted gene panel to 
be tested for somatic mutations. This was because all of them had an incidence of somatic 
mutations in  5% of CLL cases (a detail of each gene in the panel is described in Chapter 1, 
Section 1.2.4). In other words, genes with less frequent mutations were not selected. To 
increase the coverage depth, and therefore the test sensitivity, only mutated exons were 
targeted for the sequencing. The details for the targeted exons in the 15 genes are 
summarised in Table 2.2. 
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Table 2.2. Summarised information on the gene panel selected in this study 
Gene 
name 
Accession number 
(Ensembl) 
Chr. location 
( Ensembl) 
Total No. 
of exons 
Targeted exons 
in this study 
 
Pathway involved 
 
 
% of affected 
CLL cases  
 
Mutated exons 
identified in CLL 
References 
TP53 ENST00000269305 17p13.1 11 2-11 DNA damage- cell 
cycle control 
15-37% 2-11 [135, 138, 
244] 
ATM ENST00000278616 11q22.3 63 2-63 9-14% 2-63 [95, 142] 
SF3B1 ENST00000335508 2q33.1 25 7-19 RNA processing 10-17% 12-15 [102, 158] 
XPO1 ENST00000401558 2p15 25 11-16 3-5% 11-16 [13, 92] 
BIRC3 ENST00000263464 11q22.2 9 2-9 NFκB and 
inflammatory 
pathway 
4-24% 2-9 [163, 245] 
MYD88 ENST00000417037 3p22.2 5 2-5 2-10% 3-5 [168, 169] 
SAMHD1 ENST00000262878 20q11.23 16 1-16 7% 1-14 [176] 
NOTCH1 ENST00000277541 9q34.3 34 34 NOTCH signalling 5-15% 34 [114, 158] 
FBXW7 ENST00000281708 4q31.3 12 5-12 4-5% 5-12 [93] 
CHD2 ENST00000394196 15q26.1 39 12-36 Chromatin 
modification 
5% 16-35 [177] 
HIST1H1E ENST00000304218 6p22.2 1 1 5% 1 [198] 
POT1 ENST00000357628 7q31.33 19 5-19 Protection of 
telomeres 
4-8% 5-19 [173] 
LRP1B ENST00000389484 2q21.2 91 34-86 Tumour suppression 5% 34-86 [150] 
ZFPM2 ENST00000407775 8q23 8 8 5% 8 [246] 
PCLO ENST00000333891 7q11.23-21.3 25 2-24 9% 4-23 [191, 246] 
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2.2.7. HaloPlex probe design   
HaloPlex target enrichment probes were designed using Agilent SureDesign Software 
(Agilent Technologies, UK) (both Standard and Advanced Wizard settings for optimisation of 
probe number overlaid GC rich regions. See Sections 2.3.1.3 and 2.3.1.4 for more details). 
Briefly, the probes were designed for NGS platform (Ion Torrent PGM) with defaulted H. 
sapiens (hg19, GRCh37) as the human reference genome. All DNA targets were selected 
from the Ensembl archive (http://www.ensembl.org/Homo_sapiens). Genes with full 
transcripts were selected first to avoid missing any target exons [247]. Then these genes or 
exons were tailored by the genomic coordinate identifier to subtract non-targeted 
sequences (See Appendix 7.1 for more details).  
To construct the probes, the individual target genomic coordinates were submitted to the 
SureDesign Software. In addition, 10 bp from both 5’ and 3’ ends for each target region were 
extended outside of each target sequence to ensure coverage of splice sites junctions, as 
mismatches in these sites tend to have effects on gene expression by affecting the binding 
with the spliceosome for proper mRNA splicing [248]. The target regions and the amplicons 
covering the target sequences were viewed using USCS Genome Browser 
(www.http://genome.ucsc.edu).   
In total, 4606 amplicons that covered 135.420 Kbp of sequenceable region, including 52.324 
Kbp of targets were designed. The total sequenceable size and the average output of Ion 318 
Chip were used to estimate the average depth of coverage (the number of sequencing reads 
of each target base) for each sample sequenced.  
 
2.2.8. Target enrichment using HaloPlex technique 
Following the quantity and quality assessments (described in Sections 2.2.3 to 2.2.5),  40 µl 
of DNA at 4.5 - 6.5 ng/µl were prepared from each sample for target enrichment using the 
HaloPlex technique.  
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2.2.8.1. Shearing of genomic DNA 
 
HaloPlex Target Enrichment System (Agilent Technologies, UK) starts with enzymatic 
digestion of the genomic DNA. This creates fragments sized between 100 - 500 bp to 
accommodate the read length readable by Ion Torrent PGM. Furthermore, it forms 
complimentary sites critical for hybridisation of the designed probes. 16 different restriction 
enzymes were provided in two 8-well strips marked in red and green, respectively. This 
allowed digesting of each sample DNA in eight combinations.  
 
In a 1.5-ml Eppendorf tube, 34 µl of restriction enzyme buffer (RE) and 0.85 µl of bovine 
serum albumin (BSA) solution, functioning as a stabilizer of the restriction enzymes, were 
mixed for each sample digestion reaction. Then, 4 µl of the RE-BSA mixture was distributed 
into each of the 8 (0.2-ml) digestion tubes on ice for individual digestion enzyme 
combination. For each sample reaction, 0.5 µl of restriction enzyme from well A - H of the 
red strip was added respectively to the digestion tubes 1 - 8. In the same way, enzymes from 
the green strip were added to the 8 digestion tubes. This was followed by gentle vortexing 
and a brief spinning. Then on ice, 5 µl of the prepared g. DNA from one sample was added to 
each of 8 digestion tubes. After a gentle vortex and a brief spin, the digestion tubes were 
incubated at 37 oC for 30 - 55 minutes in a thermo-cycler. The temperature of the preheated 
lid was set at 45 oC to prevent evaporation. The reaction was then terminated by 
transferring these tubes to a -20 oC freezer for further processing next day.  
 
2.2.8.2. Controls for g. DNA digestion  
 
In 8 different 0.2-ml tubes, 4 µl of each the 8 digestion reactions from the CLL samples were 
heated at 80 oC for 5 minutes to inactivate the restriction enzyme. 1 µl of each heat 
inactivated restriction reaction and corresponding undigested DNA as control were loaded 
on a Agilent High Sensitivity DNA Assay chip using Agilent Bioanalyser 2100 for assessing 
results of the digestion as described in Section 2.2.5.2. 
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2.2.8.3. Hybridisation of g. DNA to HaloPlex probe and sample barcoding 
 
In this step, the designed target specific probes selectively hybridised to target regions of the 
genome. These single strand probes with a length of 100 bp, including index bound to both 
ends of the target DNA fragments to form nicked DNA circles which facilitate subsequent 
ligation. Up to 16 molecular barcodes were also incorporated into each batch of DNA 
samples. They were later used for identification of specific samples in the data analysis of 
pooled DNA sequencing. 
 
For each DNA sample, 47 - 50 µl of supplied Hybridisation Solution and 17 - 20 µl of the 
HaloPlex Probes were mixed in a 0.2-ml hybridisation tube. After a brief vortex and spin, 10 
µl of a molecular barcode was added to the sample tube. Then the 80 l of digested DNA 
(Section 2.2.8.1) were transferred individually from the 8 digestion tubes to the hybridisation 
tube and carefully pipetted up and down for at least 10 times. This was to properly mix DNA 
fragments with the probes and the barcode and completely inactivate digestion enzymes in 
the hybridisation buffer. Following a brief spin, the hybridisation tube was transferred into a 
thermal cycler block with temperature of the preheated lid set above 95oC and the 
hybridisation started under conditions presented in Table 2.3. 
 
 
Table 2.3. Conditions for hybridisation of g. DNA with HaloPlex probes and for 
barcoding  
Step Block temperature Time 
1 95 oC 
 
10 min. 
2 54 oC 
 
3 hr. 
 
 
In the meantime, a required volume of HaloPlex beads (40 µl/ sample) for the next process 
were transferred from the 4oC storage to a 0.2-ml or 1.5-ml tube to allow the bead 
temperature to restore to room temperature within 30 minutes. The bead tube was then 
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placed on a magnetic rack for 5 minutes to allow the beads to sink down before the 
supernatant was removed. Then, the same volume of the provided Capture Solution was 
added to re-suspend the beads in the tube which had been separated from the magnetic 
rack.  
After completion of hybridisation reaction, 40 µl of the homogenised HaloPlex bead 
suspension was added immediately to the hybridisation tube and mixed by pipetting up and 
down 15 times. The tube was then left at room temperature for 15 minutes.  
Following the 15 minutes incubation, the tube was briefly centrifuged and placed on the 
magnetic rack until the solution became clear. Then, the supernatant was discarded using a 
pipette set to 200 µl. By this step, the entire off-target and non-hybridised DNA was isolated 
from the target region. The capture reaction was removed from the magnetic rack and 100 
µl of Wash Solution was added and mixed by pipetting up and down for 10 times. This tube 
was then incubated at 46 oC for 10 minutes in a thermal cycler block with preheated lid. 
Immediately following the completion of incubation, the tube was briefly spun and re-placed 
on the magnetic rack until the solution became clear. The supernatant was carefully 
removed using a pipette set to 120 µl firstly and another at 20 µl. 
 
2.2.8.4. Ligation of the captured (circularised) DNA fragments 
In this step, the nicks of the circularised HaloPlex probe bounded target DNA are closed by 
using a DNA ligase. The ligation master mix was prepared by combining 47.5 µl of Ligation 
Solution and 2.5 µl of DNA Ligase for each sample reaction. After vortexing and brief 
spinning, 50 µl of the ligation master mix was added to a tube containing captured DNA and 
mixed by pipetting up to 15 times. The reaction tube was incubated at 55 oC for 10 minutes 
using a thermal cycler programme set with a heated lid. Then, the tube was taken out from 
the thermal cycler and briefly centrifuged before transferred to the magnetic rack. After the 
solution became clear, the supernatant was carefully discarded with a pipette set to 50 µl. 
Next, the tube was removed from the magnetic rack and then loaded with 100 µl of 
provided Saline Sodium Citrate (SSC) Buffer to re-suspend the beads by pipetting up to 10 
times. Following a brief spin, the tube was placed into the magnetic rack, and the clear SSC 
supernatant was removed with a pipette set at 120 µl. 
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The final elution step of the bead bound DNA was performed by adding 25 µl of freshly 
prepared 50 mM NaOH (Sigma-Aldrich, UK) to the tube. After mixing by carefully pipetting 
up to 10 times, the sample was incubated at room temperature for 1 - 2 minutes. Then, the 
tube was centrifuged briefly and transferred to the magnetic rack.  Probe-bound DNA in 20 
µl of the cleared supernatant was collected and used in the next step for PCR amplification. 
 
 
2.2.8.5. PCR amplification of DNA libraries 
PCR master mixture was prepared and kept on ice by combining the provided PCR primers 
and other reagents in a 0.2-ml tube as presented in Table 2.4.  
 
 
 Table 2.4. PCR components for HaloPlex captured DNA library amplification 
Supplier of reagents not 
provided with HaloPlex kit 
Reagent Amount for  
1 reaction (µl) 
(Agilent Technologies, UK) 5x Herculase II Reaction Buffer 10 
dNTP mix (100 mM) 0.4 
 HaloPlex Ion primer 1 (25 µM) 1.0 
HaloPlex Ion primer 2 (25 µM) 1.0 
( BD Biosciences, UK)  2 M Acetic acid 0.5 
(Agilent Technologies, UK) Herculase II Fusion DNA 
polymerase 
1.0 
(Sigma-Aldrich, UK) Nuclease-free water 16.1 
 Total 30 
  
 
 
The 20 µl of eluted target DNA was added to the above PCR mixture and PCR was performed 
in a lid-heated thermal cycler (Mastercycler AG Eppendorf, Germany) with the following 
programme shown in Table 2.5. 
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Table 2.5. Programme temperature settings for PCR amplification of HaloPlex 
captured target DNA libraries 
 
Step No. of cycles Temperature 
(oC) 
Time 
1 1 
 
98  2 min. 
2 22 
 
98   30 sec. 
60    30 sec. 
72    1 min. 
3 1 72    10 min. 
4 1 8   Hold 
          
 
 
The PCR product (amplified DNA library) was used in next step either immediately or after 
overnight storage at -20 oC. 
 
2.2.8.6. Size selection 
In this step, Agencourt®AMPure® XP beads (Beckman Coulter, UK) were used to purify the 
amplified DNA libraries from any excess probes and primers.  
 
Before starting, the XP beads were equilibrated to room temperature for 30 minutes. The 
bead suspension was vigorously vortexed until the suspension became consistent in colour. 
For each sample to be purified, 50 - 100 l of homogenous beads was mixed with 20 - 40 l 
of nuclease free water in a 0.2-ml PCR tube by vortexing. Accordingly, either 70 or 140 µl of 
diluted bead was prepared to purify 20 or 40 µl of the amplified library DNA, respectively. 
The 90 - 180 µl sample-bead mixture was incubated for 5 - 15 minutes (at room 
temperature) with continuous shaking using a shaker. The tube was then briefly centrifuged 
and placed in 0.2 ml tube-adapted magnetic rack for 5 minutes to clear the solution. Using a 
pipette set at 100 or 200 µl, the supernatant was carefully removed. Any residuals were 
discarded by a pipette set at 10 µl. While the tube was retained in the magnetic rack, an 
ethanol washing step was performed twice by slowly adding the appropriate volume (100 - 
200 µl for the sample-bead mixture of 90 µl -180 µl, respectively) of freshly prepared 70% 
molecular grade ethanol (Sigma-Aldrich, UK). After each 30 seconds wash, the supernatant 
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was removed with a pipette. The residual ethanol was carefully removed with a 20 µl tip and 
the beads were left in the tube with lid open for air drying for 5 minutes. The dried bead 
tube was removed from the rack and the beads were mixed with 20 - 40 µl of 10 mM Tris-
HCl buffer (Sigma-Aldrich, UK) by pipetting up and down for 15 times.   
 
To allow complete elution, the tube was incubated at room temperature for 2 minutes and 
then placed in the magnetic rack until the solution cleared. The supernatant (20 - 40 µl) was 
then transferred in to a fresh 0.2-ml PCR tube for repeating AMPure XP bead purification 
and then stored at -20 oC. 
 
 
2.2.9. Validation of DNA library amplification 
This verification step is essential before proceeding to the next step not only for validating 
efficiency of the library amplification, but also for determining purity and quality of the 
resulting library. For this purpose, 1 µl of each purified DNA library was loaded on an Agilent 
High Sensitivity DNA Assay chip using Agilent Bioanalyser 2100 as in Section 2.2.5.2. 
Successfully amplified and purified DNA library appeared as DNA fragments sized from 150 
to 550 bp, and did not contain readily visible free probes and PCR primers (35 - 100 bp). 
 
 
2.2.10. Nanomolar concentration measurements, pooling of DNA libraries and 
calculating the dilution factor 
 
Measurement of DNA library concentration in (ng/µl) was achieved by using Qubit® dsDNA 
HS Assay Kit as in (Section 2.2.4). The average size (in bp) of DNA fragments as measured 
with the Bioanalyser, was used to calculate approximate molecular weight (MW) for double 
stranded (ds) DNA based on the following: the average molecular weight of the four di-
nucleotides: G, C, A and T being 303.7 and the molecular weight of triphosphate molecule 
from the end of each DNA strand being 78.95. The following equations were used in this 
calculation  
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1). MW of dsDNA = (Average number of nucleotides x 607.4) + 157.9  
2). Nanomolar (nM) concentration of the DNA library = DNA library concentration (ng/ µl) ÷ 
MW of ds DNA x 1000 
 
Nanomolar (nM) library concentration was used for calculating the dilution factor to obtain 
the desired DNA molecules per 5 µl of diluted DNA library. 70 million - 140 million DNA 
molecules are required to obtain maximum number of mono-clonally enriched ISPs with 
lowest polyclonal enrichment. To quantitatively equalise the multiple (4 - 5) DNA libraries co-
sequenced on an Ion chip, the concentration of individual libraries were adjusted with 
dilution before sample pooling. The pooled DNA libraries finally reached at 10 - 25 pM in no 
less than 25 l. They were then vortexed and kept on ice until used. 
 
 
2.2.11. Preparation of template- positive Ion Sphere Particles 
At the end of this step, each solid spherical particle is expected to be attached by a single 
DNA library molecule. Through emulsion PCR, the DNA library clonal amplification occur on 
the surface of the ISPs which then by loading and directional centrifugation of the loaded 
chip, are dislodged into the micro-wells.  
 
For this purpose, initially Ion OneTouchTM 200 Template Kit v2 DL (Life Technologies, UK) and 
Ion OneTouchTM Instrument (Life Technologies, UK) were used. Later, due to discontinuation 
in market, they were replaced by Ion PGMTM Template OT2 200 Kit (Life Technologies, UK) 
and its corresponding compatible instrument Ion OneTouchTM 2 (Life Technologies). The 
procedural steps of the two systems were similar, except the new system seemed to 
perform better and was more cost effective due to eliminated request for Argon gas source. 
 
According to the manufacturer’s manual, the whole procedures including DNA library 
amplification, recovery of the enriched ISP and annealing of the sequencing primers were 
carried out consecutively. Detailed experimental steps are found in the Appendix 7.3.1.  
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2.2.12. Sequencing on the Ion Torrent PGM 
All reagents were from the Ion PGM™ Sequencing 200 v2 Kit (Life Technologies, UK) and Ion 
318™ Chip Kit v2 (Life Technologies, UK). Cleaning, initialising and chip checking steps were 
performed before loading of the sequencing chip with the template positive ISP. 
Automated cleaning of the Ion Torrent PGM machine (Life Technologies, UK) was performed 
with either 18 MΩ water alone or with Chlorite followed by 18 MΩ water washing. Detailed 
information on each step conducted can be found in the Appendices 7.3.2, 7.3.3 and 7.3.4. 
 
2.2.13. Assessment of the sequencing runs 
The quality of a run is dependent on many factors including quality and quantity of the 
template library and chip loading density. In each sequence run, the server provided 
summary statistics reports in accordance to the chip type and the sequencing kit used in the 
experiments. 
2.2.14. Data collection, processing and reporting 
Torrent Suite Pipeline v4 (Life Technologies, UK) was used for raw sequencing data 
processing. The output files were sorted by the HaloPlex Barcode specific for individual 
samples combined in each run. Total sequenced bases, the number of bases with Q scores 
>20, the number of reads and the mean read lengths were then calculated. Compared with 
the human reference genome hg19, the numbers of aligned reads were determined. The 
whole customised library target region BED file obtained from the SureDesign (HaloPlex) 
software was then uploaded for analysis with Torrent Server Reference and Target Region 
tags. In the same way, an individual target region BED file for each gene was created for 
assessing the coverage of each target region by Coverage Analysis Plugins (v4.4.2.2). A total 
of 544 coverage analyses were performed to identify average base coverage depth, 
uniformity of coverage and percentage of base coverage for the DNA targets studied.  
Torrent Variant Caller (TVC) Plugin (v4.2.1.0) was used to call somatic variants. With the 
hg19 as reference, analysis was performed with or without confinement to target and hot 
spot regions. The generic PGM analysis stringency settings were tested and customised 
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based on known levels of multiple mutations in diluted patient samples. Through adjusting 
various parameters including minimum frequency of variant alleles, minimum quality and 
coverage, and maximum strand bias, the customised settings should maximise the specificity 
and precision of analysis. After completion of TVC runs, a list of variants’ chromosomal 
positions, reference and variant bases, allele frequencies, with quality and coverage metrics 
were produced for each sample. After visualising each called variant by Integrative Genomic 
Viewer (IGV), the output VCF files were uploaded to Ion Reporter Software v5.0 (Thermo 
Fischer Scientific, UK) using the user specific account. After defining the imported sample 
files, the analysis work flow (set to Annotate Variants) was launched. The results were 
viewed for details of gene ID, variant location, c. DNA and protein change, gene ontology 
and functional consequences for each variant. The software integration with catalogue of 
somatic mutations in cancer (COSMIC-65) (http://www.sanger.ac.uk/cosmic), single 
nucleotide polymorphism (dbSNP-137) (http://www.ncbi.nlm.nih.gov/SNP) and 1000 
genome project (http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/) databases 
helped in determining the type of each variant. 
With the above information about variants in each sample, a master data file was produced 
in Excel 2010 spreadsheet. The data sheet contained data on gene ID, chromosomal 
position, reference allele, variant allele, c. DNA position, codon and amino acid change. 
Moreover, information from publicly available databases including dbSNP ID, COSMIC ID, 
and from in silico bio-informatics tools including sorting tolerant from intolerant (SIFT) 
(http://sift-dna.org), polymorphism phenotyping (PolyPhen-2) 
(http://genetics.bwh.harvard.edu/pph2/) scores were recorded. Furthermore, allele 
frequency, quality and coverage metrics for all the identified variants in the sequenced 
samples in this study were included in this datasheet. This enabled multiple samples to be 
compared and shared variants between different samples to be identified. Moreover, 
replicates of sequencing experiments of the same case and sequential samples of individual 
patients were compared and tracked using the same spreadsheet. 
For the purpose of identifying somatic non-synonymous mutations, variant calls outside 
coding regions of targeted genes were firstly filtered out. The remaining variants were then 
compared to those reported in dbSNP-137 and 1000 Genome Browser to further filter out 
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variants that were population-study confirmed germline polymorphisms. Next, the 
candidate somatic non-synonymous variants were visually checked in IGV display. Finally, 
the amino acid changes resulted from these somatic non-synonymous variants and their 
biological effects were determined and estimated by comparison with public databases 
including COSMIC-65, SIFT and PolyPhen-2.    
 
2.2.15. Allele specific PCR (AS-PCR) for validation of low level mutations 
AS-PCR was used to test the fidelity of mutations detected by Ion Torrent PGM in a 
sensitivity test experiment in which different TP53 mutations were diluted to 20% - 0.2% 
variant allele frequency (VAF). Primers were designed based on human TP53 sequence (NC-
000017.11, NCBI) and using a common tool (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). The last nucleotide at the 3’ end of the reverse primers were complimentary to 
either wild type (Wt) or mutant (Mu) allele, while a consensus forward primer was designed 
for both wild-type and mutant alleles  (Figure 2.1). All primers were ordered from Eurofins 
Genomics, Germany. 
 
 
 
 
    
 
Figure 2.1. Locations of low level TP53 mutations and the primers used for As-PCR 
The 3’ end nucleotide of each reverse primers was complimentary to either Wt (black 
arrows) or Mu alleles (red arrows) for each mutation (red dots), while consensus 
forward primers (orange arrows) were used for both wild-type and mutant alleles 
amplifications. 
 
          
Exon 5 Exon 6 Exon 7 Exon 8 Exon 9 
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Qiagen Taq polymerase kit was used and the amplification reactions were conducted under 
optimised conditions using the specific primers designed as summarised in Table 2.6. The 
products of AS-PCR were then examined by electrophoresis. For this purpose, 10 µl of each 
PCR product was mixed with 2 µl of 6 x loading dye and loaded along a 100 bp DNA size 
marker on 1% agarose gel. The gel was run at a constant 100 V in 0.5 x TBE for 90 minutes. 
The gel was then visually examined under UV illumination after staining with EtBr as 
described in Section 2.2.5.1.  
 
 
2.2.16. Statistics 
In this Chapter, the tendency of centralisation and dispersion of data distribution was 
presented as mean  standard deviation (SD), or mean  standard error (SE) if used for multi 
groups which had unequal number of samples. Pearson correlation was used to investigate 
relations between two variables, with the  level set to 0.05 for two side test. The IBM SPSS 
(version 20) was employed for all statistical analyses. 
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Table2.6. The allele specific PCR information on variants, primer sequences and corresponding PCR condition for confirmation 
of 4 variants in TP53 gene 
Location 
and 
nucleotide 
change 
(ref. hg19 ) 
Codon  
changes  
Amino 
acid 
changes 
Primer names  Primer sequence (5’-3’)  
NCBI Reference Sequence 
Accession Number  
(NC-000017.11) 
PCR components  
50 µl in 0.2-ml thin walled PCR tubes 
Amplification condition 
* Size of 
PCR 
products 
(bp) 
Primer 
(Pmole) 
MgCl
2
 
(mM) 
dNTP 
(mM) 
GoTaq 
(U) 
g.DNA 
(ng) 
5x 
buffer 
(µl) 
DMSO 
(µl) 
Temp. 
(
0
C) 
Time 
(Sec.) 
No. of 
cycles 
Wt. Mu. 
17:7577079 
C>A 
GAG>TAG p.287 
E/X 
287G-Rev (Wt) 
287T-Rev (Mu) 
280S-For 
CCCTTTCTTGCGGAGATTCTC 
CCCCTTTCTTGCGGAGATTCTA 
TACCCATCCACCTCTCATCAC 
20 
----- 
20 
----- 
20 
20 
75 10 1.25 84 10 ------ 94 
59 
72 
30 
30 
30 
32 338 
17:7576891 
T>A 
 
AAG>TAG p.319 
K/X 
319A-Rev (Wt) 
319T-Rev (Mu) 
280S-For 
CTCCATCCAGTGGTTTCTTCTT 
CTCCATCCAGTGGTTTCTTCTA 
TACCCATCCACCTCTCATCAC 
20 
----- 
20 
----- 
20 
20 
75 10 1.25 84 10 ------- 94 
59-60 
72 
30 
30 
30 
32 527 
17:7578394 
T>C 
CAT>CGT p.179 
H>R 
179A-Rev  (Wt) 
179G-Rev (Mu) 
179S-For 
CGCTATCTGAGCAGCGCTCAT 
CGCTATCTGAGCAGCGCTCAC 
AAAGCTCCTGAGGTGTAGACG 
10-20 
----- 
10-20 
----- 
10-20 
10-20 
25-75 2.5-10 1.25 60 10-20 +/- (1-2) 94 
59-67 
72 
30 
30 
30 
30-32 334 
17:7577100 
T>C 
AGA>GGA P.280 
R>G 
280A-Rev (Wt) 
280G-Rev (Mu) 
280L-For 
CCTCTGTGCGCCGGTCTC CT 
CCTCTGTGCGCCGGTCTC CC 
GAAGACTCCAGGTCAGGAGC 
20 
----- 
20 
----- 
20 
20 
25-75 7.5-10 1.25 70 10 ------ 94 
59-66 
72 
 
30 
30 
30 
 
32 
 
427 
 
*The initial denaturation temperature of 94 oC for 3 minutes and the final extension temperature of 72 oC for 5 minutes were used in common for all the 
PCR reactions
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2.3. Results 
2.3.1. Modification and optimisation of test conditions 
2.3.1.1. Good integrity of starting g. DNA 
To avoid missing targets, it is important to start the NGS with intact g. DNA. For this reason, 
the integrity of extracted g. DNA from each sample was examined before fragmentation.  In 
fact, starting g. DNA extracted from all samples used in this study were intact, appearing as a 
main band of > 10000 bp as measured with agarose gel electrophoresis as shown as an 
example in lanes 2 and 4 of Figure 2.2.A, or with Bioanalyser as shown in Figure 2.2.B. This 
was further verified by amplification of a house-keeping gene fragment of different sizes. 
Compared to partially degraded g. DNA from a FFPE sample, a large fragment (980 bp) of 
GAPDH was readily amplified using g. DNA extracted from CLL samples for this study as 
shown as an example in Figure 2.2.C and D. 
 
 
                        
                             
A 
1               2                                             3            4  
Chapter 2. Development of ultra-deep targeted NGS 
106 
 
 
 
 
 
B 
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Figure 2.2. High integrity of starting g. DNA 
As an example, 1.5 mg g. DNA extracted from two cell samples (CLL-1 and CLL-4) were 
examined by electrophoresis on agarose gel before (lanes 2 and 4) and after (lanes 1 and 
3) digestion with EcoR1 (A). The undigested, but partially degraded g. DNA prepared 
from a lacrimal sac FFPE sample and g.DNA from CLL cells of CLL-1, 4, 12, 6, 11, 17 and 
18 were visualised in Bioanalyser electrophoreogram (B). Electrophoresis on agarose 
gel showing GAPDH fragments of 110, 330 and 980 bp amplified in PCR from the intact g. 
DNA of CLL- 6 (C) and CLL-11 (D) and partially degraded g. DNA prepared from the 
lacrimal sac FFPE sample (C). 
 
 
2.3.1.2. Optimisation of digestion time for g. DNA fragmentation 
The length of DNA fragments is equally important as the integrity of the starting DNA. 
Fragments that are too big or too small affect the efficiency of target enrichment, 
amplification and/or sequencing. For Ion Torrent PGM, the ideal size of these DNA fragments 
is between 100 and 500 bp and these are determined by multiple factors, including the 
restriction map of digestion enzymes used and the limit of sequencing read length that the 
platform reaches. Conditions for digestion are keys for controlling the size of DNA fragments. 
Since most of them are fixed, we could optimise the condition only by adjusting durations of 
the digestion. Experiments digesting a CLL g. DNA sample for 4 different durations, including 
D 
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the recommended 30 minutes found that the best result was from the digestion for 55 
minutes, as the under-digestion was evident with the other time points tested, as shown in 
Figure 2.3.  
  
 
 
Figure 2.3. Comparison of g. DNA fragment size resulted from different digestion 
durations 
G. DNA from a CLL sample (CLL-1) digested with HaloPlex restriction enzymes for A. 20 
minutes, B. 30 minutes, C. 45 minutes and D. 55 minutes was examined with Bioanalyser 
electrophoreogram. The curves of fluorescent intensity between two peaks (DNA size 
markers) present the average and range of digested g. DNA. 
 
 
2.3.1.3. HaloPlex probe design and coverage depth achievable 
As shown in Table 2.7, there were a total of 246 target regions in the 15 genes with a total 
size of 52324 bp for this study using HaloPlex Standard Design Wizard (Agilent Technologies, 
UK). Since each target read was covered by multiple probes which could extend to adjacent 
regions, the number of amplicons was 4585 and the sequenceable size was 135420 bp. 
Although the software recognised all the input genomic coordinates and estimated the 
coverage for all the targets to 100%, the target regions were not covered uniformly. Thus 
some regions, particularly those with AT- or GC-rich sequences, had less chance to be 
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covered. To improve the coverage of a GC-rich region in exon 4 of TP53 gene (75 bp in 
length), HaloPlex Advanced Design Wizard was used and 19 additional probes (amplicons) 
were created. The software recognised these regions and reported them as 3 additional 
regions. Therefore, the total number of targets, amplicons and sequenceable region 
increased to 249, 4604 and 136425 bp, respectively. However, the additional targets and the 
sequenceable regions still located within the previous target region and therefore should not 
be counted as increased width.   
 
Table 2.7. Information about two designs for HaloPlex probes  
Variables Standard Advanced 
Number of genes 15 15 
Number of target regions 246 249 
Number of amplicons 4585 4604 
Target region size (bp) 52324 52475 
Total sequenceable design size (bp) 135420 136425 
                        
 
In order to have the test sensitive enough to detect as low as 1% variant alleles in patients’ 
samples, we planned to achieve an average target coverage depth to 2000 x with the 
minimum number of variant reads being 20. Based on our design, the estimated average 
coverage depth for each targeted base was calculated as follows: 
Average coverage = average sequencing output of Ion chip /total sequenceable design size x 
number of samples = 1 Gbp / 135.42 Kbp x 4 = 1846 x 
Given that the coverage for adjacent regions is smaller, the depth for the targets is bigger 
than the figure calculated. To keep a balance between test sensitivity and cost, we planned 
to include 4 samples on a chip for sequencing with an expected average coverage depth for 
targets of around 2000 x. 
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To test if the goal could be achieved, 24 DNA libraries prepared from the 11 local CLL 
patients and 5 from the ERIC study (Section 2.2.1) were prepared and sequenced on 6 chips. 
The sequencing quantity and quality are presented in Table 2.8. All experiments were 
conducted using the successive target enrichment and sequencing approaches described in 
Sections 2.2.9 - 2.2.16. The results for all the experiments showed highly specific target 
enrichment as shown in an example in Figure 2.4. Moreover, the produced sequencing data 
were of high quality and the estimated coverage depth was approached in each experiment. 
As expected, the average on-target coverage reached to 2198  192 (Mean  SD) when 4 
DNA samples were sequenced on each Ion Chip318, while it reduced to 1789  259 when 5 
samples were on each chip. These results clearly showed that our plan was achievable which 
allowed us to keep the total cost for enrichment and sequencing each sample around £265. 
 
2.3.1.4. Improvement of uniformity and target coverage in a GC-rich region with 
boosted HaloPlex probe design  
Although a satisfactory average uniformity and coverage depth were achieved as shown 
above, some target regions might not be properly covered. This is because the high 
throughput sequencing technique cannot produce absolute uniformity for all the targeted 
regions mainly due to variability in nucleotide composition. GC- or AT-rich target regions, as 
defined by presence of > 55% GC or AT in the sequence composition, frequently hamper the 
efficiency of the target amplification by PCR [249]. When examined all of the 246 target 
regions using IGV, we found a 75-nucleotide GC-rich (73%) region in exon 4 of TP53 
(chr17:7579400-7579475) that was not covered at all. 
To overcome this problem, we applied the advanced setting in design to boost probes and 
enhance their overlay over the GC-rich region. As expected, this approach indeed 
significantly improved the uniformity (from 73.41% to 92.82%) and target coverage (78.28% 
to 100%, for  100 x) for that target region (Table 2.9). These improvements were 
predictable at the time of the advanced probe design in the BED file and clearly visualised 
after target enrichment and sequencing as shown by IGV (Figure 2.5).
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Table 2.8. The sequencing performance and the average depth of coverage of 6 sequencing runs used in production of data in 
this chapter * 
Parameters Run-1 Run-2 Run-3 Run-4 Run-5 Run-6 Mean ±SD 
Number of DNA libraries loaded 4 4 4 5 4 4  
Sample’s ID CLL-1,4&24 CLL-1,4,6 &24 S-20,5,1&0.2 ERIC-1,2,3,4&5 CLL-11,12,17&18 CLL-15, 22, 30 & 32   
% of ISP loaded wells 78 82 63 64 63 77 71±8.7 
Output (Mbp) 815 827 725 735 792 899 798.83±64.28 
% of polyclonal reads 13 12 24 19 18 28 19±6.1 
Total useful reads 5981418 6000875 5073100 4946051 5379471 5587162 5494679±44581 
Av. coverage depth on targets 2200 2466 1978 2008** 2173 2368 2198.83±192.79 
Av. No. of bases with AQ17 
(Mbp)/chip 
729 784 636 653 705 818 720.83±71.47(180
.20±17.8/sample) 
Av. No. of bases with AQ20 
(Mbp)/chip 
665 718 572 618 646 762 663.5±68.44(165.
87±17.2/sample) 
Median read length (bp) 137 141 142 146 144 161 145.16±8.32 
Av. uniformity of coverage 91.1 92.56 92.40 92.43 93.31 92.37 92.36±0.7 
Av. % target base coverage at 1x 99.46 99.88 99.59 99.75 99.68 99.49 99.64±0.16 
20x 99.31 99.83 98.69 98.80 98.85 98.85 99.05±0.43 
100x 98.20 97.32 97.19 97.10 97.68 97.68 97.52±0.4 
Av. % of reads on target 89.29 93.47 90.88 90.85 89.45 89.45 90.56±1.59 
Sequencing kit used One Touch One Touch One Touch One Touch 2 One Touch 2 One Touch 2  
*In Run-1, CLL-1 & CLL-6 marked in bold had 2 DNA preparations loaded on the same chip. CLL1, 4 and 24 from Run-1 were subjected to DNA preparation with probe boost 
for GC rich regions and re-sequenced on another chip in Run-2. 
** The figure is equivalent to that for 4 DNA libraries sequenced on an Ion chip.
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Figure 2.4. An example of high specificity of HaloPlex target enrichment 
A part of sequence reads (horizontal grey bars) covering the targeted exons 2 and 3 and 
part of exon 4 (solid blue bars) of MD88 gene were shown together with the coverage 
depth (vertical grey or colour bars above the reads). There was no off-target coverage 
on exon 1 of this gene and an exon of the adjacent gene ACAA1, as well as intron-only 
regions. 
 
 
Table 2.9. Comparison of performance of two sets of HaloPlex probe in 3 CLL 
samples sequenced with or without probe enhancement for a GC-rich target 
region within exon 4 of TP53  
Parameters Sequencing results without 
boosted HaloPlex probe 
Sequencing results with 
boosted HaloPlex probe 
% of Ion 318 Chip loading 78 82 
Av. coverage depth of the GC rich target gene 2208 x 2221 x 
% of coverage uniformity in the GC rich target 
gene 
73.41 92.82 
 
% of base coverage of GC rich target 
gene at  
1x 91.16 100 
20x 91.16 100 
100x 78.28 100 
Depth 
(0-4625x) 
 
 
Exon 1                                         Exon 2                 Exon 3       
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*Targets from g.DNA of CLL patients (n=3) were enriched with HaloPlex probes without (middle 
column, Run-1 in 2.5.1.) and with (Right column, Run- 2 in 2.5.1.) boosted probe design and then 
sequenced using Ion Chip 318.  
 
 
 
 
Figure 2.5. An example of improved target coverage by boosting probe design 
A and B. The visualised BED files with the UCSC software show probes (green bars) 
designed for a targeted exon (blue bar) containing a GC-rich region (in red box) without 
(A) and with (B) probe boosting. The IGV files show the alignment of sequence reads 
(grey bars) across the GC-rich region enriched with the HaloPlex probes without (C) and 
with (D) the boosting.  
 
B 
C D 
A 
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2.3.1.5. Saving cost by reducing the amount of HaloPlex probes used for DNA 
target enrichment 
In this step, HaloPlex probes are hybridised to target DNA fragments in an in solution based 
hybridisation capture reaction. Unlike the array-based capture which is based on influx of 
large amounts of DNA and subsequent washing of the off-target DNA on a solid surface to 
which probes are fixed, the in solution-based capture is using larger amounts of probes on 
smaller amount of DNA. Through subsequent washing steps, the off-target DNA and the free 
probes are cleared. As the probes are biotinylated, they tend to be retained in all steps prior 
to PCR amplification using the magnetic field. After PCR amplification, size selection removes 
the excess primers and residual probes. This step is crucial before sequencing as ISPs 
containing only primers or probes consume capacity of the Ion chip and yield unusable short 
reads. Accordingly, the HaloPlex probes are expensive, they account for about 40% of cost 
for laboratory consumables of the test. 
 
To cut the cost, we successfully reduced the amount of probes used for the target DNA 
enrichment, from 20 µl to 17 µl per sample. As shown in Figure 2.6, this reduction (B) 
produced the same results as the recommended amount of probes did (A) in 8 un-paired 
CLL-samples.  
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Figure 2.6. Reduced amount of HaloPlex probes did not affect results of target 
enrichment 
Bioanalyser electrophoreograms showing size of DNA libraries enriched with 
recommended 20 l of HaloPlex probes (A) and 17 l of the same probes (B) in 8 un-
paired DNA samples.  
  
B 
A 
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2.3.1.6. Improvement of efficiency of DNA library size selection 
As mentioned in Section 2.2.8.1, the size of digested DNA fragments varies from 100 - 500 
bp. With probes ligated the ideal size of the DNA library for sequencing is between 150 - 550 
bp. After target enrichment and amplification, it is important to eliminate free probes and 
primers. Efficiency and quality of the purification is determined by multiple factors, including 
the duration of incubation of the DNA library with XP-beads and the number of purification 
procedures. To improve the efficiency, we initially compared the effects of the incubation 
durations for two CLL libraries. As shown in Figure 2.7. A and B, there were no visible peaks 
of recovered DNA libraries after incubation with the beads for the recommended 5 minutes 
at room temperature, while the DNA libraries were obviously recovered with the prolonged 
incubation for 15 minutes, as presented in Bioanalyser electrophoreograms Figure 2.7.C and 
D.   
 
 
Figure 2.7. Improved recovery of DNA library after optimised purification step 
Bioanalyser electrophoreograms showing no yield with the recommended 5 minutes 
DNA- XP bead incubation in 2 CLL samples, A and B efficient recovery was achieved 
(DNA peaks of 150 - 550 bp) with elongation of incubation to 15 minutes, while some 
residuals of free primers and probes are left (peaks of ≤ 100 bp), C and D. 
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However, these recovered DNA libraries still contained visible free probes and primers 
(Figure 2.7.C and D). To further remove them, we next repeated the purification procedure. 
As expected, a satisfied purity of the libraries was achieved with double purification, with no 
more visible free probes and primers in Bioanalyser electrophoreograms (Figure 2.8.A and B) 
and an increase in the average size of DNA templates in the library was obtained.  
 
 
  
Figure 2.8. Quality improvement of DNA library with double purification 
Results of purification for one of the two CLL DNA libraries showing the purity achieved 
with single (A) and double (B) procedure, as presented in Bioanalyser 
electrophoreograms. The residual primers and free probes peaks are marked with the 
two blue arrows. The two narrow fluorescent intensity peaks present two DNA size 
markers. 
 
   
2.3.1.7. Optimisation of conducting coverage analysis   
It is very important to determine the coverage uniformity and coverage depth (identify 
regions with lack of sufficient coverage) in a time efficient way to report the sensitivity of 
test specifically when clinical translation is required. For this purpose, Ion Torrent Coverage 
Analysis Plugin was used to test different coverage analysis settings including the defaulted, 
the manufacturer (Agilent technologies) recommended and the custom developed coverage 
analysis setting. As shown in Table 2.10, the defaulted setting used the whole genome as the 
target region. The disadvantages of this setting were time ineffectiveness (not feasible for 
large NGS data) and it created a misleading coverage analysis output (low coverage 
A B 
Median size 
137bp 
 
Median size 
147bp 
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compared to whole genome as a target) and regions with lack of sufficient coverage could 
not be identified without IGV visualisation. The manufacturer’s recommended setting 
required uploading of specific target region BED file created by Sure Design Software. 
Although, this setting generated a coverage analysis comparative to the specific target 
region, the output data was in a compressed form in which regions with a lack of coverage 
could not be easily identified. In contrast, the custom developed setting used an individual 
target gene strategy to obtain easily analysable information in shorter time periods. In this 
approach, the individual target gene library BED files were created and uploaded to the 
server, the tabular information provided for each target gene was not compacted and 
specific target regions with low coverage could be easily identified and reported without the 
need to IGV visualisation. 
 
 
Table 2.10. Comparisons of performance of various setting of Ion Torrent 
sequencing coverage analysis 
 Defaulted 
setting 
Manufacturer’s 
recommended setting 
Custom developed 
setting 
Uploaded file(s) Number 0 1 15 
Type NA Whole target BED Target gene specific BED 
Number of coverage analysis run(s) 
performed/ sample 
1 1 15 
Output comparative to Whole genome Whole target region Specific target gene 
Condition of data Compressed Compressed Not compressed 
Identification of regions with low 
coverage without IGV visualisation 
No No Yes 
Time spent to analyse data (hr.)/ 
sample 
6 6 2 
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2.3.1.8. Optimisation of stringency of variant calling to improve sensitivity and 
precision of the test 
Besides coverage depth, criteria set for variant calling affect both sensitivity and precision of 
the NGS test. This is particularly important for testing low level mutations. For this reason 
we compared analysis results of 5 known mutations in TP53, all of which were diluted to 1% 
VAF and 4 of which to 5% in wild-type DNA, using three different settings: the defaulted high 
and low stringent settings and a customised setting. Unsurprisingly, the defaulted high 
stringent setting identified only 3 of the 9 mutations, while the low stringent setting 
identified all 9 mutations but also 2 false variants. However, with the finely adjusted setting 
(the different minimum variant Phred quality = 16, minimum mismatched base reads = 10, 
minimum coverage on either strand = 2, maximum strand bias = 0.95, minimum relative read 
quality = 8.5 and maximum common signal shift = 0.25), we were able to detect all of the 9 
mutations without false negatives and false positives (Table 2.11). An example of the 
difference in results between the three settings visualised in IGV display is shown in Figure 
2.9. The customised setting was the best for both sensitivity and precision, and therefore 
applied to subsequent studies. 
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Table 2.11. Comparison of specificity and sensitivity of various stringency settings 
of TVC v4.2. for calling 9 TP53 mutations diluted to 5%-1%Settings 
Settings 
Defaulted high 
stringency 
Defaulted low 
stringency 
Customised 
stringency 
Minimum variant Phred quality 10 (P = 0.100) 6 (P = 0.250) 16 (P = 0.025) 
Minimum mismatched base reads 20 6 10 
Minimum coverage on either strand 3 2 2 
Maximum strand bias 0.9 0.95 0.95 
Minimum relative read quality 8.5 6.5 8.5 
Maximum common signal shift 0.25 0.2 0.25 
Maximum homo-polymer length 8 8 8 
True positive 3 9 9 
False negative 6 0 0 
False positive 0 2 0 
Results 
Sensitivity: 33% 
Precision: 100% 
 
Sensitivity: 100% 
Precision: 82% 
 
Sensitivity: 100% 
Precision: 100% 
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Figure 2.9. An example (IGV view) of variant detection and variant calling using 
TVC pipeline for TP53 mutations using different stringency settings 
The IGV displays show results of a sequencing test for a somatic non-synonymous 
mismatch in TP53 (17:17576891T>A, gated in the middle of the displays) of a CLL DNA 
sample diluted to 1% VAF with wild-type DNA, as analysed with defaulted high stringent 
(A), defaulted low stringent (B) and the customised (C) settings. Note that the blue-and-
red bars above the probe (Taza 3) region bar (blue) are the variant calls, the numbers of 
which are different for the three settings.  
 
A 
B 
C 
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2.3.2. Good test reliability 
2.3.2.1. Using known germline SNPs as an indicator  
Single nucleotide polymorphisms (SNPs) are germline variants inherited from an individual’s 
parents. They therefore exist in all cells including the tumour cells. There are about 1.42 
million SNPs in human genome at a density of 0.47 per 1 Kbp [250]. We therefore, firstly 
compared this density with that found in our study cohort. With this Ion Torrent PGM 
sequencing, we detected 21.2  2.1 (Mean  SD) in the target regions (52.324 Kbp) of each 
sample. The calculated SNP density was indeed, 0.41  0.04 (Mean  SD), which was very 
similar to the expected. 
 
Because the expected allele frequency of a SNP is 50% in heterozygous state and 100% in 
homozygous state [251], we secondly used them to exclude test allele bias introduced in PCR 
amplification, indicated by disparity of their frequencies from 50% or 100%. For this purpose, 
we summarised distribution of VAF of the total of 233 SNPs identified with the test (Figure 
2.10). As expected the VAF was between 40% and 60% and 90% and 100%, although there 
were a few of them fallen outside of the two peaks which might be due to mosaic 
chromosomal loss or gain that commonly occur in tumour samples. 
 
Moreover, each individual has a unique SNP pattern which can be used to exclude DNA 
contamination between samples. We therefore finally compared the pattern in the 11 CLL 
samples (Table 2.12), which clearly show the difference among this cohort of DNA samples, 
with no samples sharing a similar pattern. These formed evidence strongly supporting the 
good reliability of our test.   
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Figure 2.10. Distribution of identified SNP variant allele frequencies in 12 CLL 
samples sequenced by Ion Torrent PGM 
A total of 232 SNPs in 11 CLL cases were examined for distribution of allele frequencies. 
As expected, 97% of the SNPs fallen in between 40 - 60 and 90 - 100 VAF%.  
           
 
 
2.3.2.2. The expected transitions/transversions ratio functioned as quality control  
 
Transitions to transversions (Ti/Tv) ratio have been used as quality control in multiple 
studies [252, 253]. Transitions (Ti) involve interchanges of nucleotide between purines (A 
and G) or between pyrimidines (C and T), while transversions (Tv) involve interchanges 
between purines and pyrimidines. Theoretically if these interchanges occur randomly, the 
chance of Tv changes are 2 folds of that of transitions. But in fact, Ti changes occur more 
than Tv changes due to their chemical properties. Furthermore, the ratio differs across 
different regions in human genome. Inside exons, the Ti/Tv ratio is 3 or higher, while it is 
only 2 inside introns [254]. In target (exon) regions of the 11 samples included in this 
chapter, this ratio was 3.6 ± 0.4 (Mean ± SD), which was expected and therefore further 
confirmed the good reliability of our test.  
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Table 2.12. SNP patterns in 11 different CLL DNA samples  
 
 
Variant info. R V dbSNP CLL-1 CLL-4 CLL-6 CLL-11 CLL-12 CLL-15 CLL-17 CLL-18 CLL-22 CLL-24 CLL-32
2:61719275 T C rs3816341 0 0 0 0 52 0 0 0 0 0 0
2:61722724 G T rs6171632 0 0 0 0 100 0 0 0 0 0 0
2:141032088 C T rs1386356 49 100 100 50 50 100 48 100 48 51 100
2:141072519 C G rs17386226 0 0 0 0 0 0 0 0 0 0 54
2:141092084 T G rs79879036 0 0 0 0 0 0 0 53 0 0 0
2:141116420 C T rs150879175 0 0 0 0 0 0 48 0 0 0
2:141116447 G T rs35546150 0 0 0 47 0 0 0 0 45 0 0
2:141128779 C G rs76554185 0 0 0 0 0 52 0 0 0 0 0
2:141130695 C T rs16843864 0 47 0 0 0 44 0 46 0 0 0
2:141232800 C T rs72899872 0 0 0 0 0 0 0 0 0 45 48
2:141242918 T C rs34488772 0 0 0 0 0 52 0 0 0 0 0
2:141245204 T C rs74789055 0 0 0 0 0 46 0 0 0 0 0
2:141259283 G A rs35296183 0 40 0 0 0 47 45 0 0 99 99
2:141259376 G A rs35164907 0 48 0 0 0 100 46 0 0 100 100
2:141260668 A G rs4444457 50 49 53 50 50 100 100 0 51 100 100
2:141267573 G A rs35821928 60 0 0 64 0 0 0 0 70 0 0
2:141272253 C T rs61732738 0 0 0 0 0 0 0 47 0 0 0
2:141274504 G A rs75124368 0 0 0 0 0 0 0 0 0 0 100
2:141274576 T C rs4954672 50 99 47 51 99 100 47 97 49 98 97
2:141457962 C T rs34694228 0 0 52 0 0 0 0 0 0 0 0
2:141457985 T A rs13431727 0 41 0 0 0 0 0 0 0 97 99
2:198265526 A G rs788018 100 100 0 46 49 0 100 53 48 54 0
2:198274685 C T rs377192403 0 0 43 0 0 0 0 0 0 0 0
6:26157073 A G rs2298090 0 0 0 0 0 0 47 0 0 0
7:82435033 C T rs12668093 54 41 0 0 0 0 0 49 0 49 51
7:82451836 G A rs146099474 0 41 0 0 0 0 0 0 0 0 0
7:82453708 A C rs2522833 100 100 53 51 0 50 0 44 51 51 48
7:82544987 A G rs17156844 0 57 54 51 51 0 0 99 49 0 0
7:82579183 T C rs201013392 0 0 0 0 0 0 0 0 0 44 0
7:82580293 A T rs199626449 0 0 0 0 0 0 0 0 0 0 0
7:82581859 C T rs976714 57 58 49 51 51 54 46 0 48 0 0
7:82582258 T G rs10261848 0 0 0 0 0 0 0 0 0 0 0
7:82582846 C T rs10954696 49 59 50 48 46 50 48 0 49 0 0
7:82583280 C T rs17148149 0 0 0 0 0 0 0 0 0 0 0
7:82583388 A G rs10487647 0 0 0 0 0 0 0 0 0 100 0
7:82583609 A C rs10487648 37 0 0 0 47 44 0 0 0 0 0
7:82584574 G T rs61995911 0 0 0 42 0 0 0 0 48 0 0
7:82585803 G C rs114445550 0 0 0 0 0 0 0 0 0 0 0
7:82595324 C T rs9969358 0 0 0 0 0 0 0 0 0 46 0
7:82595742 T C rs28680905 0 0 0 0 0 0 0 45 0 0 0
7:82764425 C G rs2877 58 100 100 0 0 100 55 100 0 45 0
7:82784456 A G rs6972461 47 38 0 100 100 0 44 45 100 0 44
7:82784501 G T rs201808333 0 0 0 0 0 0 0 0 0 0 0
7:82785097 T C rs61741659 0 0 0 0 0 46 45 46 0 48 44
7:82785099 T G rs61741653 0 0 0 48 50 0 0 0 52 0 0
7:124481185 C A rs  35536751 0 0 0 48 0 0 0 0 50 0
8:106813518 C G rs11993776 49 0 0 100 0 50 0 0 100 0 50
8:106813672 A G rs920628 0 0 0 66 0 0 0 0 73 0 0
8:106813888 G T rs200643137 0 0 0 0 0 0 0 0 0 0 0
8:106814086 T C RS16873732 0 0 0 64 0 0 0 0 64 0 0
8:106814279 A G rs28374544 0 0 0 0 0 0 0 0 0 0 0
8:106814656 G C rs2920048 0 0 0 0 52 0 53 0 0 0 0
8:106814695 C G rs355998713 0 0 0 67 0 0 0 0 65 0 0
8:106815286 T C rs1442320 0 0 0 62 0 0 0 0 61 0 0
8:106815474 C T rs16873741 0 0 0 0 0 0 100 0 0 0 0
8:106815517 C T rs11995760 0 0 100 0 0 0 0 0 0 0 0
8:106815679 A G rs16873744 0 0 48 0 0 0 0 0 0 0 0
9:139390958 T C rs11574911 0 0 0 45 0 0 0 0  0 0
9:139391636 G A rs2229974 0 50 100 50 53 100 52  0 100
11:102207851 G A rs1055088 100 0 0 46 99 100 0 100 50 100 100
11:108160350 C T rs1800058 0 0 57 0 0 0 0 0 0 0 0
11:108163487 C T rs1800889 44 0 0 0 0 0 0 0 0 0 0
11:108175462 G A rs1801516 0 0 50 0 0 0 0 0 0 0 0
11:108183167 A G rs659243 100 100 100 100 100 100 100 100 100 100 100
15:93510603 A G rs4777755 99 99 48 98 98 99 53 99 98 53 49
15:93521604 A G rs11074121 100 99 35 100 99 99 53 99 98 43 47
15:93536197 C T rs2272457 47 100 0 0 47 55 0 0 0 0 49
15:93552488 C T rs34315566 0 0 0 0 0 0 0 0 0 51 0
17:7579472 G C rs1042522 97 97 96 64 49 61 58 97 0 97
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2.3.3. Sensitivity of the test 
2.3.3.1. Serial dilution test 
Analytical sensitivity designates both the lowest limit of detection and the lowest limit of 
quantitation. The former is likelihood of a test to reliably distinguish the lowest analyte 
concentration from blank. While the latter not only include reliable detection, but also the 
lowest concentration measurement without bias or imprecision [255]. Both of them were 
important for successful development of our NGS test. Balanced between clinical 
requirement and test cost, we set up the limit of detection of this test at 1% VAF as 
mentioned in Section 2.3.1.3. We then tested this limit in a serial dilution experiment, in 
which 4 known mutations in TP53 were diluted down to 0.2% VAF with wild-type DNA.   
We selected 4 CLL samples that carried 4 distinct TP53 point mutations (55% - 97% VAF) as 
detected by FASAY and Sanger sequencing. One of the 4 samples contained an extra 
mutation at only 5% as found with the deep NGS. As mentioned above, each of these 5 point 
mutations was diluted to 20%, 5%, 1 % and/or 0.2%. As shown in Table 2.13, all of these 
mutations diluted to 20%, 5% and 1% were detected under the optimised test conditions. 
Even at the lowest level of 0.2%, the mutations were detected in 4 out of the 5 samples. 
Regarding the accuracy, the actual levels measured with the NGS method were very close to 
the expected, being 20.33  5.78, 4.27  0.82, 1.16  0.14 and 0.15  0.06 (Mean  SE), 
respectively, as shown in Figure 2.11. These results provided strong evidence that our test is 
able to detect mutations down to at least 1% with a high accuracy.  
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Table 2.13. Details of the point mutations tested in a sensitivity test experiment using HaloPlex and Ion Torrent PGM 
techniques* 
ID 
TP53 point mutations in the original samples using 
FASAY and Sanger sequencing 
Obtained data for serial dilutions to 
S-20 % S-5 % S-1 % S-0.2% 
Exon Chr. location Ref Var 
VAF 
% 
Codon VAF VQ Cov. VAF VQ Cov. VAF VQ Cov. VAF VQ Cov. 
CLL-6 5 17:7578394 T C 98 179 H>R 21% 2451 1987 4.90% 96 2097 1.0% 26 3434 0.30% 26 1565 
CLL-A 7 17:7577539 G A 96 248 R>W 10% 668 2244 2.20% 33 4365 1.0% 32 3211 0.04% 19 4261 
CLL-4 8 17:7577100 T C 74 280 R>G 30% 1373 600 3.90% 20 636 1.7% 33 1004 0.00% …. 711 
CLL-1 
9 17:7576891 T A 24 319 K/X NA …… ….. 6.10% 127 1370 1.0% 30 2273 0.06% 29 1531 
9 17:7577079** C A 5 287 E/X NA …… …. NA …. ..… 1.1% 30 638 0.19% 26 1013 
 
* For each variant allele (Var.), the reference allele (Ref.), the chromosomal location (Chr. location) using Human reference sequence hg19, the exon and the 
codon change for each CLL sample using the identification (ID) code are shown. The % of the obtained variant allele frequency (VAF) as well as the variant 
call Phred Quality score (VQ) and coverage depth (Cov.) for each particular nucleotide are presented. CLL-6, CLL-A and CLL-4 had mutations detected by 
FASAY and Sanger sequencing. CLL-1 (harboured two distinct point mutations) was not included (NA) in the 20% serial dilution sample. Moreover, in the 5% 
serial dilution sample (S-5%), the mutation with original 5% allele frequency is not expected to be found at 5% level and hence its allele frequency lags by 5 
folds behind the dominant mutation which was located at codon 319. CLL -24 which had Wt. TP53 gene was used as the diluent. 
* * This mutation was detected by re-screening of the sample by Ion Torrent PGM
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Figure 2.11. Serial dilution of TP53 point mutations   
The 4 artificial samples were created by mixing and serially diluting 4 CLL samples with 
5 distinct TP53 point mutations in a TP53 wild type DNA to obtain allele frequency of 
20%, 5%, 1% and 0.2% for each variant in these samples, respectively. The optimised 
stringency settings of TVC variant caller (v4.2) facilitated the readily mutation 
identification without increase in false positive calls. 
 
2.3.3.2. Confirmation of low-level mutations identified by the NGS using AS-PCR 
As mentioned in Section 1.3.2.4, AS-PCR is highly sensitive for confirmation or detection of 
known mutations [256]. We employed it to confirm mutations at a low level around 1% 
detected by NGS. In order to avoid both false positive and false negative results, the PCR 
conditions had been carefully optimised before use by adjusting the amount of DNA, 
concentrations of primers, MgCl2 and dNTP with or without addition of DMSO, annealing 
temperature and/or cycle number of PCR, as shown in Table 2.6. Using the optimised AS-
PCR, we successfully confirmed all of the 4 TP53 mutations in the patient samples still 
available at a level of 1% and 0.2% VAF as diluted in wild-type DNA, as shown in Figure 2.12. 
Notably, AS-PCR product amplified from 0.2% of a mutation, which was undetectable at that 
level with the NGS method, was also visible, although not as strong as those from the same 
level of other mutations (Figure 2.12.D). These results steadily confirmed the fidelity of 
mutations detected with the NGS method at the level of detection limit (1%).
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Figure 2.12. Agarose gel electrophoresis images for validation of NGS-detected 
TP53 point mutations by AS-PCR 
As described in (Section 2.3.3.2.), serially diluted mutated DNA was used for the AS-PCR. 
A. PCR bands of 338 bp were amplified from wild-type (G) and mutant (T) alleles. B. PCR 
bands of 527 bp from wild-type (A) and mutant (T) alleles. C. PCR bands of 427 bp from 
wild-type (A) and mutant (G) alleles, and D. PCR bands of 334 bp from wild-type (A) and 
mutant (G) alleles.  
Chapter 2. Development of ultra-deep targeted NGS 
130 
 
2.3.3.3. High repeatability of the Ion Torrent PGM sequencing test  
Although most conditions for the NGS test were controllable, the sequencing on the PGM 
might vary due to conditions out of our own control, e.g. template DNA amplification on 
beads and loading on chip. It was therefore necessary to test repeatability of the sequencing 
results. To do so, we sequenced DNA libraries prepared from 4 patients under the optimised 
conditions on separate Ion chips in different runs. The total number of variants called, 
including both germline and somatic variants, in target regions was very similar between the 
two runs (Table 2.14). Moreover, statistical analysis revealed a good linear correlation of the 
mutation VAF% between the two runs for all of the 4 DNA libraries as shown in Table 2.14 
and Figure 2.13. Notably, such a correlation existed even for mutations with VAF lower than 
20% (see those in red boxes in Figure 2.13).     
 
 
Table 2.14. Summary of Ion Torrent PGM reproducibility test performed for 4 CLL 
samples in 2 sequencing runs 
CLL-ID Runs Number of variants R2 Regression P 
Germline and 
somatic synonymous 
Somatic non-
synonymous  
Total 
CLL-1 A 22 8 30 0.977 B=2.89+0.95A <0.001 
B 22 7 29 
CLL-4 A 29 3 32 0.966 B=1.18+1A <0.001 
B 29 3 32 
CLL-6 A 23 2 25 0.991 B=2.08+1.02A <0.001 
B 23 2 25 
CLL-24 A 24 1 25 0.996 B=1.25+0.96A <0.001 
B 24 1 25 
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Figure 2.13. Comparisons between VAF% of all the mutations detected in replicates 
of Ion Torrent PGM experiments in 4 CLL samples 
Statistical analysis showing a positive linear correlation between the frequencies of 
mutant alleles detected in repeated experiments for 4 CLL samples (CLL-1, CLL-4, CLL-6 
and CLL-24) using Ion Torrent PGM method. 
 
 
 
 
2.3.3.4. Good reproducibility confirmed with alternative methods in multi-centre 
blind studies 
Determining inter-operator variability is an essential step for establishing a new method as it 
is an approach to confirm the reported results with alternative technologies. Moreover, 
double blind multicentre studies reduces risk of bias for all types of variants, including indels, 
which are more likely to be false positive as detected with the Ion Torrent PGM technique 
[257, 258]. For that reason, we sent 7 DNA samples of our study cohort to the group led by 
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Professor Stankovic in University of Birmingham to screen mutations in ATM with alternative 
methods. Among these samples four had a total of 6 mutations (all > 30% VAF, including a 
deletion of 10 nucleotides), one had 2 mutations including a point mutation with 14.7% VAF 
and a single nucleotide insertion with 14.4% VAF, and two had no mutations in target 
regions of this gene as tested with our NGS method (Table 2.15). Without any information 
provided, the Professor Stankovic’s laboratory confirmed all of the 6 mutations with VAF > 
30% with DHPLC and Sanger sequencing, with no mutations detected in the two wild-type 
samples. Not surprisingly, the 2 mutations with < 15% VAF were not confirmed, most likely 
due to the detection limit of Sanger sequencing.   
In a double blinded multicentre study organised by the European Research Initiative on CLL 
(ERIC), 5 anonymous CLL samples were sent to us and 45 other centres over the world to 
screen for mutations in TP53 using different methods, including DHPLC + Sanger sequencing,  
FASAY + Sanger sequencing and NGS methods. Using the Ion Torrent PGM method, we 
detected all of the 5 mutations in 4 samples, as identified by ERIC using DHPLC and Sanger 
sequencing. In addition, we detected an extra mutation with the VAF being only 4.3% in 
sample 4 (Table 2.16). More importantly, the VAF of mutant alleles measured with our NGS 
method correlated very well with that recorded by ERIC, with the correlation coefficient 
being 0.99, P < 0.001, slop in regression equation close to 1 (0.972) and the intercept as 
small as 3 (Figure 2.14). Those results further confirmed that results generated with our NGS 
test are well reproducible by conventional methods, although low-level mutations were not 
included due to the limited sensitivity of those alternative methods.  
  
Chapter 2. Development of ultra-deep targeted NGS 
133 
 
Table 2.15. Summary of ATM mutations detected by the University of Birmingham and the Ion Torrent PGM technique *  
CLL-ID 
ATM sequence information detected by Ion Torrent PGM 
Confirmed by 
DHPLC and Sanger 
Mutational 
status 
 
Exon 
Chr. location 
(hg 19) 
Ref. 
 
Var. c. DNA Codon 
VAF 
% 
VQ Coverage 
CLL-11 Mu 
10 11: 108121763 G A c.1571 p.524 W/X 37 5033 1582 Yes 
57 11:108213973 G A c.8293 p.2765 G>S 38 5478 1655 Yes 
CLL-12 Mu 41 11:108186598 T C c.6055 p.2019 Y>H 98 8523 559 Yes 
CLL-15 
Mu 22 11:108143528 T G c.3233 p.1078 L>R 14.7 1898 2906 No 
 33 11:108168106-07 - C c.5001-2 p.1668 L/fs 14.4 126 529 No 
CLL-17 
Mu 41 11:108186599 A G c.6056 p.2019 Y>H 47 9822 2354 Yes 
 58 11:108216582-86 TTTGG --- c.8531-35 p.2845 W/fs 48 4797 1483 Yes 
CLL-18 Mu 48 11:108198445-54 TAGAAAATCC --- c.7049-58 p.2351 E/fs 31 2185 1553 Yes 
CLL-22 Wt          Yes 
CLL-32 Wt          Yes 
 
*Details of chromosomal location (Chr. location) using human reference (hg19). Reference allele (R.), variant allele (V.), c. DNA position, protein code and 
exon harboured the mutations already detected by other centres using DHPLC and Sanger sequencing in ATM gene for 4 CLL samples (A-D) are shown. The 
variant allele frequency (VAF %), variant Phred quality score (VQ) and coverage depth are illustrated for each variant detected by Ion Torrent PGM. As only 
the protein coding sequences of the gene are targeted in the PGM method, the sequence information for the two mutations located in exon 1 (non-coding 
exon) could not be obtained. 
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Table 2.16. TP53 gene mutations detected by ULM, Germany and the Ion Torrent PGM technique (our lab)* 
CLL ID Ion Torrent PGM (our laboratory) 
 
DHPLC, Sanger (ERIC) 
TP53 
mutational 
status 
Exon Variant chr. 
locarion 
hg 19 
R. V. c.DNA Codon VAF % VQ Coverage TP53 status VAF % 
ERIC-1 Wt          Wt  
ERIC-2  
Mu 
7 17:7577566 T C c.715 p.N239D 54.2 11531 1999 Mu 44 
ERIC-3  
Mu 
5 17:7578413 C A c.517 P.V173L 41.4 4220 1125 Mu 47 
ERIC-4 Mu 6 17:7578203 C G c.646 p.V216L 4.3 65 2000 Mu ------ 
8 17:7577127 C A c.811 p.E271X 45.6 4548 1052  41 
4 17:7579317 A G c.370 p.C124R 39.9 5880 1660 38 
ERIC-5 Mu 10 17:7573999 T - c.1028 p.E343fsX 91.6 19291 1435 Mu 93 
 
*Details of chromosomal location (Chr. location) using human reference (hg19), reference allele (R.), variant allele (V.), c. DNA position, protein code and 
exon harboured the mutations detected by other centres using DHPLC, Sanger and NGS technique in TP53 gene for 5 CLL samples (ERIC1- ERIC5). The variant 
allele frequency (VAF %), variant Phred quality score (VQ) and coverage depth are illustrated for each variant detected by Ion Torrent PGM. 
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Figure 2.14. Comparison of mutant TP53 VAF% detected with our Ion Torrent PGM 
methods to the blinded VAF% identified with DHPLC and Sanger sequencing by 
ERIC 
Statistical analysis showing a positive linear correlation between the frequencies of 
mutant alleles detected with the standard ERIC method and our Ion Torrent PGM 
method. 
 
 
 
2.4. Discussion and conclusion 
In this chapter, we aimed to develop a highly sensitive and clinically useful next generation 
sequencing approach using Ion Torrent PGM to screen recurrent mutations in a panel of 
genes in CLL. The high sensitivity is required to detect mutations with low variant allele 
frequencies which are undetectable with conventional methods or even with high 
throughput NGS techniques with limited coverage depth [259]. The detection of low allele 
frequency variants is particularly useful to study CLL mutant clonal evolution and for 
molecular monitoring of patients at early stages and throughout the disease course. Not 
only in CLL, but also in various types of haematological malignancies and solid tumours, 
there is still a clinical need for accurate, reproducible methods to measure treatment 
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response and adequately monitor tumour burden during treatment in order to identify 
patients who might benefit from individualised therapy [260]. 
By examining the feasibility of this NGS technique in our laboratory and optimisations of 
procedures step by step in this chapter, we showed that this method is practically applicable 
to studies in next chapters which include monitoring clonal evolution in CLL. 
The gene panel selection and particularly targeting the disease related coding sequences, 
provided reasonable coverage. This was important as valuable genetic information is 
enriched within the coding sequences of genes [261]. The optimised HaloPlex target 
enrichment design provided uniform coverage across a problematic GC rich target region in 
TP53 as it increased the number of probes and amplicons overlaid this region. This problem 
has been commonly reported in other studies of next generation sequencing [262]. For this 
reason, efforts have been made to modify PCR conditions [263, 264], however no significant 
improvement in the uniformity and coverage were obtained. This might be due to that 
different PCR conditions required for different template DNA amplification.  
Reduction in the amount of probe being used for enrichment of each sample, not only was 
useful for better purification, it also reduced the total cost of enrichment per sample. The 
incorporation of double purification step with AMPure XP beads (yet with the same cost by 
the strategy of halving the amount of DNA library purified) resulted in improvement of the 
read length and total elimination of probes and preserved the chip capacity for deeper 
coverage of useful bases. Engaging to this approach facilitated saving of up to 16% of the 
probes which was sufficient for enrichment of 8 extra samples.  
Another problem in high throughput short read sequencing is the occurrence of false 
positive or false negative errors in identifying variants. For this reason, increasing the depth 
of coverage has been proposed so as to reduce regions with low coverage supply and false 
negatives. However, coverage depth is not the sole quality filter for variant detection. 
Various sequencing and mapping criteria can affect the identification of variants specifically 
for somatic mutations with low allele frequency [265-267].  
This process tends to be complicated because of many facts: firstly, tumour samples are 
enriched in chromosomal abnormalities such as loss of heterozygosity and chromosomal 
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rearrangements; besides, they tend to be mixed with normal cells by which the proportion 
of tumour cell alleles to the total number of alleles is attenuated. Additionally, it is not 
always possible to isolate specific tumour cells before sequencing especially when 
manipulating clinical samples, as this procedure is time consuming, adds extra cost and does 
not guarantee 100% purification. Moreover, low level mutations are difficult to be 
distinguished from background error noise. Therefore, testing the stringency of variant 
calling and pinpointing the extent to which each filter includes and excludes true somatic 
mutations with low allele frequency in tumour clinical sample was essential.  
Based on optimisation of stringency of variant calling (TVC plugin software by adjusting the 
parameter’s thresholds) for various known true variants with low allele frequency (range 20-
0.2%), we could increase the test sensitivity and precision in mutation detection. This 
enabled accurate detection of mutations diluted to allele frequency as low as 1% with high 
precision which was further validated by highly sensitive AS-PCR.  
We also demonstrated the high reproducibility of the technique by testing different samples 
starting from DNA preparation step in the same sequencing experiment or from replicates of 
sequencing experiments. The high concordance of the PGM results with multicentre results 
in blinded studies for various genes and various types of mutations (including point 
mutations and short deletions and insertions) imply the reliability and robustness of the 
method. 
In conclusion, we established a highly sensitive NGS test by optimising conditions for both 
the target DNA enrichment with HaloPlex and analysis of Ion Torrent PGM sequencing data. 
This was necessary for us to reach the subsequent study goals set up for subsequent 
chapters of this thesis to establish mutation profile and to study clonal evolution of mutant 
CLL clones in patients with advanced CLL. 
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Chapter 3. Targeted gene mutation profile and chromosomal copy 
number changes of patients with progressive and/or chemo-resistant 
CLL using ultra-deep NGS and array based whole genome profiling 
Chapter 3. Targeted gene mutation profile.. 
3.1. Introduction and aims 
As mentioned earlier in Chapter 1, CLL is characterised by a heterogeneous disease course in 
terms of disease progression and response to therapy. It has been suggested that somatic 
genomic aberrations contribute to this clinical diversity.  
Shortly before the start of this work, two independent studies using whole genome and 
whole exome sequencing approaches had found a number of recurrently mutated genes 
irrespective of clinical stages of CLL [148, 149]. In addition to those in the two previously well 
studied genes TP53 and ATM, the two studies had identified novel mutations in other genes 
including SF3B1, NOTCH1, MYD88 and BIRC3. Similar to TP53 and ATM mutations, a possible 
link of these novel gene mutations to biology as well as diverse clinical course of the disease 
was proposed [150, 245]. Moreover, identification of the main chromosomal copy number 
changes including del11q, del13q, del17p and trisomy 12 by FISH has been used to 
prognosticate CLL patients. A strong association between del17p and TP53 mutations has 
been found. Recent studies have combined FISH and more recently low resolution array 
based hybridisation techniques with gene mutation analysis to refine the prognostic 
stratification. This has led to identification of novel chromosomal copy number 
abnormalities which have been linked to poor prognosis. Largely because of the low 
sensitivity nature of the sequencing and the array techniques employed, information on the 
actual incidence, co-occurrences of these lesions, clonal or subclonal architecture of somatic 
mutations and copy number changes of progressive and or chemo-resistant CLL was scarce. 
In parallel with our study, in 2013, a newer study employing whole exome sequencing 
revealed that heterogeneity of gene mutation architecture and chromosomal copy number 
changes at early stages possibly fuel CLL clonal evolution over time of disease progression 
and relapse [198]. Thereby, we hypothesised that the genetic alterations that exist at later 
stages of disease are expanded from earlier stages and they contributed to disease 
progression and/or therapy resistance. These alterations are therefore likely to be targets 
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requiring monitoring from an early stage of the disease. The aims of this chapter were 
primarily to apply the fast, affordable and sensitive next generation sequencing technique 
developed based on HaloPlex target enrichment system and Ion Torrent PGM to detect and 
build up mutation profiles in the panel of 15 genes at a late stage of the selected CLL cases. 
The secondary aim was to study whole genome copy number alterations (CNA) using high 
resolution CytoSNP-850K Illumina Bead Chip array to identify possible associations between 
gene mutations, chromosomal copy number changes and clinical outcome. 
 
3.2. Materials and methods 
3.2.1. CLL samples and criteria for case selection 
All of the cases included in this chapter were from the Liverpool CLL Bio-bank. They were 
consented patients and anonymised for research. They were selected to meet the following 
criteria: firstly, they were diagnosed as typical CLL and had a history of progressive and/ or 
chemotherapy resistant disease according to the updated IWCLL criteria published in 2008 
(as described in Sections 1.1.4 for typical CLL diagnosis and 1.1.6.2 for disease progression 
and treatment resistance); and secondly, they had serial samples taken not only after 
disease progression and/or therapy resistance, but also at earlier stages, so that the study on 
clonal evolution as planned for Chapter 4 could be performed. 
 
There were 120 cases in the Bio-bank meeting these criteria. Among them 32 were selected 
because they fulfil regulations of the Bio-bank that only release samples with more than 10 
vials in storage at any time points of sampling. The cryopreserved CLL cell samples taken at 
the latest time from these 32 patients were used for study in this chapter. As shown in Table 
3.1, an additional sample from a stable (indolent) CLL (CLL-33) was used as a control. In this 
cohort, the median age at diagnosis was 62 (range: 33 - 82), while median age at sampling 
was 67.5 (range: 35 - 86). Each of the 32 patients had a history of progressive disease that 
required initiation of therapy. 22 of them had received therapy at time of sampling, while 10 
of them had not received the treatment when sampled. According to IWCLL (2008), 17 
patients showed resistance to treatment (refractory to chemotherapy). Only 6 patients 
partially responded to treatment but for short periods (6 – 24 months). 
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Table 3.1. Clinical and laboratory features of the CLL cases used in this study 
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CLL-1 M 50 63 C 5 9.8 152 99 2.04 <5 Y Flux6 NR 
CLL-2 F 59 70 B 3 10.8 19.4 236 0 <12 Y Clbx2 NR 
CLL-3 F 51 63 B 3 12.5 104.8 221 7.5 <5 Y FCRx4 PR/9m 
CLL-4 M 54 55 B 3 12.3 105.2 201 0 <5 Y Clb,Rx6 - 
CLL-5 M 51 55 B 4 14.2 166 156 0.34 <4 Y  -  - 
CLL-6 M 62 67 B 3 11.5 61.9 110 3.47 <3 Y Clb x6 NR 
CLL-7 M 74 79 B 3 11.5 57 315 0 <4 Y Clbx6 NR 
CLL-8 M 60 65 C 1 14.5 19.7 59 0.35 <3 Y CHOPx6 NR 
CLL-9 M 62 69 B 4 12 126.3 211 3.72 <12 N  NA  NA 
CLL-10 F 66 68 C  - 9 51.5 301 - <4 N NA NA  
CLL-11 F 73 77 B 3 10.4 198.3 183 1.39 <8 Y Clb,FCx4 NR 
CLL-12 M 57 62 C 2 11 800 81 0 <12 Y Flu x6 NR 
CLL-13 M 57 67 C  - 12.1 132.8 46 0.34 <6 Y Clbx6 PR/7m 
CLL-14 M 65 67 C 3 9.3 365 248 0 <6 Y Clb,Alemx4 NR 
CLL-15 M 33 35 B 3 14.5 53.5 182 0.67 <12 N  NA  NA 
CLL-16 M 47 54 C 3 10.5 289 80 2.43 <12 Y Clbx2 NR 
CLL-17 M 65 74 C 0 10.5 127 58 2.5 <10 Y Clbx6 PR/24m 
CLL-18 M 55 59 C 5 10.6 54.5 212 0 <3 N NA NA 
CLL-19 M 54 65 B 5 11.7 87 121 8 <12 Y Clbx6 PR/12m 
CLL-20 M 69 70 C 3 9.3 150 26 0.34 <4 Y Clbx1 NR 
CLL-21 F 73 76 C 0 9 171 160 0.42 <10 Y Clbx6 PR/6 m 
CLL-22 F 65 66 B 3 11.8 33 197 4.5 <7 Y Clbx2 NR 
CLL-23 M 77 82 C  - 9.6 362.3 48 0.34 <6 Y Clbx6 NR 
CLL-24 F 62 70 B 3 10.2 81.6 189 4.5 <3 Y Clbx6 PR/6m 
CLL-25 M 65 67 C 4 11.1 298 68 0 <12 N NA NA 
CLL-26 F 79 86 C  - 10.3 61.4 52 10.4 <12 Y Clbx6 NR 
CLL-27 M 62 76 B 3 11 112.6 204 0 <10 N NA NA 
CLL-28 M 82 85 B 3 11.6 53.4 185 0 <3 N NA NA 
CLL-29 M 59 66 C - 10.2 129.9 63 0.67 <12 Y Clbx5 NA  
CLL-30 M 78 84 C  - 9.4 53.3 165 0 <12 N NA NA 
CLL-31 F 76 86 C 0 7.7 130 216 0.37 <8 N NA NA 
CLL-32 F 69 73 C  - 8.9 40.6 142 8.9 <12 N NA NA 
CLL-33 M 74 79 A 0 14.2 26.8 170 7.07 - N NA NA 
 
^: Indolent and stable CLL. *: F, Female and M, Male. **: Binet stages A, B and C. LDT: Lymphocyte 
doubling time. * **: Treatment  Y, Yes and N, No. Flu: Fludarabine. Clb: Chlorambucil. C: 
Cyclophosphamide. H: Doxorubicine. O: Vincristine. P: Prednisolone. R: Rituximab.  Alem: 
Alemtuzumab. NR: No response (stable disease). PR: Partial response according to IWCLL (2008).  
NA: Not applicable. -: Information missed.
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3.2.2. Genomic DNA extraction 
Genomic DNA from the CLL samples were extracted from the cryopreserved cells and stored 
in a -20 oC freezer after measuring the concentration and quality control as described in 
Section 2.2.2. 
 
3.2.3. DNA concentration measurement and quality control 
For measuring the concentration, purity and integrity of starting DNA, respective 
fluorometric concentration measurement and spectrophotometry and on-chip microfluidic 
electrophoresis for DNA were used as described in Sections 2.2.3, 2.2.4 and 2.2.5.2. 
 
3.2.4. Target enrichment using HaloPlex technique 
Each CLL samples’ genomic DNA was digested then was hybridised to the designed HaloPlex 
probe and PCR amplified using the optimised conditions as explained in Section 2.2.8. 
Validation of DNA library amplification was performed after using double bead purification 
of the PCR products of each samples’ library as described in Section 2.2.9. 
 
3.2.5. Sequencing template preparation and sequencing on Ion Torrent PGM 
Ion Torrent PGM sequencing on Ion 318 chips loaded with equimolar amounts of 4 barcoded 
DNA libraries were performed as described in Sections 2.2.10, 2.2.11, and 2.2.12. A total of 8 
experiments were needed to complete the screening of the cohort comprising the 32 CLL 
samples. 
  
3.2.6. Sequencing runs assessment, variant calling and sorting  
The quality of each sequence run was assessed and recorded by the Torrent Server in a 
summary statistics report. The quality of raw sequencing data and number of mapped reads 
were also recorded by the Server. Variant calling was performed for each sample using the 
optimised custom stringency settings as mentioned in Sections 2.2.13 and 2.2.14. Target 
region BED file was uploaded to the variant caller software to assign variants only within the 
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target region, so that variants outside the target regions were discarded. As shown in Figure 
3.1, the retained candidate variants were annotated using both Ensembl Variant Effect 
Predictor and Ion Reporter Software. The variants were compared to available population 
databases for both somatic mutations (COSMIC-65) and germline mutations (dbSNP-137 and 
1000 Genome Project). A group of variants were sorted as SNP and were tabulated for all the 
samples using excel spread sheet. This was based on their record of validated reference in 
population based studies namely dbSNP-137 and 1000 genome project. Any identified new 
variants not reported in the above databases was considered as a SNP, if was found in more 
than one sample with VAF% of 40 - 60% or 90 - 100% [231]. Similarly, variants with both 
dbSNP-137 and COSMIC-65 database references were sorted as SNP, if the earlier described 
conditions existed. Moreover, additional conditions for sorting a variant as somatic mutation 
were applied including VAF% between 2 - 40% or 60 - 90% and a changeable VAF% identified 
in its corresponding sample(s) sequenced at earlier stages of the disease for the clonal 
evolution study in Chapter 4. 
 
 
Figure 3.1. The process of sorting variants called by the optimised TVC and final 
reporting 
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3.2.7. Sanger sequencing for validation of randomly selected variants 
Using Sanger sequencing, so far, we have validated 10/22 (45.5%) of the ATM and TP53 
mutations detected by the PGM method in the cohort in this chapter as shown in Chapter 2, 
Sections 2.3.3.2 and 2.3.3.4. It was also important to validate the mutations detected in 
other genes. 
 
As shown in Table 3.2, various mutations (n = 16) including point mutations (n = 8) and small 
indels (n = 8) in 11 samples with VAF ranging between 8.5% - 86% in 3 other targeted genes 
including NOTCH1, SF3B1 and PCLO were selected to be validated by PCR and Sanger 
sequencing. Those three genes were selected because they were more frequently mutated 
than other genes (Table 3.6). Therefore, we were able to validate these mutations in 
multiple samples with the same amplification and Sanger sequencing experiment. The 
primers required for PCR and sequencing were designed using the NCBI Reference Sequence 
to amplify regions bearing these mutations as detected with the deep NGS method. The 
sequence of each primer was compared to the human genome with Blastn Suite 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) to exclude any possibility of producing nonspecific 
sequences. 
   
PCR amplification was set individually for each mutation using the Promega Taq polymerase 
kit (Promega, UK). All reactions were performed in 0.2-ml PCR tubes in an Eppendorf 
Mastercycler with standard components, but with individualised DNA amounts and 
annealing temperature. The details of each mutation and conditions of corresponding PCR 
are presented in Table 3.2. The specific PCR products were visualised by agarose gel 
electrophoresis as described in Section 2.2.5.1 to validate successful PCR amplification for 
each primer set used. Afterwards, 2 - 3 of 50-µl PCR reactions were performed for each 
sample using the same corresponding PCR conditions to amplify sufficient amounts of PCR 
products to be used as a template for Sanger sequencing. Following the electrophoresis and 
visualisation of the bands, the specific bands were excised and purified using the Promega 
Wizard SV gel and PCR purification kit. 
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According to the manufacturer’s instructions, up to 600 mg of gel slice was melted in 600 µl 
of membrane binding solution in a 1.5-ml tube with continuous shaking for 10 minutes at 
65oC. The tube was spun at 14000 rpm for 1 minute after incubation with a DNA binding 
column at room temperature for 1 minute. The column-bound DNA was washed in 1200 µl 
of membrane wash solution and centrifuged for 6 minutes at 14000 rpm. The DNA was then 
eluted from the column using 40 µl of nuclease free water. The purified products were 
quantified and sent to Lark Technologies Inc. for bi-directional sequencing using the 
corresponding primers. Sequences were analysed with Chromas Lite v2.1.1 (Technelysium 
Pty Ltd, Queensland; Australia) and compared to published wild type NCBI Reference 
Sequence for the corresponding gene.  
Sanger sequencing was provided as a service by Beckman Coulter Genomics (Stortford, UK). 
The forward and reverse PCR primers were used for the sequencing from both directions.  
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Table 3.2. Genes, primer sequences and PCR conditions used to validate various somatic non-synonymous mutations detected 
by the PGM in different CLL cases 
Gene 
  
Primer name 
  
  
Primer sequence (5’-3’) and the 
NCBI reference sequence 
accession number 
PCR 
product 
size  
bp 
Mutation(s) to be 
validated 
Hg19 
CLL sample code and 
(VAF% by PGM) 
PCR components  
50 µl in 0.2 ml thin walled PCR tubes 
Amplification condition* 
Each 
Primer 
pmole 
MgCl
2
 
mM 
dNTP 
mM 
Gotaq 
U 
g.DNA 
ng 
5x 
buffer 
µl 
Temperature 
 oC 
Time 
sec. 
No. of 
cycles 
NOTCH1 NOTCH1-For 
NOTCH1-Rev 
GGCGGTGCACACTATTCTGC 
CATCCACAGAGCGCACACAG 
(XM-011518717.1) 
385 9:139390649-50 
del CT 
CLL-15 (8.5%) 
CLL-10 (11.3%) 
CLL-27 (12.4%) 
CLL-28 (24.0%) 
CLL-9 (86.0%) 
20 75 10 1.25 100 10 94 
60 
72 
30 
30 
30 
32 
  
SF3B1 
  
SF3B1A-For 
SF3B1A-Rev 
TATTACCAACTCATGACTGTCC 
CATAGTAAGACCCTGTCTCC 
(NC-018913.2) 
374 2:198267491 C>A 
2:198267385 A>G 
2:198267370 T>C 
CLL-5 (47.4%) 
CLL-4 (49.8%) 
CLL-20 (80.2%) 
20 75 10 1.25 120 10  94 
56 
72 
  
 30 
30 
30 
  
 32 
  
  
SF3B1B-For 
SF3B1B-Rev 
TCTGGATGATATTGTGTAACTTAG 
CTCATCAGGAGACTGGAATTC 
(NC-018913.2) 
430 2:198266834 T>C 
 
2:198266611 C>T 
CLL-12 (29.9%)    
CLL-6 (52.8%) 
CLL-21 (40.6%) 
20 75 10 1.25 100 10 
PCLO PCLO-For 
PCLO-Rev 
CCAACTCCTGGAAAACCTCC 
CCTTAGCTGGAGACTGTAGC 
(NM-033026.5) 
376 7:82784832 C>G 
 
7:82784834-35 
Ins 30 
CLL-5 (36.0 %)    
CLL-14 (37.2%) 
CLL-5 (23.5%) 
CLL-25 (38.2%) 
CLL-14 (41.4%) 
20 75 10 1.25 100 10  94 
58 
72 
  
 30 
30 
30 
  
 32 
  
 
*The initial denaturation temperature of 94 oC for 3 minutes and the final extension temperature of 72 oC for 5 minutes were used in common for all the 
PCR reactions
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     3.2.8. High resolution SNP microarray for identification of chromosomal copy 
number aberrations (CNA) 
In collaboration with Merseyside and Cheshire Regional Genetic Laboratory, we planned to 
study CNA in samples from 30 CLL cases of the cohort who still had enough (>2μg) DNA 
available. So far, DNA samples from 14 cases have been tested with CytoSNP 850K array 
(Illumia, UK). Samples from the remaining 16 cases will be studied in due course. In these 
samples, 8 recurrent copy number alterations identified by FISH were used as quality control 
of the SNP array. 
The basis of this array technique is Infinium assay as described in Chapter 1 (Section 1.3.1.2). 
Briefly, DNA samples were amplified, digested and then hybridised to the CytoSNP-850K 
BeadChip according to manufacturer’s instructions. Next, the Chips were scanned using the 
NextSeq 550 System (Illumina, UK) and raw data files were produced that were further 
processed using Bluefuse Multi v4.3 (Illumina, UK) software. Log R ratios (measure of signal 
intensity) were used to identify copy number changes while frequencies of B allele (measure 
of genotype) were used to identify loss of heterozygosity. 
All SNP array analyses (including quality assessment) were performed using the same 
software. Only CNAs ≥ 5 Mbp and loss of heterozygous state (LOH) ≥ 10 Mbp were included 
in the downstream analysis [268]. Germline copy number alterations were excluded based 
on comparison with common polymorphisms listed in the Database of Genomic variants 
(http://dgv.tcag.ca/) [269]. Cancer genes within regions of both copy number change and 
loss of heterozygosity were identified based on disease gene status within Online Mendelian 
Inheritance in Man (OMIM) [270], followed by annotation in the Atlas of Genetics and 
Cytogenetics in Oncology and Haematology (http://AtlasGeneticsOncology.org/) [271]. 
 
3.2.9. Statistical analysis 
All statistical analyses were conducted using IBM SPSS v21. Mann- Whitney and Chi square 
tests were used to assess significance of difference in numbers of mutation events and 
number of mutated genes between patients with or without chemotherapy prior to 
sampling. Dominance of mutated genes occurred either as a sole event or co-occurred with 
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other gene mutations was tasted using Chi square test. Statistical significance was defined as 
P <0.05. All P values were double sided. 
 
 
3.3. Results 
3.3.1. Good quality of NGS sequencing runs for the CLL cohort 
The sequencing data successfully passed all the quality control filters including FASTQC, 
mapping quality control and the variant calling quality control. As shown in Table 3.3, the 
coverage analysis revealed homogenously average coverage depth (2252 x) for all of the 33 
sequenced samples which was slightly higher than the estimated (1846 x). In detail, almost 
all (99.98%) of the 52-Kbp target regions were covered by at least one read, with 98.89% by 
 20 reads and 96.92% by  100 reads. Although only 38% of the sequenceable sequences 
were on targets, the average on-target base reads reached to 60.82%. Furthermore, 
coverage depth for each target gene of each sample was identified and reported. As shown 
in Figure 3.2, a high mean coverage depth > 1600 x was achieved for 93.3% (14/15) of the 
target genes. 
 
Table 3.3. High level of coverage quality in the NGS sequencing of the study cohort 
Average coverage depth 
 
2252 x 
Average uniformity of coverage 
 
92.23% 
Average target base coverage at                                
1 x 
20 x 
100 x 
 
 
99.98% 
98.89% 
96.92% 
Average % of base reads on target 
 
60.82% 
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Figure 3.2. Mean coverage depth per gene 
High coverage depth achieved for the targeted regions of specific genes. MYD88 had the 
highest coverage depth while NOTCH1 had the lowest.  
 
 
3.3.2. Implementation and fulfilment of criteria set to categorize somatic 
mutations in the cohort 
Using the data analysis setting optimised in Chapter 2, the total number of called variants 
within the target regions was 812 in the 33 CLL samples analysed (Figure 3.3). As there was 
no available non-tumour germline material for the cases to be compared to distinguish 
germline mutations from somatic mutations, we implemented the methods being used in 
previously published works to separate somatic mutations as mentioned in Section 3.2.6. 
This enabled us to identify 79/812 somatic non-synonymous mutations that fulfilled at least 
2 of the criteria set to be sorted as somatic including being reported in COSMIC-65 database, 
VAF% of 2-40% or 60-90% [272] and change in VAF% when earlier samples were sequenced. 
As shown in Table 3.4, the median VAF% change at follow up was 66.66% (range: 0.26% - 
2072.72%). All in all, the 79 somatic non-synonymous mutations (mutation events) occurred 
in 28 patients, with median being 2.0 (range: 1 - 8)/sample. The sample CLL-33 from a case 
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with stable disease was used as control. As expected, no non-synonymous somatic 
mutations were detected in it. Notably, 4 other patients with progressive and/or therapy 
resistant disease had none of these types of mutations detected. Among the 724 germline 
alterations, only one mutation was not previously reported and did not meet the criteria for 
somatic mutations as shown in Figure 3.1.  
 
 
 
 
Figure 3.3. Types and proportions of variants identified within the target gene 
regions in the 33 CLL samples 
 
 
3.3.3. Genomic fingerprints across the cohort ruled out the possibility of sample 
cross contamination and SNP bias 
Similar to Section 2.3.2.1 in Chapter 2, the SNP patterns of this cohort were used to exclude 
cross sample contamination. These patterns clearly showed a unique fingerprint of each 
sample (Table 3.5). This provided good evidence not only for the unbiased SNP calling, but 
also non-contamination between samples in the tests. Moreover, we calculated the total 
number of non-synonymous germline mutations for the whole cohort and the indolent CLL 
79
9
724 Somatic non-synonymous
Somatic synonymous
Germline
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case, a mean ± SD of 8.45 ± 2.1 of non-synonymous SNPs reported in dbSNP-137 data base 
was identified/sample as shown in Table 3.5. 
 
3.3.4. Validation of candidate somatic non-synonymous variants by additional 
methods 
 
3.3.4.1. Validation of 9:139390649-50 deletion CT in NOTCH1   
NOTCH1 is a gene frequently mutated in patients with CLL and Richter’s transformation. 
Exon 34 is the only exon found to be affected by mutations in CLL. The most common 
mutation reported in this disease is a deletion of a dinucleotide which is located at the 3’ 
end of the coding sequence of this exon. Shallow coverage over a stretch of 300 bp at this 
end of the coding sequence is frequently encountered. This is because this region is rich in G 
or C nucleotides. In our cohort, the most common mutation repeatedly found in multiple 
samples was this hotspot. To exclude possibility of sequencing error particularly for an indel 
in NOTCH1 which had shallower coverage depth (Mean: 1235 x) (Figure 3.2) relative to the 
high coverage depth for all genes (Av: 2252 x) (Table 3.3), bidirectional Sanger sequencing 
method was used to validate the mutation status of 7 CLL cases from the cohort who had 
been identified as wild type (Wt., n = 2) and as mutated (Mu., n = 5) by the deep NGS. The 
mutated samples had different variant allele frequencies ranging from as low as 8.5% to 
86%. The wild type samples were chosen to be used as controls. The results showed a high 
agreement of the location and VAF between the two sequencing methods (Figure 3.4). 
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Table 3.4. Criteria set for somatic non-synonymous mutations 
 
 
Not being reported VAF% categories VAF Changes at followup
Gene Chr.location (hg19) Ref Var Amino-acid change   COSMIC 65 dbSNP 137    2-40% or 60-90% % of change Comments
TP53 17:7572969 8N  - p.HPPX380X Yes Yes 1425%
TP53 17:7576854 T C p.Q331R Yes No 11.14%
TP53 17:7576891 T A p.K319X Yes Yes 257.14%
TP53 17:7577079 C A p.E278X Yes Yes 233.30%
TP53 17:7577100 T C p.R280G Yes Yes 0.26% Short follow-up interval 
TP53 17:7577118 C G p.V274L Yes Yes 100%
TP53 17:7577120 C T p.R273H Yes Yes Yes No follow-up
TP53 17:7577538 C T p.R248Q Yes Yes Yes 29.01%
TP53 17:7577551 C T p.G244S Yes yes 161.07%
TP53 17:7577567 A C p.C238W Yes Yes Yes No follow-up
TP53 17:7577568 C T p.C238Y Yes No 416%
TP53 17:7577580 T C p.Y234C Yes Yes 200%
TP53 17:7578211 C A p.R213L Yes No 296.35%
TP53 17:7578394 T C p.H179R Yes No 2072%
TP53 17:7578413 C A P.V173L Yes Yes 451%
TP53 17:7578525 G C p.C135W Yes Yes 98.71%
ATM 11:108106443 T A p.D126E Yes Yes No 5.50%  Reached clonal level
ATM 11:108121763 G A p.W524X Yes No 8.60%
ATM 11:108143528 T G p.L1078R Yes Yes 23.12%
ATM 11:108168106-107  - C p.L1668fs Yes Yes 13.38%
ATM 11:108175530-31 - T p.H1876fs Yes yes 66.66%
ATM 11:108183216 A - p.S2000fs Yes yes No follow-up
ATM 11:108186598 T C p.Y2019H Yes No 1.90% Reached clonal level
ATM 11:108186599 A G p.Y2019C Yes No 23.9
ATM 11:108186757 G A p.E2039K Yes No No follow-up
ATM 11:108198445-54 10N - p.E2351fs Yes No 62.90%
ATM 11:108213973 G A p.G2765S Yes Yes 1.86%
ATM 11:108216487 T - p.S2812X  Yes Yes 500%
ATM 11:108216582-27 5N - p.W2845fs Yes No 5%
ATM 11:108236179 G C p.A3039P Yes Yes 660%
Being reportedVariant information
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Table 3.4. Criteria set for somatic non-synonymous mutations (continued)
Not being reported VAF% categories VAF Changes at followup
Gene Chr.location (hg19) Ref Var Amino-acid change   COSMIC 65 dbSNP 137    2-40% or 60-90% % of change Comments
SF3B1 2:198266611 C T p.G742D Yes No 83.71%
SF3B1 2:198266834 T C  p.K700E Yes Yes 199%
SF3B1 2:198267360 T A p.K666M Yes Yes Yes 250%
SF3B1 2:198267370 T C p.T663A Yes Yes 46.08%
SF3B1 2:198267385 A G p.W658R Yes No 0.80% Short follow-up  interval
SF3B1 2:198267491 C A p.E622D Yes No 17.32%
SF3B1 2:198267699 G A p.R594X  Yes Yes 490%
SF3B1 2:198268383 G A p.R549C Yes Yes 320%
SF3B1 2:198269834 A T p.L502X  Yes Yes 300%
PCLO 7:82390770 T C p.K5016R Yes No 54.56%
PCLO 7:82508679 G A p.A4543V Yes Yes 305%
PCLO 7:82581607 C T p.V2888I Yes No 161.07%
PCLO 7:82581658 G T p.P2871T  Yes 590%
PCLO 7:82583008 G A p.P2421S Yes Yes No follow-up
PCLO 7:82784832 C G p.Q375H Yes Yes Yes 3.76%
PCLO 7:82784834-35 - 30N p.Q374_Q375Ins10 Yes Yes 8.12%
LRP1B 2:141032021 T A p.N4372Y Yes Yes No 17.50%
LRP1B 2:141032152 T A p.Y4328F Yes Yes 380%
LRP1B 2:141259338 C T p.R2923K Yes Yes 590%
 SAMHD1 20:35526319 C T p.R551Q Yes No 0.60%  Reached clonal level
SAMHD1 20:35526885-86  -  A p.K523fs* Yes Yes 52.50%
SAMHD1 20:35545207 T - p.N327fs Yes Yes 210%
SAMHD1 20:35580045 A T p.M1K Yes Yes 23.96%
 XPO1 2:61719472 C T p.E571K Yes Yes 50.00%
FBXW7 4:153247330 C G p.G491A  Yes Yes 980%
FBXW7 4:153249384 C A p.R465L Yes Yes 20.45%
HIST1H1E 6:26156965 C T p.A116 V Yes No 22.37%
NOTCH1 9:139390649-50 CT  - p.F2482Ffs*2 Yes Yes 50% CLL hot spot
NOTCH1 9:139390945 G A p.Q2416X Yes Yes 491.42
BIRC3 11:102207709 A - p.V565fs Yes Yes 827%
CHD2 15:93499738 A T p.H620L Yes Yes 29.57%
CHD2 15:93499735  C G p.A619G Yes Yes 38.49%
Variant information Being reported
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Table 3.5. SNPs being reported in dbSNP-137 and identified within the target region in the cohort of 33 CLL cases* 
 
Chr.location  (hg19) Ref Var Class dbSNP C
LL
-1
C
LL
-2
C
LL
-3
C
LL
-4
C
LL
-5
C
LL
-6
C
LL
-7
C
LL
-8
C
LL
-9
C
LL
-1
0
C
LL
-1
1
C
LL
-1
2
C
LL
-1
3
C
LL
-1
4
C
LL
-1
5
C
LL
-1
6
C
LL
-1
7
C
LL
-1
8
C
LL
-1
9
C
LL
-2
0
C
LL
-2
1
C
LL
-2
2
C
LL
-2
3
C
LL
-2
4
C
LL
-2
5
C
LL
-2
6
C
LL
-2
7
C
LL
-2
8
C
LL
-2
9
C
LL
-3
0
C
LL
-3
1
C
LL
-3
2
C
LL
-3
3
11:102201850 G A Missense rs17881197 52 51
11:102201948-9 AG - Frameshift del rs151072309 59
11:102206908 CT - Frameshift del rs370069893 59
11:102207851 G A Synonymous rs1055088 100 50 100 48 50 100 39 46 99 60 100 43 98 48 100 100 100 36 100 100 99 99 100 48 100 100 41
11:108119770 C G Synonymous rs1800727 42
11:108121446 A G Synonymous rs4987943 49
11:108138003 T C Missense rs1800056 51 49 56
11:108143456 C G Missense rs1800057 52 47 49
11:108160350 C T Missense rs1800058 54
11:108163487 C T Synonymous rs1800889 44 54 50
11:108170506 A C Missense rs1800059 57 56
11:108175462 G A Missense rs1801516 48 50 95 55 52 44
11:108183167 A G Missense rs659243 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
11:108196260 A C Missense rs45481995 31
11:108216487 T - Frameshift del rs1800889 51
15:93510603 A G Synonymous rs4777755 99 99 98 99 50 51 97 50 98 56 98 98 98 52 99 99 53 99 99 99 55 98 49 52 98 100 51 99 99 50 99 49 99
15:93521604 A G Synonymous rs11074121 100 100 99 100 50 46 98 48 98 52 100 99 99 53 99 99 53 100 99 99 49 99 50 52 98 100 47 99 99 46 100 47 100
15:93536197 C T Synonymous rs2272457 47 48 48 100 50 51 50 47 91 55 48 49 100 53 50 48 49 47 48 46 49 49
15:93552488 C T Synonymous rs34315566 52 49 51
17:7578210  T  C Synonymous rs1800372 51 50
17:7579472 G C Missense rs1042522 97 39 68 97 98 28 99 96 65 49 90 93 62 99  47 48 57 61 99 96 95 98 91 99 98 95 97 98 55
2:141032021 T A Missense rs149644677 49
2:141032088 C T Synonymous rs1386356 49 48 47 100 100 100 47 100 50 50 53 49 100 48 49 100 91 100 99 50 50 100 48 48 46 100 49 49 100 51
2:141072519 C G Missense rs17386226 42 55 50
2:141092084 T G Missense rs79879036 52
2:141116420 C T Missense rs150879175 49
2:141116447 G T Missense rs35546150 47 54 53
2:141128779 C G Missense rs76554185 52 46
2:141130695 C T Synonymous rs16843864 54 45 100 48 48 44 47 90 100 48 49
2:141232800 C T Missense rs72899872 50 52 48
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Table 3.5. SNPs being reported and identified within the target regions in the cohort (continued) 
 
 
Chr.  location (hg19) Ref Var Class dbSNP C
LL
-1
C
LL
-2
C
LL
-3
C
LL
-4
C
LL
-5
C
LL
-6
C
LL
-7
C
LL
-8
C
LL
-9
C
LL
-1
0
C
LL
-1
1
C
LL
-1
2
C
LL
-1
3
C
LL
-1
4
C
LL
-1
5
C
LL
-1
6
C
LL
-1
7
C
LL
-1
8
C
LL
-1
9
C
LL
-2
0
C
LL
-2
1
C
LL
-2
2
C
LL
-2
3
C
LL
-2
4
C
LL
-2
5
C
LL
-2
6
C
LL
-2
7
C
LL
-2
8
C
LL
-2
9
C
LL
-3
0
C
LL
-3
1
C
LL
-3
2
C
LL
-3
3
2:141242918 T C Missense rs34488772 52 53
2:141245204 T C Synomymous rs74789055 46 41
2:141259283 G A  Synonymous rs35296183 48 47 48 47 45 51 46 99 47 47 99 45 99
2:141260668 A G Synonymous rs4444457 50 50 47 53 52 46 50 50 51 51 100 100 49 100 100 50 100 100 45 47 100 100 100 100 53
2:141272253 C T Synonymous rs61732738 50
2:141274576 T C Synonymous rs4954672 50 100 99 98 99 47 51 99 99 53 51 99 94 49 100 98 47 99 100 99 98 98 100 50 99 98 98 53 51 49 97 52
2:141298635 C T Missense rs146867394 52 53
2:141457962 C T Missense rs34694228 50
2:141457985 T A Synonymous rs13431727 49 48 48 48 43 44 90 45 98 46 51 99
2:198265526 A G Synonymous rs788018 100 100 100 100 53 100 100 100 53 46 49 55 45 100 100 100 100 100 52 53 52 50 100 100 47 50 46 100
2:198274685 C T Missense rs377192403 45
2:61719275 T C Synonymous rs3816341 52 51
2:61722724 G T Synonymous rs6171632  41
3:38182062 T C Missense rs148149492 39
6:26157073 A G Missense rs2298090 47 49
7:124481185 C A Missense rs 35536751 55 48 50
7:82435033 C T Synonymous rs12668093 54 42 42 50 49 50 52 49 100 51
7:82451836 G A Synonymous rs146099474 40
7:82453708 A C Missense rs2522833 100 47 49 100 53 48 48 51 47 97 50 95 47 96 50 49 47 98 97 49 48 95
7:82544510 C T Synonymous rs61995908
7:82544987 A G Synonymous rs17156844 59 42 53 42 51 51 49 53 52 47 51 50 51 50
7:82545070 G A Missense rs150669313 51
7:82579183 T C Missense rs201013392 44
7:82580293 A T Missense rs199626449 47
7:82581489-90 - TCA Nonframeshift ins rs10630259   99 98 99      99 99 48 98 99 98 98
7:82581859 C T Missense rs976714 57 51 57 44 51 46 51 51 56 55 54 99 46 50 100 48 50 52 49 52 100
7:82582258 T G Missense rs10261848 52
7:82582846 C T Missense rs10954696 49 51 56 40 52 47 48 46 52 48 50 100 48 50 100 52 51 46 50 47 100
7:82583280 C T Missense rs17148149 49
7:82583388 A G Missense rs10487647 51
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Table 3.5. SNPs being reported and identified within the target regions in the cohort (continued) 
 
* The distinct SNP information including chromosomal location using Hg19 as reference, nucleotide change, effect on the amino-acid and dbSNP-137 
reference numbers are shown (rows). The SNP status for each sample (columns) are marked as heterozygous (VAF 40% - 60%) by green, 
homozygous (VAF 90% - 100%) by red and no call (VAF 0%) by blank.
Chr.  Location (hg19) Ref Var Class dbSNP C
LL
-1
C
LL
-2
C
LL
-3
C
LL
-4
C
LL
-5
C
LL
-6
C
LL
-7
C
LL
-8
C
LL
-9
C
LL
-1
0
C
LL
-1
1
C
LL
-1
2
C
LL
-1
3
C
LL
-1
4
C
LL
-1
5
C
LL
-1
6
C
LL
-1
7
C
LL
-1
8
C
LL
-1
9
C
LL
-2
0
C
LL
-2
1
C
LL
-2
2
C
LL
-2
3
C
LL
-2
4
C
LL
-2
5
C
LL
-2
6
C
LL
-2
7
C
LL
-2
8
C
LL
-2
9
C
LL
-3
0
C
LL
-3
1
C
LL
-3
2
C
LL
-3
3
7:82583609 A C Missense rs10487648 37 47 47 41 44 44 97 40 39 43
7:82584574 G T Missense rs61995911 42
7:82585803 G C Missense rs114445550 38
7:82595324 C T Synonymous rs9969358 54
7:82595742 T C Missense rs28680905 47
7:82764425 C G Missense rs2877 58 52 100 100 100 60 47 53 50 100 100 99 55 41 100 100 57 59 39 44 43 47 100 46 99 100
7:82784456 A G Missense rs6972461 47 44 41 38 34 43 41 100 100 44 44 46 100 47 45 40 47 42 46 45 100 44
7:82784501 G T Missense rs201808333 53
7:82785097 T C Missense rs61741659 44 46 50 43 46 45 45 41 40 49 44 46 44 43
7:82785099 T G Synonymous rs61741653 53 48 50 50 54
7:82785271 G A Missense rs1121444 47
7:82785304 G A Missense rs61738783 50 55
8:106813518 C G Missense rs11993776 49 100 100 50 49 50
8:106813672 A G Synonymous rs920628 51 66
8:106814086 T C Synonymous rs16873732 64
8:106814279 A G Missense rs28374544 52
8:106814656 G C Missense rs2920048 51 52 99 53 51 47 51
8:106814695 C G Synonymous rs355998713 67
8:106815286 T C Synonymous rs1442320 62
8:106815474 C T Missense rs16873741 41
8:106815679 A G Synonymous rs16873744 100
9:139390958 T C Synonymous rs11574911 42 45
9:139391636 G A Synonymous rs2229974 51 50 100 100 53 100 100 58 50 53 52 51 100 52  100 53 100 53 51 100 100 100 53 52 100 53
9 8 11 7 5 11 5 9 6 12 10 7 12 7 11 11 7 5 8 9 8 9 9 6 10 9 5 10 7 7 10 8 11Total No. of non-synonymous SNPs
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Wt; FW 
CLL-15: VAF 8.5% 
FW 
 
 
Wt; RV 
 
 
 
CLL-15: RV 
VAF 8.5% 
 
 
RV 
VAF 8.5% 
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CLL-10: VAF 11.3% 
FW 
FW 
 
 
CLL-27: VAF 12% 
FW 
 
 
CLL-27; RV 
VAF 8.5% 
 
 
CLL-10: RV 
FW 
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Figure 3.4. NOTCH1, 9:139390649-50 del CT validation using bidirectional Sanger 
sequencing 
The forward (FW) and the reverse (RV) Sanger sequencing chromatograph is illustrated 
for a wild type (Wt) and the 5 mutated (Mu) cases marked with their IDs. The different 
levels of variant allele frequencies VAF % identified by the Ion Torrent PGM are shown 
to demonstrate the high concordance between the VAF % and the chromatograph peaks 
of the mismatched bases. The dinucleotide (CT) deleted is enclosed with the small box.  
CLL-28: VAF 24% 
FW 
 
 
CLL-9: VAF 86% 
FW 
 
 
CLL-28: RV 
VAF 8.5% 
 
 
CLL-9: RV 
VAF 8.5% 
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3.3.4.2. Validation of mutations in SF3B1  
This gene was the most frequently mutated gene in this study. We selected various 
mutations in this gene to be validated by bidirectional Sanger sequencing as described in 
Section 3.2.7. The mutated samples as well as wild type control samples for these 
chromosomal locations were subjected to PCR amplification using the primer pair and PCR 
conditions described in Table 3.2. There was high concordance between the Sanger 
sequencing and the NGS results as shown in Figure 3.5. 
 
 
 
 
 
Wt; 2:198267491 G 
 
 
 
 
CLL-5: 2:198267491 G>T 
VAF 47.4% 
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 Wt; 2:198267385 T 
 
 
 
 
 
CLL-4; 2:198267385 T> C 
VAF: 49.8% 
 
 
 
 
 
CLL-20; 2:198267370 A> G 
VAF: 80.2% 
 
 
 
 
 
Wt; 2:198267370 A 
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Wt; 2:198266834 T 
CLL-12  
2:198266834 T>C 
VAF: 29.9% 
CLL-6 
2:198266834 T>C 
VAF: 52.8% 
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Figure 3.5. Sanger sequencing for validation of various mutations in SF3B1 
The chromatograph of 6 CLL cases marked by their identification code, the SF3B1 point 
mutation and the variant allele frequency (VAF %) along the corresponding wild type 
and reference allele for each mutation are demonstrated (only chromatograph of 
sequencing from forward direction is shown for each mutation in each sample). The 
results were highly consistent with the Ion Torrent PGM mutational status assigned for 
each case. The nucleotides enclosed in small boxes denote the reference in the wild type 
sample (Wt) and the variant allele in the corresponding mutated sample(s). 
 
 
 
3.3.4.3. Validation of mutations in PCLO by Sanger sequencing 
This gene was among the most frequently mutated gene in this study. We selected various 
mutations including a point mutation and a 30 bp insertion to be confirmed. A sequence gap 
between the point mutation and the insertion of only 1 nucleotide was detected by the 
PGM. 2 CLL samples carried both changes but with different allele frequencies while another 
CLL case had the same insertion without the point mutation (as shown in Table 3.2). PCR 
amplification and subsequent Sanger sequencing was performed in both forward (FW) and 
reverse (RV) directions to validate the exact location and the size of the insert. According to 
Wt; 2:198266611 C  
CLL-21; 2:198266611 C>T 
VAF: 40.6% 
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the Ion Torrent PGM result, the 30bp sequence of insert was 
CTCTTGGTCCTGCTAAGCCTCCAGCTCAGC. The bidirectional Sanger sequencing confirmed 
both the single nucleotide changes in the 2 samples identified by NGS. While Sanger 
sequencing for the 30 bp insertion in each of the three samples were consistent to the NGS 
result only in the forward sequencing direction and not in the reverse direction. The 
variation figured as a gap of 30 bp between the point mutation and the insertion in samples 
harboured both variants rather than the 1 bp gap identified by the PGM (Figure 3.6). Further 
analysis revealed that there was a nucleotide sequence of 30 bp identical to the 30 bp 
sequence of the insert beyond which the event (insertion) occurred. The resultant repeated 
sequence concealed the chromatogram peaks generated by the Sanger sequencing and thus 
the Sanger’s results were misinterpreted by us (Figure 3.7). 
 
 
 
 
 Wt; 7:82784832 C 
CLL-5 
7:82784832 C> G 
VAF: 36% 
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 CLL-5; FW 
7:82784834-35 Ins30; 
VAF: 23% 
CLL-5; RV 
  
CLL-14, 7:82784832 C> G 
VAF: 37.2% 
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Figure 3.6. Sanger sequencing for validation of 2 adjacent variants in PCLO 
detected repeatedly in 3 samples  
Highly consistent results for the point mutation were found, while the 30 bp insertion 
was consistent only in forward sequence and not in the reverse sequence. 
 CLL-25; FW 
7:82784834-35 Ins 30; 
VAF: 38% 
CLL-25, RV 
CLL-14; FW 
7:82784834-35 Ins 30  
VAF: 41% 
CLL-14; RV 
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Figure 3.7. Sanger sequencing and Ion Torrent PGM for a 30 nucleotides insertion 
in PCLO  
A. The IGV snapshot of Ion Torrent PGM of a CLL case shows sequence reads (horizontal 
grey lines) carrying a point mutation C>G change gated in the middle of the window. The 
adjacent 30 bp insertion 2 nucleotides away from the right side of the point mutation 
appear as violent marks on the reads carrying the insertion. B. Sanger sequencing 
(reverse direction) chromatogram of the same case shows the point mutation C>G 
(marked by the box and the arrow in the left side of the window) and the 30 bp gap to 
the start of the insertion (marked by blue arrow in the right side of the window). C. The 
sequence of the insert, the Wt. allele and the mutant alleles are shown from 3’> 5’.   
A 
B 
C 
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To sum up, so far, 13/14 (92.8%) and 10/12 (83.3%) of somatic non-synonymous mutations 
subjected to validation in respective replicated Ion Torrent experiments and Sanger based 
and /or As-PCR methods were confirmed as shown in Chapter 2 (Section 2.3.3.2). In addition, 
we have successfully confirmed 16/16 (100%) of somatic non-synonymous variants detected 
in other samples included in this chapter by PCR and Sanger sequencing. Accordingly, 39/42 
(92.85%) of all variants subjected to validation were verified. That is, 100% of all variants (n = 
24) with VAF% > 20% and 15/18 (83.3%) of those with VAF of < 20% (lowest detection limit 
of Sanger) were confirmed (Figure 3.8). As has been used in other studies [137], tracking of 
mutations in different samples from the same case supports mutations validity. Taking this 
in to account, additional to the above 39 validated mutations, sequencing of 23 serial 
samples (from the same patients but at earlier stages for study of clonal evolution in Chapter 
4) tracked a total of 63/79 mutations. This strategy confirmed the existence of 32 extra 
mutations and extended the number of total validated mutations to 71/79 (89.8%).  
 
Figure 3.8. Validated somatic non-synonymous mutations initially identified with 
the NGS method 
Venn diagram shows numbers of the mutations and methods used in the validation.  
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3.3.5. Somatic mutational profile in CLL with progressive and/or chemotherapy 
resistant disease  
After the stringent variant calling and filtering (summarised in Figure 3.1), it was found that 
87.5% (28/32) of the patients carried at least one somatic non-synonymous mutation in one 
of 12 targeted genes included in the 15 gene panel (Figure 3.11). Among the 12 targeted 
genes, 9 were mutated in more than one sample. Each of these mutated genes affected 
more than 5% of the patients in this cohort. Thus, SF3B1 mutations occurred in 34.3% of the 
patients followed by ATM (31.2%) and TP53 (28.1%). Other commonly mutated genes were 
PCLO and NOTCH1, which occurred in 25% and 15.6%, respectively. Each of LRP1B and 
SAMHD1 mutations was found to occur in 9.3% of the cases, while each of XPO1 and FBXW7 
in 6.2% of patients (Figure 3.9).  
 
 
Figure 3.9. Percentage distribution of samples bearing the mutated genes in the 
cohort of 32 CLL cases 
 
Regarding individual somatic non-synonymous mutations, 79.7% (63/79) of the mutations 
were unique for each sample and 20.2% (16/79) were recurrently detected in more than one 
case. The recurrent mutations occurred in 6 codons of 5 of the 12 genes analysed including 
NOTCH1, SF3B1, ATM, PCLO, and XPO1. Of the 28 patients harboured the mutations, 39.2% 
(11/28) had single gene mutations of which 36.3% (4/11) had at least another mutation in 
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the same gene. TP53 and ATM mutations did not coexist in any samples. All patients with 
TP53 mutations had at least another mutated gene, of whom, 66.6% (6/9) had mutations in 
SF3B1 (Table 3.6). Moreover, 30% (3/10) of samples with mutated ATM had SF3B1 
mutations. That gave 81.82% of SF3B1 mutations co-occurred with mutated TP53 or ATM. 
Similar to mutual exclusiveness of TP53 and ATM mutations, mutations in NOTCH1 and its 
upstream gene FBXW7 did not co-associate in any samples.  
It is recognised that somatic mutation hotspots do exist in some genes, but not others. In 
agreement with this, our study found that 61.5% (8/13) of SF3B1 mutations were localised in 
only 3 (exons 14 - 16) out of 14 exons sequenced and not surprisingly, 83.3% (5/6) of 
NOTCH1 mutations affected a single codon p.F2482Ffs*2. 
 
3.3.6. Somatic missense mutations predominated most of the targeted genes 
In this cohort, various types of gene mutations were found including single nucleotide 
mutations and insertions or deletions of 1-30 nucleotides. Notably, missense single 
nucleotide variants were the most prevalent, accounting for 63.3% (50/79) (Figure 3.10). 
Missense point mutations were the most common mutations in TP53, while in NOTCH1 and 
BIRC3 no missense mutation was identified. Short indels prevailed NOTCH1 mutations and 
the hotspot p.F2482Ffs*2 mutation was found in 5 of the CLL patients. Consistent with the 
finding by a previous study [273], indels were most prevalent among BIRC3 mutations, we 
only found a single case affected by a single nucleotide deletion at codon p.V565fs*. 
 
Considering SF3B1, 2 distinct nonsense mutations were identified; one of them was located 
outside the heat repeats (HR), while the other nonsense mutation located inside the HR2 
and not the HR 5 - 8 which commonly occur in CLL. It has been found that mutations outside 
the HRs do not result in similar patterns of alternate splicing as found with mutations 
affecting the HRs [274]. Similar to findings reported by another study [275], SF3B1 mutation 
p.K700E was the most recurrent mutation found in this cohort. Other hotspot mutations 
p.G742D (splice site variant) and p.K666M were found, but not repeatedly. 
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Table 3.6. Somatic non-synonymous mutations detected in progressive and/or chemotherapy resistant CLL cases* 
Genes 
CLL cases 
 Fre
q
u
en
cy
 
 
% CL
L-
1
 
C
LL
-2
 
C
LL
-3
 
C
LL
-4
 
C
LL
-5
 
C
LL
-6
 
C
LL
-7
 
C
LL
-8
 
C
LL
-9
 
C
LL
-1
0  
C
LL
-1
1  
C
LL
-1
2  
C
LL
-1
3  
C
LL
-1
4  
C
LL
-1
5  
C
LL
-1
6  
C
LL
-1
7  
C
LL
-1
8  
C
LL
-1
9  
C
LL
-2
0  
C
LL
-2
1  
C
LL
-2
2  
C
LL
-2
3  
C
LL
-2
4  
C
LL
-2
5  
C
LL
-2
6  
C
LL
-2
7  
C
LL
-2
8  
C
LL
-2
9  
C
LL
-3
0  
C
LL
-3
1  
C
LL
-3
2  
TP53 25 38 42 74 83 96 54 44 73 
                   
    9 28 
ATM 
         
50 40 98 10 7 18 42 48 50 5 
         
    10 31 
SF3B1 8 
 
4 50 47 53 
 
2 
 
6 
 
30 
    
2 
  
80 41 
       
    11 34 
PCLO 6 49 
  
36 
  
4 
     
41 
         
5 38 59 
  
    8 25 
NOTCH1 
        
81 21 
    
8 
           
12 24     5 16 
LRP1B 6 
        
6 
           
48 
      
    3 9 
SAMHD1 
             
72 
    
21 
   
49 
     
    3 9 
XPO1 
 
25 
          
24 
               
    2 6 
FBXW7 
      
10 
           
4 
         
    2 6 
HIST1H1E 
                         
45 
  
    1 3 
BIRC3 
   
13 
                        
    1 3 
CHD2 
                  
29 
         
    1 3 
MYD88 
                            
    0 0 
ZFPM2 
                            
    0 0 
POT1                                 0 0 
Total 4 3 2 3 3 2 2 3 2 4 1 2 2 3 2 1 2 1 4 1 1 1 1 1 1 2 1 1 0 0 0 0 56   
 
*Genes with multiple mutations in the same patient, only the mutation with highest allele frequency is presented. The cells left as blank grey if no mutation was identified
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Figure 3.10. Distribution of acquired somatic mutations by class across all genes 
analysed 
 
3.3.7. Frequency of mutant alleles 
The variant allele frequency of 30.3% of the mutations (24/79) were below 10% and 37.97% 
( 30/79) of the mutations were below 20% which is outside the detection limit offered by 
WES studies as well as Sanger sequencing, respectively. Consistent to findings by a previous 
study on a large cohort of CLL patients conducted by Jeromin et al [92], we identified 2 CLL 
samples that harboured FBXW7 mutations with variant allele frequency below 10%. It is 
documented that even low levels of FBXW7 gene mutation can exert oncogenic activity due 
to dominant negative effects which result in abnormal activation of NOTCH signalling (Figure 
3.11). 
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Figure 3.11. Distribution of variant allele frequencies of the identified somatic non-
synonymous mutations in targeted genes analysed 
 
3.3.8. Treatment history and its relation with the mutations 
In this study cohort, 22/32 patients had received treatment with DNA damaging agents 
before the time of sampling, with mean and median number of treatment cycles being 3.48 
and 4.0, respectively. To examine the impact of treatment on mutation, we firstly compared 
the number of mutation events (Figure 3.12.A) and the number of mutated genes (Figure 
3.12.B) identified among the cases at the latest stages between cases with and without the 
previous chemotherapy. The untreated group (n = 10) had a lower number of mutation 
events median: 1 (range: 0 - 6) compared to the treated group (n = 22), median: 2.0 (range: 0 
- 8), although the difference was not statistically significant, P = 0.075 (Mann-Whitney test). 
Likewise, we examined the number of mutated genes between the untreated and the 
treated group, the former had a lower number of mutated genes median: 1.0 (range: 0 - 4) 
compared to the latter group median: 2 (range: 0 - 4), with the P value (0.058, Mann-
Whitney test) being close to the  level.  
Next, we explored the interrelationship between the number of treatment cycles and the 
number of mutated genes. We applied the median number of treatment cycles received at 
time of sampling in this cohort as a cut-off to divide the cohort into two groups. Hence, the 
number of patients with ≤ 3 cycles of chemotherapy was 15 and that with > 3 cycles was 17. 
When counted cases with  2 mutated genes (the median in this cohort), we found a 
statistically significant difference between the 2 groups (P = 0.036, 2 test) (Figure 3.12.C). 
Thus, more than one mutated genes were identified in 13/17 (76.5%) cases who received > 3 
cycles of therapies, but only in 5/15 (33.3%) of the remaining patients.   
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Figure 3.12. Relationship of chemotherapy with somatic mutations 
Comparison of the number of mutation events A. and number of mutated genes B. 
between patients with and without previous chemotherapies. Comparison of the 
frequency of multiple mutated genes between cases received at least 3 chemotherapy 
cycles and the remaining cases C.   
 Chemotherapy  
P 
≤ 3 cycles > 3 cycles 
Samples with < 2 mutated genes 10 4 0.036 
Samples with  2 mutated genes 5 13 0.036 
 
A 
B 
C 
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3.3.9. Gene mutations in ATM/p53 and other pathways  
When we analysed somatic mutations in signalling pathways, we found that those in genes 
involved in RNA processing and splicing, SF3B1 and XPO1, occurred in 13 patients, but they 
were dominant, being either the only mutated gene or the one with the biggest VAF, in only 
3 (23.1%) samples. Mutated genes involved in the NOTCH signalling pathway, FBXW7 and 
NOTCH1, were identified in 2 and 5 samples, respectively. Only, NOTCH1 mutations were 
dominant in 3 (42.9%) samples. Mutations in histone modification genes, CHD2 and 
HIST1H1E occurred in 2 samples. Only the CHD2 mutation predominated in the multigene 
mutated sample. Mutations in NFB signalling genes BIRC3 and SAMHD1 occurred in 1 and 3 
patients, respectively. SAMHD1 mutations were dominant in 2 samples. However, the 
tumour suppressor and DNA repair gene TP53 and its upstream activator ATM were the 
most commonly mutated genes detected in 59.3% (19/32) of the sample cohort (Table 3.6). 
More importantly, both of them were the dominant mutant genes detected in 14 of the 19 
(73.7%) samples. 
 Chi-Square test confirmed that the dominant mutations in ATM and TP53 were significantly 
more frequent than that in other genes studied in this chapter (73.7% versus 37.8%, P = 
0.011) (Figure 3.13). These findings suggest defective DNA repair pathway play a dominant 
role in genomic instability and may facilitate acquisition of additional mutations in CLL.    
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Figure 3.13. Comparison of dominant somatic mutations in ATM and TP53 and 
other genes in samples from patients with advanced CLL 
The dominant mutation was defined as that was either the only mutated or the one with 
the biggest VAF. 
 
 
3.3.10. SNP array analysis showed high quality of data of the whole genome copy 
number changes 
As mentioned in Section 3.2.8, 14 mutated CLL samples from the cohort were subjected to 
genome-wide SNP array analysis. CytoSNP-850K array data quality control was measured 
using the data quality metrics. Visual inspection of Log R and B-allele frequency charts of 
sample CLL-8 revealed high levels of genomic background noise (Figure 3.14). This sample 
was therefore excluded from subsequent analysis. Data from all of other samples showed 
good quality similar to sample CLL-7 as shown in Figure 3.14. 
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Figure 3.14. Examples of good and poor quality SNP array data from visual display 
of Log R ratio and B allele frequency 
Log R ratio chart of CLL-7 shows acceptable noise and clear negative shifts from the 
baseline (close to 0) in some regions indicating large-scale deletions. Accordingly, the B 
allele frequency chart of (CLL-7) show clear deviations from the baseline in the same 
regions. For CLL-8, high levels of genomic background noise resulted in loss of clear cut 
demarcation of normal and abnormal genomic status. 
 
 
Genotyping accuracy (as estimated by calculation of the frequency of heterozygous SNP calls 
of male X-chromosome SNPs) was 100%, P = 0.001. Furthermore, all the 8 recurrent copy 
number aberrations previously identified by FISH were also correctly profiled in the 
corresponding samples, as shown in Table 3.7. 
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Table 3.7. An overview of X chromosome and previous FISH analysis used to assess 
sensitivity of the CytoSNP-850K BeadChip array 
CLL 
cases 
Gender Identified No. of X-
chromosome by 
CytoSNP-850K array 
FISH results available Identified by 
CytoSNP-850K 
array 
CLL-1 male 1   
CLL-3 female 2 Biallelic 13q14.2- yes 
CLL-4 male 1   
CLL-7 male 1 Monoallelic 17p13.3- yes 
CLL-10 female 2   
CLL-11 female 2 Biallelic 13q14.2- yes 
CLL-12 male 1 Monoallelic 13q14.2- and 11q21.23- yes 
CLL-17 male 1 Monoallelic 13q14.2- yes 
CLL-19 male 1  12+ yes 
CLL-20 male 1  12+ yes 
CLL-21 female 2   
CLL-23 male 1   
CLL-26 Female 2   
 
 
3.3.11. SNP array analysis identified recurrent and non-recurrent copy number 
aberrations in CLL 
Chromosomal abnormalities were detected in 92.3% (12/13) of the patients. 10 of them had 
at least 2 aberrations and 7 had complex karyotypes (as defined in Chapter1, Section 
1.2.3.3). Chromosomal gains (n = 9) were less frequent than chromosomal losses (n = 34). As 
shown in Figure 3.15, among the recurrent copy number changes in CLL, 13q114.2 - q14.3 
deletion was the most common cytogenetic abnormality and occurred in 6 patients 
(monoallelic loss in CLL-1, CLL-4, CLL-12 and CLL-17 and biallelic losses in CLL-3 and CLL-11). 
This lesion did not occur as solitary abnormality in any cases. The median size of this deletion 
was 3 Mbp although only in one CLL sample a large deletion spanning 27 Mbp was identified 
that affected the RB1 locus (CLL-4).  
Moreover, trisomy 12 was the 2nd most common cytogenetic abnormality in this cohort 
occurred in 4 patients, 75% of which occurred in combination with other cytogenetic 
changes. 17p13.3 - p11.2 deletion occurred in 2 cases harbouring TP53 mutations. In 
addition, a smaller region of 9,150,800 bp was affected by copy neutral loss of 
heterozygosity (CNN-LOH) in another patient with TP53 mutations. Sample CLL-1 harboured 
TP53 mutations with VAF below 25%, but did not have detectable 17p abnormality. Hence, 
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3/4 (75%) of the patients with TP53 mutations lost the wild-type allele and all of these three 
cases harboured complex karyotype. 
  
Considering 11q abnormalities, loss of 11q21 - q23.3 occurred in 2 patients (CLL-4 and CLL-
12), who carried BIRC3 and ATM mutations, respectively. Conversely, CNN-LOH of 11q13.2 - 
q25 and gain of 11q22.3 - q25 occurred in another 2 patients LL-26 and CLL-7, respectively, 
who lacked identifiable mutations in the two targeted genes mapped on 11q. 
 
 
Figure 3.15. The types and numbers of recurrent cytogenetic aberrations detected 
with the SNP array assay in the 13 CLL samples  
 
Notably, 69.2% (9/13) of the patients had at least one genetic aberration other than the 
recurrent copy number abnormalities mentioned above (Table 3.8). Interestingly, some of 
these affected chromosomal arms were identified in multiple samples, with the same or 
different region sizes. For instance, loss of 6p25.2 - p25.3 spanning from 3,077,141 - 
4,394,814 which harbour interferon regulatory factor IRF4 locus occurred in 2 patients (CLL-7 
and CLL-17). However, losses of 6q mapped between 6q11 and 6q27 or between 6q14 and 
6q15 were identified in 3 patients. Similarly, deletions of 7q21.11 -7q34 and 7q33 - 7q34 
2
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were detected cases CLL-7 and CLL-26, respectively. Additionally, a gain of another copy 
spanning the entire length of chromosome 7 was identified in CLL-4. 
Losses of chromosome 8 short arm (8p12 - 23.3) were identified in CLL-7 and CLL-11. Gains 
of 8q23.3 - q24.3 and 8q21.11 - q24.3 were found in CLL4 and CLL-11, respectively. CNN-LOH 
of 9q21.11 - q34.3 (carrying NOTCH1 locus) occurred in one sample (CLL-10) which 
harboured NOTCH1 mutations. Similarly, CNN-LOH of 2q14.3 - q37.3 (containing SF3B1 
locus) occurred in one patient with SF3B1 mutations. All the other non-recurrent 
chromosomal aberrations did not structurally associate with somatic mutations detected in 
this study. A possible chromothripsis event affected chromosome 6 (5 oscillating loss of 
heterozygosity affected the 6p) (described in Chapter 1, Section 1.2.3.5) and occurred in one 
patient who harboured TP53 mutations and 17p 13 deletions (CLL-7). However, for definitive 
chromothripsis we need to identify that the event occurred as a single cellular catastrophe 
on the same homolog and not as multistep accumulation of cytogenetic changes on different 
homologs [276]. Details of each chromosomal aberration start and end points are presented 
in Appendix 7.3.6. 
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Table 3.8. Integrated targeted NGS and high resolution genome wide SNP array analysis*  
 
* The displayed number for each gene is VAF% of the dominant mutation identified if multiple mutations existed in a sample and colour coded by the 
CNA identified. Only the chromosome aberration with the biggest size in one chromosome arm is presented for each sample.
Genes CLL-1 CLL-3 CLL-4 CLL-7 CLL-10 CLL-11 CLL-12 CLL-17 CLL-19 CLL-20 CLL_21 CLL-23 CLL-26
TP53 25 42 74 54  
ATM  50 40 98 48 5
SF3B1 8 4 50 5 30 2 80 41
PCLO 6 59
NOTCH1 21
LRP1B 6 6
SAMHD1 21 49
FBXW7 10 4
HIST1H1E 45
BIRC3 13
CHD2 29
Chromosomes
2p 2p25.3-11.2
2q 2q14.3-37.3
4p 4p16.3-15.1
4q 4q21.1-21.3 4q34.2-35.2
6p 6p22.3-11.2 6p25.3-25.1
6q 6q13-15 6q14.1-27 6q14.1-21
7p 7p22.3-
7q 7q36.3 7q31.1-36.3 7q33-34
8p 8p23.3-12 8p23.3-12
8q 8q21.3-24.3 8q21.11-24.3
9q 9q21.11-34.3
10q 10q24.1-26.3
11q 11q22.1-24.1 11q22.3-25 11q21-23.3 11q13.2-25
12p 12p13.33- 12p13.33- 12p13.33- 12p13.2-13.1 12p13.33-
12q 12q24.33 12q24.33 12q24.33 12q24.33 Keys for CNA 
13q 13q14.2-14.3 13q14.2-14.3 13q14.2-22.2 13q14.2-14.3 13q14.2-14.3 13q14.2-14.3 Gain
17p 17p13.3-11.2 17p13.3-13.1 17p13.3-11.2 CNN-LOH
18p  18p11.32-11.21 Biallelic Loss
18q 18q22.1-23 18q11.2-23 Monoallelic Loss
19p 19p13.11-13.11 Chromothripsis-like event
20q 20q11.21-13.33
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The novel (non-recurrent chromosomal aberrations) chromosomal aberrations were also 
analysed for their genomic contents, a large proportion of cancer genes and some CLL 
mutated genes listed in Chapter 1 (Section 1.2.4.3) were found to be affected. Notably, a 
large proportion of DNA repair and cell cycle control genes were affected as shown in Table 
3.9. 
 
Table 3.9. Novel CNAs identified in the CLL cohort with SNP array analysis  
Cytogenetic 
aberration 
Biggest affected band 
identified by the SNP array 
Genes Function (NCBI,2016) 
2p- 2p11.2 - 2p25.3 
ADAM17 
MYCN 
EFEMP1 
HTRA 
Cell cycle control 
Cell cycle control 
 Cell cycle control 
Cell cycle control 
2q- 2q14.3 - 2q37.3 
CXCR4 
IL1B 
ITGA6 
Lymphocyte differentiation 
Lymphocyte activation 
Cell migration 
4P- 4p15.14 - p16.3 CD38  Apoptosis 
4q- 4q21.1 - 4q35.2 FAT1 Control cell proliferation 
6p- 6p11.2 - 6p25.2 
IRF4 
RIPK1 
NFKBIE 
PIM1 
Transcription activation 
Inflammatory and apoptotic pathway 
B cell inhibitor 
Proto-oncogene in B cell lymphoma 
6q- 6q14.1 - 6q27 
NT5E 
TNFAIP3 
Lymphocyte differentiation 
7q- 7q21.11 - 7q36.3 
HGF 
ING3 
BRAF 
CAV1 
EZH2 
Cell cycle control 
Cell cycle control 
Cell cycle control 
 Cell cycle control 
Transcription control 
8p- 8p12 - 8p23.3 
WRN 
MTUS1 
DNA repair 
Tumour suppressor 
8q+ 8q21.11 - 8q24.3 
ZFPM2 
MYC 
NDRG1 
             Transcription control 
Cell cycle control 
Cell cycle control 
9q CNN-LOH 9q21.11 - 9q34.3 
SMARCA2 
TLR4 
NOTCH1 
Chromatin regulation 
Immune regulatory pathway 
NOTCH pathway 
20q CNN-LOH 20q11.21 - 20q13.33 ASXL1 Transcription regulator 
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3.3.12. Relationship of CNA with gene mutations and chemotherapy 
With SNP array data of the 13 patients available, we then tried to examine any possible 
impact of previous chemotherapy on the combined number of mutation events and the 
CNA. There was no statistically significant difference between the two groups. This was most 
likely due to the small size of samples and the bias of distribution of patients in both groups 
to be compared. In fact, only one case in this cohort was untreated at time of sampling and 
only 2 cases had received treatment ≤ cycles at time of sampling.  
Moreover, there was no statistical correlation between the number of CNA and the number 
of mutated genes detected. However, the combined number of somatic mutation events 
and the CNA was significantly different (P = 0.026, Mann-Whitney test) between samples 
with TP53 or ATM mutations, median: 8 (range: 4 - 19) and those with other gene mutations 
median: 4 (range: 1 - 5) (Figure 3.16). 
 
 
Figure 3.16. Relationship of combined number of CNAs and target gene mutation 
events with TP53 or ATM mutations in the cohort of 13 CLL patients 
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3.4. Discussion and conclusions 
At the beginning of this work, two earlier high throughput studies identified novel recurrent 
gene mutations and CNAs in a limited number of unselected CLL patients [245, 277]. It was 
unclear how these somatic mutations and CNAs are distributed across CLL patients with 
aggressive clinical phenotype. As exploratory studies, they were designed to globally screen 
genomic aberrations with WGS or WES, and therefore did not provide information about 
subclonal architecture and its relations with disease progression and relapse of CLL. 
Moreover, information on copy number alterations from these studies was limited as they 
were identified with FISH or low resolution SNP array. In our project, we designed a 
longitudinal study of progressive and/or chemo-resistant CLL using an ultra-deep targeted 
NGS technique and a more sensitive SNP array assay to deepen our understanding of 
somatic mutation pattern, subclonal architecture and their interrelations throughout the 
disease course. In this chapter, we started our study with establishing a profile of these 
recurrent genomic aberrations in a cohort of patients with progressive and/or chemo-
resistant CLL. This was necessary for our further study on mutated subclonal evolution in 
Chapter 4.  
Firstly, our analysis of coverage depth, the stringent quality control assessment and the 
successful validation of candidate variants with additional methods suggested the high and 
reliable quality of sequencing data produced by the NGS method. Although our gene panel 
did not include all recurrent mutated genes identified subsequently by other centres [272, 
278-280], the somatic mutation profile of the 32 CLL patients with advanced CLL clearly 
showed that 87.5% of them harboured at least one mutation in 12 of the 15 selected genes. 
This indicates the importance of these recurrent mutations and their involvement in 
pathogenesis of the disease. As shown in Figure 3.11, 30.3% of the detected mutations had 
variant allele frequency below 10% which is below the detection limit of WGS or WES and 
Sanger sequencing. This emphasises the importance of deep NGS techniques, so that the 
variants with low allele frequency can be identified at an early stage of the disease. 
Moreover, TP53 and ATM mutations dispersion throughout the coding sequences explains 
the unfeasibility of Sanger sequencing for screening either large genes or multiple genes in a 
single test and further underscores the necessity of large-scale analysis obtainable through 
NGS techniques. 
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Consistent with the findings in a recent study in CLL with targeted deep sequencing 
(published in 2015) [231], our study showed that missense single nucleotide variants 
predominated in the somatic mutations of the majority of the genes, except NOTCH1 and 
BIRC3 in which indels were most prevalent. In agreement with L. Wang’s finding in 2013, we 
found SF3B1 as the most commonly mutated gene in patients with progressive and therapy 
resistant CLL [281]. However, most of them co-existed with mutations in other genes, 
especially TP53 and ATM (see below). However, in the current study two distinct nonsense 
mutations were identified with a variant allele frequency below 10%, of which one was 
located outside the Heat Repeat region, emphasising a necessity to extend the target region 
beyond the hot spot in studies with deep sequencing approaches. Not surprisingly, no 
somatic mutations in MYD88 were detected in this cohort of samples. This was possibly 
because all samples tested by us had been taken at a stage of disease progression and/or 
treatment resistance and because the MYD88 mutations predominately occur in patients 
with favourable prognostic features [169, 282].  
The most interesting finding in this chapter was the possible role of mutations in two genes 
involved in cell-cycle and DNA-repair pathways namely, ATM and TP53, and their association 
with other genetic alterations. Firstly, most mutations in ATM and TP53 have been reported 
in patients with aggressive diffuse large B cell lymphoma as recorded in the COSMIC data 
base, indicating their driving roles in CLL progression. Secondly, they were among the most 
common somatic mutations identified in this study cohort, accounting for 41.77% of the 
total mutation events (Table 3.6). Thirdly, in most cases they were dominant, in terms of 
clone size over co-exiting mutations in other genes, including the most commonly affected 
SF3B1 and PCLO (Section 3.3.9 and Table 3.6). Fourthly, samples with ATM or TP53 
mutations harboured more genomic aberrations, including somatic mutations detected with 
the NGS method and CNA as detected with the SNP array, than other samples (Figure 3.16). 
Furthermore, a clear trend of positive correlation between previous chemotherapy and the 
number of somatic mutations was found in this cohort of patients in different statistical 
analyses (Section 3.3.8), although some P values were just above the pre-set  level (0.05) 
possibly due to the small size and/or biased distribution of samples. Giving the well-known 
functions of the ATM-p53 pathway in DNA repair and genomic stability, our results strongly 
suggest that defects in this pathway contribute to acquired genomic aberrations and 
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therefore the clonal evolution. Whether the clonal evolution resulted from new mutations 
induced or pre-existing mutations selected by the DNA damaging therapies will be addressed 
in the longitudinal study in Chapter 4.   
Using the high resolution SNP array assay, we were able to detect both the commonly 
recurrent (13q-, 11q-, 17p- and 12+) and novel chromosome CNAs in CLL. As expected, we 
found 13q deletions to be the most common abnormality in this cohort of 13 patients 
studied. All the 13 q deleted samples had at least another chromosomal aberration; only in 
one sample (CLL-4) the RB1 locus was affected. Alteration of this gene locus is found to be 
associated with fast disease progression in CLL [283]. In two other patients biallelic 13q14 
deletions were found. However, the significance of clinical impacts of biallelic 13q deletion 
remained controversial [284], and we could not exclude any role of the co-existing gene 
mutations and/or other CNAs. In addition, novel cytogenetic changes were identified. They 
affected chromosomes 2, 4, 6, 7, 8, 9, 10, 18, 19 and 20. Some of them were found in more 
than one sample (Table 3.8), suggesting possible hotspots of CNAs in CLL patients. In these 
regions, genes related to human cancers including CLL, were identified (Table 3.9). They play 
role in cell cycle control, DNA repair, chromatin modification, inflammatory and cell 
migration. These findings emphasize the roles of these pathways in CLL pathogenesis [177, 
185, 285]. 
The heterozygous deletion of 17p, 2q and 9q resulted in CNN-LOH of TP53, SF3B1 and 
NOTCH1 in patients with mutations in those genes, respectively. Although this has been 
previously reported for TP53 and SF3B1 mutations, there has not been any report for 
NOTCH1 mutations in CLL. Despite of no additional predicting value of LOH for TP53 in CLL, it 
is still not clear if the combined deletion and mutation will accelerate CLL progression in 
patients with LOH of SF3B1 or NOTCH1.  
Regarding the clinical impact of the gene mutations found in this cohort of CLL samples, our 
statistical analysis did not show any significant difference in treatment free survival (TFS) 
calculated from diagnosis to treatment or death and overall survival (OS) calculated from 
diagnosis or time of test to the last follow-up or death between patients with different gene 
mutations (data not shown). This might be because the mutation profile presented at the 
latest stage of the disease has no predictive value for the TFS and the OS calculated from the 
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time of diagnosis. It might be also not suitable for the OS calculated from time of sampling, 
as most of those case died shortly after the last sampling. We therefore planned to correlate 
clinical outcome of those patients with mutation profiles found at early stages in the 
longitudinal study in the Chapter 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 4. A longitudinal study of mutant clonal evolution… 
187 
 
Chapter 4. A longitudinal study of mutant clonal evolution using 
targeted ultra-deep NGS in patients with progressive and/or chemo-
resistant CLL 
 
 
Chapter 4. A longitudinal study of mutant clonal evolution… 
4.1. Introduction and aims 
As mentioned earlier, the WGS studies have revealed a number of recurrently mutated 
genes in CLL shortly before the start of this study. Subsequent studies with combined 
chromosomal copy number change [242, 286] and high throughput NGS sequencing 
techniques [137, 277] have suggested that CLL cells in a patient can bear different subclonal 
mutations or copy number changes that may evolve over disease course. More recently, the 
application of highly sensitive NGS allowed detection of a small size of TP53-mutated 
subclones and its clinical relevance has been elucidated [138]. In addition, the presence of 
subclonal driver mutations in other genes has been suggested as an influential factor for a 
clinically aggressive CLL phenotype [198].  
 
Despite a growing body of evidence for the association of genomic alterations and CLL 
clinical heterogeneity, the role of these minor mutated subclones involved in other 
recurrently mutated genes and their evolution dynamics are still not well understood. This 
might be partly because small subclonal mutations are underestimated due to limited 
sensitivities of the employed techniques. However, these subclonal mutations possibly exist 
at earlier stages or before disease progression and therapy resistance in CLL.  
 
Therefore, for a better understanding of the order of gain and selection of these genomic 
aberrations, we applied a more sensitive deep sequencing technique in this chapter. 
Primarily, we planned to reliably explore subclonal diversity and define the evolution pattern 
of these subclones over the period of disease progression and/or relapse. Secondly, we 
aimed to explore the possible mechanism of mutation operating in CLL evolution and relapse 
by identifying the pattern of somatic mutations before and after therapy. We analysed 
sequencing data of serial samples from the 23 mutated CLL patients with aggressive clinical 
Chapter 4. A longitudinal study of mutant clonal evolution… 
188 
 
phenotype to address these questions. Such information might be helpful in developing 
novel biomarkers for better stratifying patients (predicting disease progression and 
resistance to treatment) at early stages. In addition, we applied genome wide high 
resolution SNP array for integrated analysis of evolution at chromosomal levels in a CLL 
patient with 2 TP53 mutations that differentially affected p53 function. 
 
 
 
4.2. Materials and methods 
4.2.1. CLL samples   
At the time of study for this chapter, samples from 25 of the 28 mutated cases (in Chapter 3) 
taken at earlier stages were selected. We selected 38 such samples from these 25 cases for 
this longitudinal study. These samples covered different time-points (range 2 - 4 time points) 
of the disease course including stable phase, disease progression prior to chemotherapy, and 
relapse. They were cryopreserved either as isolated CLL cells (inside the Bio-bank) or as 
prepared g. DNA (outside the Bio-bank). The clinical information for these samples is 
summarised in Table 4.1. 
Moreover, the 2 DNA samples from CLL-7 taken at time of diagnosis and after disease 
progression but before chemotherapy administration were also studied for integrated 
analysis of copy number changes and gene mutation evolution over disease progression and 
after relapse.   
 
 
 
 
 
 
Chapter 4. A longitudinal study of mutant clonal evolution… 
189 
 
Table 4.1. Clinical information of the additional time points of 23 CLL cases 
analysed for clonal evolution* 
CLL 
cases 
Time point 1 Time point 2 Time point 3 
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CLL-1 160 B Relapse       
CLL-2 108 B Stable after Dx          
CLL-3 116.9 A Stable after Dx 81 NA Progression    
CLL-4 39.5 NA Dx       
CLL-5 NA A Progression       
CLL-6 23.8 C Start of 1st Tx       
CLL-7 7 B Dx 61.6 B Start of 1st Tx    
CLL-8 43.7 A Dx 129.9 C Relapse    
CLL-10 9.7 A Dx       
CLL-11 120 A Dx       
CLL-12 90 C Dx and start of 
Tx 
104.1 C Relapse    
CLL-13 127 A Remission 316 C Relapse    
CLL-14 147 B Dx       
CLL-15 12.7 A Stable after Dx       
CLL-17 184 B Stable after Dx 10.3 B Remission 263 C Relapse 
CLL-18 13.6 B Dx       
CLL-19 36.7 B Remission       
CLL-20 123.3 B Dx       
CLL-21 120.1 A Dx 287.4 B Start of 1st Tx    
CLL-22 129.8 A Dx 268 C Start of 1st Tx    
CLL-23 314 A Stable after Dx       
CLL-25 102 A Dx       
CLL-26 35 A Dx 110.4 B Start of 1st Tx    
 
*Dx: diagnosis; Tx: chemotherapy, NA: information not available. Stable after Dx: If the sample was 
not taken at date of diagnosis, but no progression occurred until the date of sampling. Grey filled 
spaces: no further serial time points were sequenced.  
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4.2.2. DNA preparation, target enrichment, deep sequencing and data analysis 
These procedures were the same as described in Chapter 2, Materials and Methods Section 
2.2.  
 
4.2.3. CytoSNP array for monitoring of chromosomal copy number changes 
In collaboration with Merseyside and Cheshire Regional Genetic Laboratory, the 2 DNA 
samples mentioned in section 4.1, were subjected to CytoSNP 850K array (Illumia, UK) as 
described in Chapter 3, Section 3.2.8. 
 
4.2.4. Statistical analysis 
Statistical analysis was conducted using IBM SPSS v21. Medians and ranges were presented 
for variables with skewed distribution. Statistical significance of association with clonal 
evolution between AID-, ageing- and other factor-related mutations were assessed using 
Chi-square test. Wilcoxon- Rank test was used for testing significance of changes occurred in 
follow up for each group of mutations. ANOVA was applied to test the significance of 
difference in mutation doubling time (from the earliest to latest time of sampling) between 
multiple gene mutation groups. Mann-Whitney test was used to test the significance of 
difference between two independent groups. For testing clinical impact of gene mutations, 
Kaplan-Meier survival curves and Log-rank test were used. Overall survival (OS) was defined 
from the diagnosis or time of first sampling to the time of death (as the event) or last follow-
up (censored). Treatment free survival (TFS) was measured from the diagnosis or time of 
first sampling to the time of first treatment/death (as the event) or last follow-up (censored). 
Statistical significance was defined as p < 0.05. All P values were calculated in double sided 
test. 
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4.3. Results  
4.3.1. SNP fingerprints intrinsically controlled tracking of serial samples 
Before tracking the mutant CLL clones in the serial samples sequenced, the samples had to 
pass a number of quality filters to ensure reliable data. These filters included all the 
sequencing quality control metrics (Chapter 2) as well as an intrinsic control namely SNP 
fingerprint match. Because germline SNP fingerprint is the only way to correctly track serial 
samples from the same individual, we sorted the sequence data from all the serial samples 
using dbSNP database to identify the germline variants unique to each case. Within the 63 
sequenced serial samples, 58 of them matched well with their corresponding samples and 
only 5 (Table 4.2) did not match this criteria, 3 of which had been received from outside the 
Bio-bank. Thus, 96.8% of the Bio-bank serial samples matched completely. The unmatched 
samples were excluded from the subsequent analysis.
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Table 4.2. An example of a number of germline SNPs used as fingerprints in tracking serial samples*         
 
*Each variant (horizontal bars) labelled as wild type (white cells), heterozygous (green) and homozygous (yellow). Proposed serial sample(s) for 
each CLL case are labelled by (X) if no match or by () if perfect match for SNP pattern was found with the last sample
CLL-1  CLL-1 CLL-1 CLL-9 CLL-9 CLL-16 CLL-16 CLL-16 CLL-19 CLL-19 CLL-19
Chr. Location  Ref.  Var dbSNP  VAF%  VAF% VAF% VAF% VAF% VAF% VAF% VAF% VAF% VAF% VAF%
2:141032088 C T rs1386356 100 44.1 49 100 100 100 100 100 100 100
2:141108531 G A rs16843826 100
2:141259283 G A rs35296183 47.2 47.8 50.2 47.8
2:141260668 A G rs4444457 100 51.5 50 48.8 46.4 49.2 100 100
2:141274576 T C rs4954672 47.9 49 50 49.6 99 97.3 47.7 98.4 100 97.5 98.8
2:141274504 G A rs75124368 49.8
2:141457985 T A rs13431727 42.8 47.9 43
2:141274504 G A rs75124368 49.8
2:141130695 C T rs16843864 47.7 46.4 100 46.6 47.7
2:141116420 C T rs150879175 47.9
2:141116447 G T rs35546150 51.1
2:141128779 C G rs76554185 52.1 48.1
2:141242918 T C rs34488772 53.3 52.3
2:141245204 T C rs74789055 51.8 50.4
2:198265526 A G rs788018 100 100 100 100 100 52.9 49.5 100 100 100 100
6:26157073 A G rs2298090 47.2
7:82453708 A C rs2522833 50.8 98.2 100 46.7 47.5 43.6 46.1 95.3 97.8
7:82544510 C T rs61995908 54.5
7:82544987 A G rs17156844 50.7 98.6 51.9 53
7:82581859 C T rs976714 51.1 51.2 57 44.2 49.1 99 49.3
7:82582846 C T rs10954696 48.9 49.5 49 46.7 46.6 100 46.1
7:82764425 C G rs2877 100 46.2 58 47.3 53.1 100 49.1 99 100
7:82785097 T C rs61741659 45.9 46.2 45.9 46.3
7:82435033 C T rs12668093 47.3 54 48.9
x  x x x x 
Variant information
SNP pattern match
Chapter 4. A longitudinal study of mutant clonal evolution… 
193 
 
4.3.2. AID-related mutations were associated with subclonal evolution  
Defining mutational signatures is an important part of the analysis of the cancer genome to 
identify the operating mutational process [287]. Recently, distinct patterns of somatic 
mutations from WGS data of the initial CLL study (n = 4 by Puente et al) has revealed a high 
incidence of C>T changes in CLL [245]. A later study of unselected CLL cases (n = 28 by 
Alixandrov et al) decomposed the signature by analysing the nucleotide changes within the 
sequence context; thus provided a higher resolution of the derived mutational signatures 
[288]. In agreement with the former study, the later study revealed a predominance of C>T 
/G>A changes at CpG sites consistent with the physiological (ageing related) spontaneous 
conversion of cytidine to thiamine at CpG sites [289]. Moreover, a non-canonical cytidine de-
aminase (nc-AID) enzyme-related signature characterised by genome-wide non-clustered 
A>C/T>G changes at WA/TW sites (where W = T or A) was identified. This signature is 
produced by downstream error prone polymerase ɳ enzyme function. In addition, APOBEC3 
signature characterised by C>T/G>A at TCW/WGA motifs was found [290]. A subsequent 
study of 30 CLL samples at a single time point by Kasar et al (published in 2015) revealed 
canonical (c-AID) mutational signature. This signature is characterised by C>T /G>A at WRCY 
/RGYW (where W = A or T, R = purine, Y = pyrimidine) motifs [137]. The production of such 
signature is associated with restorative function of downstream Uracil DNA glycosylase 
enzymes (UNG) which usually occur as regionally clustered mutations. Furthermore, based 
on clonality of the mutations determined by VAF%, it has been proposed that c-AID-induced 
mutations possibly occurred before and after the latest selective sweeps. As both ageing 
(which is an ongoing process) and c-AID-related mutations had clonal and subclonal 
fractions, therefore a possibility of ongoing c-AID activity was suggested [290]. 
Here, our NGS data from 23 CLL samples at different stages of the disease provided an 
opportunity to test this hypothesis. Initially, the acquired somatic non-synonymous 
substitutions in the 23 tested samples taken at latest time points were examined for 
mutation signatures. Of these samples, only 21 carried single nucleotide mutations (the 
other 2 samples carried only indels). The 60 single nucleotide mutations in the 21 samples 
were examined using their immediate nucleotide sequence context. For each point 
mutation, we analysed three nucleotides, including the two at immediate 5′ and 3’ sides of 
the mutated nucleotide. Thus each of the 6 possible mutations had 16 triplets, giving a total 
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number of 96 somatic substitutions in Watson and Cricks orientation [290]. In our analysis of 
the results for samples taken at the latest time point, C:G > T:A substitutions (n=18) were 
found to be highest, accounted for 30.0% of all point mutations (Figure 4.1.A). We then 
examined the nucleotide substitution profile between the samples before and after 
treatment in 14 cases. It was found that C>T changes increased from 28% to 36% (Figure 
4.1.B and C). 
Although C>T changes can be induced by AID, they may also associate with ageing and other 
factors, e.g. APOBEC3 family members. We therefore examined in detail their mutational 
signatures in the latest samples of the 21 cases described above. 9 of the 60 mutations were 
identified as ageing signature (C >T mutations at CpG sites), 8/60 were AID-related signature 
and 44/60 were others. Next, we questioned whether there is any difference between the 
evolution of ageing-related, AID-related and other factors mutations throughout the course 
of CLL. We compared other aspects, including age of the patients and time interval between 
sampling. There was no significant difference in age (P = 0.882) or the time interval (P = 
0.915) among these three signatures (Table 4.3). However, as shown in Table 4.4, we found 
that, 7 out of the 8 (85.7%) of AID-related clonal mutations showed the evolution (that is 
increase in the VAF) while the remaining one showed clonal stability. 
Similarly, 26/43 (60.47%) of other factor-related mutation clones showed evolution. While 
only 2 out of the 9 (22.22%) ageing-related mutation clones had an increase in the VAF. This 
showed a clear difference among the three groups (P = 0.021, 2 test). In addition, the clonal 
expansion in both AID and other factor-related mutations reached statistical significance (p = 
0.018 and <0.001, respectively, Wilcoxon test). In contrast, there was no statistical 
difference in clonal size in the follow-up in patients with ageing-related mutations (p = 0.484, 
Wilcoxon test). 
Table 4.3. Ages and follow-up in patients with different mutation signatures  
Variables 
Mutation signatures 
Ageing AID Others 
Ages (median (range)) 
 
66 (55-82) 65.5 (37-76) 70.5 (55-79) 
p = 0.882 (ANOVA test) 
Time intervals (median (range)) 
32 (7-61) 26 (18-60) 44 (4-61) 
p = 0.915 (ANOVA test) 
Chapter 4. A longitudinal study of mutant clonal evolution… 
195 
 
 
 
                                                      
Figure 4.1. Analysis of somatic non-synonymous single nucleotide substitutions 
Distribution of nucleotide substitutions in tri-nucleotide sequence context in 21 CLL samples with point mutations (A). % of various 
nucleotide substitutions in 14 CLL cases before (B) and after therapy (C).   
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Table 4.4. Summary of different signatures VAF% in earliest and latest CLL samples 
Signatures Case Gene Earlies sample VAF% Latest sample VAF% Time interval (months)
Aging related CLL-2 XPO1 29 25 18
CLL-3 SF3B1 5 4 60
CLL-5 TP53 65 84 7
SF3B1 4 2
PCLO 15 4
CLL-12 LRP1B 3 0 61
CLL-13 XPO1 36 24 55
CLL-20 SF3B1 0 5 11
CLL-23 SAMHD1 49 49 24
 
CLL-1 LRP1B 0 6 18
TP53 15 40
PCLO 49 49
CLL-3 TP53 1 43 60
CLL-10 NOTCH1 3 21 24
CLL-15 ATM 14 18 28
CLL-21 SF3B1 22 41 44
CLL-26 HIST1H1E 39 48 74
  
1 6
4 14
PCLO 0 6
3 10
2 4
7 25
1 3
CLL-2 LRP1B 3 0 18
CLL-3 ATM 0 6 60
SF3B1 49 49
TP53 74 74
SF3B1 40 47
PCLO 36 36
SF3B1 45 53
4 1
4 96
FBXW7 0 10
36 31
14 54
2 11
1 0
ATM 54 51
LRP1B 0 4
SF3B1 2 5
37 40
38 37
SF3B1 10 30
ATM 98 98
CLL-13 ATM 11 10 55
PCLO 39 37
ATM 0 6
SAMHD1 58 72
CLL-15 ATM 0 6 28
ATM 41 48
SF3B1 8 2
FBXW7 5 4
CHD2 21 28
CHD2 21 30
CLL-20 SF3B1 55 80 11
LRP1B 48 49
ATM 4 0
CLL-23 MYD88 4 0 24
CLL-26 PCLO 44 59 74
CLL-22
Others
CLL-1
CLL-5
24
CLL-11 ATM 40
34
CLL-14 34
CLL-17 61
CLL-19 10
SF3B1
18
TP53
CLL-4 4
CLL-8 40
AID related
CLL-2 18
7
CLL-6
CLL-12 61
52
TP53
CLL-7 48
TP53
 CLL-8 TP53 40
CLL-10 
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4.3.3. Ageing-related mutations were associated with UM-IGHV in CLL 
Following the above observations, we questioned whether there is any difference in these 
signatures between IGHV mutated and un-mutated cases. When calculating and comparing 
the frequency of the occurrence of each type of these signatures in each IGHV group, we 
found that C:G>T:A and C:G>G:C substitutions are more frequent in IGHV unmutated cases 
(Figure 4.2.A). Furthermore, all ageing-related mutations were presented in this group 
(Figure 4.2.B). This frequency (46.15%, 6/13) was obviously different from that (0) in cases 
with M-IGHV (P = 0.051). However, there was no statistically significant difference in AID- or 
other factor-related mutations between IGHV mutated and unmutated groups (P = 0.612 
and 0.356, respectively, Fisher’s exact test). 
 
 
  
Figure 4.2. Comparison of single nucleotide substitutions and mutation signatures 
between patients with M- and UM-IGHV 
A. Frequency of each type of single nucleotide substitution is shown in this histogram 
plot. B. Distribution of number of case with different mutation signatures in the two 
groups.  
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4.3.4. Evidence of complex subclonal architecture before and after disease 
progression and its persistence in relapse   
 
Recently, a number of CLL studies applied high throughput, but less sensitive techniques 
(e.g. WGS and WES) to define molecular heterogeneity and clonal/ subclonal architecture at 
various time points. Hence, small mutated subclones might not be detected. As a result, the 
definitive relevance of subclonal heterogeneity in CLL development has not been fully 
understood yet. Therefore, it was obviously worth to track the subclones with recurrent 
mutations throughout CLL progression and/or relapse by ultra-deep and highly sensitive 
sequencing, as planned in this chapter.  
 
As shown in Figure 4.3, 89.3% of the mutated clones/subclones identified at the latest time 
point were detectable at time of diagnosis or prior to treatment. Specifically, TP53 mutated 
subclones existed prior to treatment and became dominant after treatment (CLL-1, CLL-2, 
CLL-3 and CLL-6). In contrast, subclones with ATM mutations or deletions were mostly stable 
at both early and late stages. However, the ATM mutations in CLL-14 and CLL-15 clearly 
occurred later than the background genetic event (11q-, as detected by FISH). In 9/11 of the 
SF3B1 mutated samples, co-existing ATM or TP53 mutations were found. In the evolutionary 
process, almost invariably co-existing subclones carrying SF3B1 mutations were overcome by 
clones carrying ATM or TP53 mutations. While sole SF3B1 mutations were present and 
evolved over disease progression and at relapse in CLL-20 and CLL-21, highlighting the 
possible role of this gene in CLL progression and relapse.  
 
Like the subclones in the above mutated genes, all the remaining subclones with mutations 
in other genes showed expansion over time of follow-up until the VAF reached close to 100% 
or around 50%, depending on whether or not the wild-type allele was deleted (Sections 
3.3.11 and 4.3.8). However, the number and type of mutations and genes with such 
mutations in these subclones remained unchanged and preserved throughout the course of 
the disease.  
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Figure 4.3. Mutation dynamics and subclonal architecture of 23 CLL cases with progressive disease 
Serial samples taken before (-) and after (+) the first treatment (0) were screened for the recurrent mutations. For genes with multiple 
mutations, the mutation with highest VAF% is presented to show clonal size
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4.3.5. Mutations in TP53, SF3B1, NOTCH1 and BIRC3 demonstrated faster clonal 
evolution   
To assess the contribution of each targeted gene mutation to disease progression, we 
compared the VAF doubling time of these mutations. This will provide useful information of 
risk of each gene alteration for CLL disease progression. 
 
We reasoned that highly fit CLL subclones grow faster over time of evolution; mutations 
related to high fitness can be characterised by rapidly increasing mutant allele frequency 
within the tumour. Though the fitness potential is not measurable and that the rate of 
evolution is not the sole indicator of fitness, it is at least a sign of strength. Given this, the 
speed of mutant allele frequency doubling for each gene was calculated. We noted that the 
magnitude of expansion is not the same for subclonal and clonal mutations; mutations found 
to be clonal at the earliest time point did not show further expansion at time of follow-up. 
This is because the maximum limit of extension was already reached; therefore we excluded 
all the clonal genetic lesions in this analysis. 
 
As expected, there were clear differences in the doubling time among different mutated 
genes. A shorter median doubling time of < 2.5 years was observed for mutations in TP53, 
SF3B1, NOTCH1 and BIRC3 as compared to other targeted genes (the medians ranged from 
0.16 to 2.2 year) (Figure 4.4.A). Therefore, mutations in these genes were likely to drive 
higher fitness or more aggressive clones which might result in progression of CLL. According 
to the most recent risk classification of CLL, these four genes can be classified as high risk, 
while ATM as intermediate risk, for which we also found a longer median doubling time 
(10.95 years). We grouped the gene mutations according to the above proposed risk 
classification [291] into high risk, unknown risk and intermediate risk. Statistical analysis 
revealed significant differences between the 3 groups (P = 0.01, ANOVA test). Further 
analysis confirmed the significance of difference between the doubling time of the high risk 
and the intermediate risk genes (p = 0.008, Mann-Whitney test) while no difference for 
unknown risk gene mutations (CHD2, LRP1B, SAMHD1, HISTH1E and PCLO) (median doubling 
time 2.55 year) as shown in Figure 4.4.B. Therefore, for risk stratification of this group of 
genes, it might be possible to be in between the high and intermediate group. 
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Figure 4.4. Doubling time of mutant alleles in the targeted genes 
The doubling time was calculated based on VAF (%) of each mutation detected at earliest 
and latest time points for the 23 patients as shown in Figure 4.5, and presented as 
median and quadrants for A. each mutated gene. B. for grouped mutations with known 
and unknown risk categories (high risk: TP53, SF3B1, NOTCH1 and BIRC3; intermediate 
risk: ATM; and unknown risk: CHD2, LRP1B, SAMHD1, HIST1H1E and PCLO). 
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4.3.6. Evidence of growth priority for subclones with deleterious mutations  
Generally, the process of positive selection of somatic mutations contributes to tumour 
plasticity in cancer. In our longitudinal study, 20 out of the 23 cases harboured more than 
one mutated subclones. When focusing on the dominant mutations, we found that the most 
commonly affected genes in the early collected samples were TP53 and ATM, each of which 
was detected in 5 cases. However, the number of mutated TP53 increased to 8 in samples 
taken at the late stages. In addition, NOTCH1 overtook ATM as the dominant mutated gene 
in CLL-10. The numbers of other dominant mutated genes were either not changed (in ATM, 
SAMHD1, PCLO, LRP1B and CHD2) or reduced (in SF3B1 and XPO1) (Table 4.5 and Appendix 
7.3.5). More interestingly, we also found convergent subclonal evolution in CLL-7 and CLL-
11. Multiple mutations were identified in TP53 and ATM in the former and the latter, 
respectively, and one of them became the dominant mutation. 
To understand the possible roles of dysfunction of those affected genes in the subclonal 
evolution, we defined deleterious mutations in the order: truncating or shift of reading 
frame > missense mutations; and in case of missense mutations in TP53, non-functional > 
partially functional as estimated based on its transcriptional activities (TA) in the database of 
International Agency for Research on Cancer (IARC) TP53 (http://www-p53.iarc.fr/) [292]. In 
the early sample taken before chemotherapy from CLL-11, there were two subclones (A and 
B) both with a separate mutation in ATM, with 37% and 38% VAF, respectively. The mutation 
in subclone A was deleterious and resulted in truncation of the gene at exon 10, while the 
one in another subclone was a missense mutation close to the C terminal (exon 57). Not 
surprisingly, subclone A with the deleterious mutation expanded to dominate over subclone 
B (VAF 40% versus 37%) after the treatment (Figure 4.5.B). 
Likewise, CLL-7 had two different TP53 mutations within the DNA binding domain with 
changeable VAF in the three serial samples tested. As presented in Figure 4.5.D, the 
missense mutation (p.C135W) that partially retained TA of p53 (median (range): 38.45 (21.0 
- 79.6)) was initially the dominant mutation and showed an expansion together with the 
increase of circulating lymphocyte count and lymph node size (Figure 4.5.C) before 
chemotherapy. However, it declined after the treatment. In contrast, another subclone with 
a different missense mutation (p.R213L),resulting in total loss of the TA, (median(range): 
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00.00 (0 - 3.8)) markedly expanded with the VAF increasing from below 15% before 
treatment to over 54% in less than 2 years of follow-up after the treatment. 
 
 
Table 4.5. Comparison of dominant mutated genes and clones between the earliest 
and latest collected samples in cases with ≥ 2 mutations  
 
 
Earliest Latest
CLL-1 TP53 (C) TP53 (C)
CLL-2 PCLO + XPO1 PCLO + TP53
CLL-3 SF3B1 TP53 
CLL-4 TP53 TP53
CLL-5 TP53 TP53
CLL-6 SF3B1 TP53
CLL-7 TP53 (A) TP53 (B) Yes
CLL-8 TP53 (A + B) TP53 (A + B)
CLL-10 ATM (A) ATM (A)
CLL-11 ATM (B) ATM  (A) Yes
CLL-12 ATM ATM 
CLL-13 XPO1 ATM
CLL-14 SAMHD1 (B) SAMHD1 (B)
CLL-15 ATM (A) ATM (A)
CLL-17 ATM ATM
CLL-19 CHD2 CHD2
CLL-20 SF3B1 (A) SF3B1 (A)
CLL-22 LRP1B LRP1B
CLL-23 SAMHD1 SAMHD1 
CLL-26 PCLO PCLO  
Dominant gene (clone)
Cases Convergent clonal evolution
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Figure 4.5. Convergent clonal evolution favours deleterious mutations  
Clinical information available for longitudinal samples of CLL-11 (A) and CLL-7 (C) at 
various time points shown in months before (-) and after (+) the first treatment (0) is 
shown. NGS results show evidence of growth priority for deleterious mutations of ATM 
and TP53 in a background mixture of multiple independent point mutations in CLL-11 
(B) and CLL-7 (C), respectively. 
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4.3.7. Linear clonal evolution prevailed the patterns of evolution  
By definition, the branched evolutionary path in clonal evolution is a replacement of parent 
clones by the progeny in a single or multiple successive full selective sweeps, while the linear 
evolutionary trajectory is co-existence of multiple subclonal populations which compete for 
growth [286]. Therefore, one can predict the shape of evolution from tumour subclonal 
components before and after disease progression and/or relapse from the variant allele 
frequency and the trend of change in sequential samples [201]. 
 
To address the question of which pattern of evolution is predominant in our cohort, we 
analysed the subclonal mutation profiles in these serial samples taken at the earliest and 
latest time points. In only 6 of the 23 cases we found gain of additional subclonal mutations 
(Table 4.6). Moreover, none of these newly emerged subclones became dominant in the 
follow-up. While 5 small mutations (VAF 1% to 4%) in TP53, ATM, LRP1B and MYD88 in CLL-
8, CLL-22, CLL2, CLL-12 and CLL-23, respectively, became undetectable. In contrast, 20 of the 
23 cases showed clonal expansion from the same subclones previously identified as shown in 
Figure 4.4. These observations clearly showed that the linear clonal evolution pattern was 
dominant within our cohort.  
 
Table 4.6. Timing of additional subclonal gene mutations gained in 6 CLL cases 
 CLL-1 CLL-7 CLL-10 CLL-14 CLL-15 CLL-20 
Genes LRP1B and 
PCLO 
FBXW7 LRP1B ATM ATM SF3B1 
Time After relapse After 
treatment 
After disease 
progression 
After 
treatment 
After 
treatment 
After 
treatment 
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4.3.8. Longitudinal copy number analysis revealed clonal evolution in a CLL 
patient  
As mentioned in Section 4.2.1, 3 serial samples belonging to CLL7 taken at time of diagnosis, 
at time of disease progression (before treatment) and after treatment (when the disease 
relapsed) were subjected to CytoSNP 850K array. The retrieved raw data was checked for 
quality control. As data from the sample at diagnosis did not pass the quality control, 
therefore it was excluded from subsequent analysis. 
We observed complex karyotype before and after treatment with chromothripsis-like event 
affecting chromosome 6 in both analysable samples. Compared to the sample before 
treatment, the post treatment sample acquired CNA involving 5 additional bands of 3 
chromosomes (Chromosomes 10, 11 and 19) (Table 4.7). 
 
 Table 4.7. Evolution of chromosomal copy number changes in a CLL case studied ● 
 
 The blue filled CNAs denote gains and the white filled CNAs are losses 
 
 
 
4.3.9. Clinical impact of mutations detected at early stages of CLL 
To understand whether these mutations have predictive value for adverse clinical outcome 
in CLL, we studied the relationship of mutations detected in samples taken at the earliest 
stage (10 to 65 months before of the latest sampling) (Figure 4.3). When compared with the 
Case
Start Cyto End Cyto Start End Size (bp) Start Cyto End Cyto Start End Size (bp)
2p25.3 2p21 14,238 46,082,995 46,068,757 2p25.3 2p16.1 14,238 58,795,436 58,781,199
2p16.3 2p16.1 48,771,605 59,409,979 10,638,375 2p13.2 2p11.2 73,361,948 83,633,730 10,271,783
2p13.1 2p11.2 73,556,155 84,249,446 10,693,292 6p25.2 6p24.3 3,077,141 9,275,594 6,198,454
6p25.2 6p24.3 3,205,325 9,745,037 6,539,713 6p22.3 6p22.3 16,998,804 19,017,212 2,018,409
6p21.33 6p21.2 30,724,430 38,723,575 7,999,146 6p21.33 6p21.2 30,770,000 38,728,142 7,958,143
6p21.1 6q12 44,568,740 66,916,257 22,347,518 6p21.1 6p11.2 44,509,266 58,630,693 14,121,427
6q13 6q15 74,217,278 88,021,118 13,803,841 6q11.1 6q12 61,891,118 67,977,326 6,086,209
7q21.11 7q21.12 80,512,536 86,608,786 6,096,251 6q13 6q15 74,166,098 88,152,535 13,986,438
7q31.1 7q32.1 112,044,527 127,479,262 15,434,736 7q21.11 7q21.12 79,585,451 87,226,690 7,641,240
7q32.3 7q36.3 131,304,940 159,126,310 27,821,370 7q31.1 7q36.3 112,071,795 159,126,310 47,054,516
8p23.3 8p11.23 164,984 36,646,217 36,481,234 8p23.3 8p12 164,984 35,042,190 34,877,207
10q24.1 10q26.3 99,267,639 135,477,883 36,210,245
11q22.3 11q25 107,617,257 134,934,063 27,316,807
17p13.3 17p11.2 12,344 21,246,375 21,234,032 17p13.3 17p11.2 12,344 20,117,151 20,104,807
19p13.3 19p13.11 5,830,302 18,342,477 12,512,176
19p13.11 19p11 18,347,539 24,487,350 6,139,812
Before treatment After treatment
CLL-7
Chapter 4. A longitudinal study of mutant clonal evolution… 
207 
 
4 having no mutations (CLL 29, 30 31 and 32, in Table 3.6.), the 23 patients with mutations in 
the earliest samples had a similar OS (measured either from time of diagnosis or the time of 
1st sampling). This was the same in a comparison among cases with no mutation, non-driver 
mutation and driver mutation (data not shown). Similar to what found in Chapter 3, there 
was no difference in the TFS measured from the diagnosis between patients with and 
without the mutations (data not shown). However, when it was measured from time of the 
1st sampling, the TFS became clearly shorter in patients with the mutations (Median TFS: 10 
months versus 24 months), although the P value (0.061) was above the pre-set  level (0.05) 
(Figure 4.6.A). Moreover, by dividing the former group into those with and without driver 
mutations, we could not find a difference in TFS measured either from the diagnosis or time 
of the 1st sampling between them. This prompted us to explore whether the size of 
subclones with driver mutations had an impact on the TFS. 
To do so, we used the criteria reported by Davide Rossi et al [293] to select the significant 
size of all of the five driver mutated genes detected in our cohort: BIRC3  1%, SF3B1  35%, 
NOTCH1  25%, SAMHD1  7% and TP53  1%. As expected, a statistically significant 
difference in the TFS measured from time of the 1st sampling was observed among the three 
groups of CLL patients (P = 0.037, Log-rank test), with those harbouring a large driver 
mutation showing the shortest TFS (Figure 4.6.B).   
 
 
 
A 
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Groups of CLL patients No. of samples Median TFS 95% CI P 
Without gene mutation 4 24.0 0.00 - 62.22 
0.061 
With gene mutation 23 10.0 0.61 - 19.39 
 
 
 
 
 
 
 
 
Groups (code) No. of samples Median TFS 95% CI P 
Driver mutation (A) 11 6.0 0.60 - 11.39 
0.037 Non-driver mutation (B) 12 13.0 0.00 - 26.57 
No gene mutation (C) 4 24.0 0.00 - 62.22 
 
Figure 4.6. Effects of target gene mutations detected at an early stage on TFS 
measured from the time of sampling 
A. Kaplan-Meier curve and Log-rank test showing a trend in which patients with the 
mutations had a shorter TFS than those without them. B. Kaplan-Meier curve and Log-
rank test showing statistically significant differences in the TFS between cases with and 
without the large-size driver mutations.   
B 
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4.4. Discussion and conclusions 
In Chapter 3, we have clearly shown that the majority of CLL patients carry at least one of 
the recurrently mutated genes when tested at the stage of disease progression and/or 
chemotherapy resistance. In this chapter we aimed to investigate the evolution of these 
mutant subclones in the course of the disease. Other studies have shown evidence of 
complex subclonal architecture and its association with disease progression and relapse in 
CLL. However, with a limited coverage depth and therefore a low sensitivity of either whole 
genome or whole exome sequencing approaches [198], they might have underestimated 
small subclones and thus had not provided a complete picture of subclonal composition. 
However, NGS approaches targeting only the coding sequence of a limited number of genes 
such as TP53 has massively increased the sensitivity [273]. They provide a useful tool to 
study the more comprehensive subclonal architecture and its dynamics. This would possibly 
re-shape the portrait of intra-tumour subclonal complexity at various stages of the disease 
and depict the effects of treatment on the evolutionary dynamics. We therefore applied 
such an approach to investigate the clonal evolution of those recurrent somatic non-
synonymous mutations and its relations with clinical outcomes of patients with CLL. Here, 
we described the results of the longitudinal study using sequential samples taken at 
different time points from patients with mutations detected in Chapter 3. Use of the same 
deep sequencing approach allowed us not only to track minor subclones, but also to collect 
data that were suitable for comparison with those produced using samples taken at the late 
disease stage and sequenced in Chapter 3. For example, the SNP patterns matched well in 
serial samples from each individual case. This was successfully used as a genomic fingerprint 
to reconfirm the real source of those serial samples and guaranteed the truthfulness of 
results from the paired samples presented in this chapter. 
After this, we investigated the mutation signature both archetypically and contextually 
within tri-nucleotide sequences. This topographic information was important for defining 
the operating mutational process before and after disease progression and/or relapse in CLL 
in general, as well as in different subgroups with mutated or unmutated IGHV. Using 
mutation signature information based on the type of nucleotide changes and sequence 
context, we were able to identify three main mutational signatures to be operative in CLL, 
including AID- and ageing-, and other factor-related signatures.  
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AID is the key enzyme contributing to the immunoglobulin somatic hypermutation process in 
B-cell development and is responsible for affinity maturation of antibodies [294]. Its 
enzymatic activity is tightly regulated to target IGV region genes by catalysing cytosine 
deamination to produce uracil, thus creating U: G mismatches [294]. It has been suggested 
that off-target (aberrant) activity of AID may contribute to oncogenic mutations outside IGV 
and chromosomal instability [290]. In this respect, the AID mutational signature has been 
very recently identified in an unsupervised analysis of mutational signatures for 30 
unselected CLL cases at a single time point using WGS [290]. Here, in analysis of mutation 
signatures recorded in the longitudinal study, we are the first to find that AID-related 
mutations were most likely associated with subclonal evolution in CLL. Our finding supports 
the hypothesis proposed in a recent study suggesting the possible role of AID activity in 
evolution of mutated subclones in this disease [290]. Notably, AID seems to be not the only 
factor that contributes to this, as clonal expansion was also observed in our study for 
mutations not related to this enzyme. These non-AID-related mutations may relate to ageing 
and other factors. To support this, 2 of the 9 ageing-related mutations identified by us had 
subclonal expansion in the disease course, although it was not as frequently as AID-related 
mutations. In addition, the ageing-related mutations occurred more frequently in IGHV- 
unmutated patients, suggesting its association to tumour cells with higher replicative 
capacity as reported by others [295] and therefore supporting the notion that unmutated 
IGHV have greater proliferative capacity and worse prognosis [296]. Taken together, these 
findings decipher the independent mutational signatures operative in these samples. The 
ongoing activity of AID might have an influence on clonal evolution in the off-target genes. 
Our study did not provide direct evidence for specifying any other factors. However, other 
members of the APOBEC3 family, in which AID is one, may involve in the subclonal evolution. 
This is because they induce the same initial nucleotide changes as AID does [297].    
Considering the mutation spectrum and subclonal complexity, we clearly showed a complex 
subclonal architecture of TP53 and ATM mutated patients from early stages of the disease 
(Figure 4.3). An important question addressed here is whether difference in clonal evolution 
pattern is due to different pathways which are affected by the mutations. Here we reported 
that TP53, SF3B1, BIRC3 and NOTCH1 mutations were associated with the fast expansion of 
the subclones. It is well known that p53 as a gatekeeper at cell cycle check points is vital in 
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regulation of DNA repair, in addition of other functions, e.g. activation of apoptosis. In CLL, it 
has been found that genomic aberrations of TP53 and its upstream regulator ATM are 
frequently enriched in patients with resistance to DNA damaging agents [137]. Moreover, 
these genetic lesions allow acquisition of additional genomic alterations contributing in CLL 
phenotypic transformations [191]. 
 
Considering other driver mutations, SF3B1 (a recurrently mutated gene in CLL) has been 
found to be associated with clonal evolution [298]. It has also been reported by Schwaederlé 
et al in 2013 using Sanger sequencing technique that SF3B1 mutation expansion could occur 
with or without therapy administration [299].  
 
Moreover, subclonal mutations in other drivers such as NOTCH1, BIRC3 have been linked to 
faster disease progression and poor survival [300]. We observed a similar trend related to 
NOTCH1 and BIRC3 mutations, both of which were associated with a fast subclonal 
expansion (Figure 4.4). Despite of the requirement for a bigger number of samples for a solid 
conclusion, this finding provided a further support for the notion that subclonal mutations in 
BIRC3 and NOTCH1 can predict poor prognosis as these lesions could quickly evolve over 
time [138, 273]. 
  
Regarding the cause of growth priority in convergent clonal evolution (defined by presence 
of independent somatic mutations in the same gene) that has been observed in previous 
longitudinal studies of CLL in which SF3B1, NOTCH1, ATM, TP53 and BIRC3 genes were 
affected [201, 273]. Here, we documented the convergent clonal evolution in two cases with 
mutated ATM or TP53. We were able to use mutation types and their causal impact on wild-
type protein functions (for p53 only) to explore their relationship with the subclonal 
evolution. We found that the truncating mutation at the N-terminal in ATM, and the non-
functional mutation in TP53 became predominant over the missense at the C-terminal and 
partially functional mutations in the same two genes, respectively, after chemotherapy. This 
finding emphasised an importance of these deleterious mutations in the subclonal selection 
process, which may involve competition over growth conditions in the micro-environment 
and adaption to extrinsic pressure such as chemotherapy [301]. 
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To infer temporal order of gene mutations and the pattern of clonal evolution, phylogenetic 
trees are often employed by assuming that common predecessors are early events, but this 
method typically needs larger number of alterations than the ones available in our cohort 
[302]. Furthermore, standard statistical techniques have extremely limited power to assess 
the significance of different branches using longitudinal data from patients in few selected 
driver genes. Therefore, we used similar approach used by P. Quillette et al, published in 
2013 [286] and depicted the pattern of evolution based on the presence or absence of the 
mutations and the trend of evolution during the time of follow up. In agreement with the 
models proposed [242], our study identified both linear and branch clonal evolutions in CLL, 
however, the majority of these mutant subclones followed a linear evolution, while 
branching evolution was rare in our cohort. The reasons for this are not yet known, but it 
might be due to deeper and higher sensitivity of the methodological approach applied in this 
study. Thus, more tiny subclones existing at early stages were detectable. In addition, this 
might also be because of a fast evolution occurred in very late samples that were only 
available in patients at a late stage, as those included in our study.  
In our CNA analysis for a single case harboured TP53 mutation as detected by the NGS, we 
showed clonal evolution as an increase in the number of involved bands of previously 
affected chromosomes and emergence of new chromosomal regions at time of disease 
relapse. 
The clinically important finding in this chapter was the effect of targeted gene mutation on 
TFS when TFS was calculated from time of sampling (Figure 4.6), but not from time of 
diagnosis. This is possibly because the gene mutations might not have occurred long before 
the screening or may be due to some drivers required to reach a certain VAF% to exert their 
effects. A shorter TFS was observed for cases harbouring at least one target gene mutation. 
More interestingly a statistically significant association of shortest TFS with driver mutations 
(defined using the pre-determined VAF thresholds) was observed in this cohort. This finding 
further supports the influence of driver mutations in disease progression.  
Taken together, these findings in this longitudinal study firstly show the necessity of deep 
sequencing approach to identify minor mutant subclones of prognostic potential. Secondly, 
not all convergent mutations play the same role in subclonal evolution. Therefore, 
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identification of the deleterious mutations is important for more targeted therapies which 
are available now. Thirdly, AID-related mutations play a role in CLL subclonal evolution, 
although it is unlikely to be the only factor. Fourthly, among these recurrent mutated genes, 
some (including TP53, SF3B1, NOTCH1 and BIRC3) contribute to the subclonal evolution 
more profoundly than others. This will help to target these fast expanding subclones in order 
to maintain a balance between the subclones and preserve the clonal stability [242].  
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Chapter 5. Applying the ultra-deep NGS test for CLL recurrent 
mutations in clinical samples 
 
 
Chapter 5. Applying the ultra-deep NGS.. 
5.1. Introduction and aims 
As described in General Introduction, the recent availability of a number of targeted 
therapies for various cancers, including CLL may pave the way for personalised medicine in 
the future [303]. To a great extent, the success of such treatments relies on the genetic 
profile of the individual tumour being treated; therefore, new clinical trials to select 
treatment based on specific mutations found in individual patient may be underway in this 
hospital (region).  
Having developed the fast, inexpensive and highly sensitive NGS test for multiple gene 
mutations in stored mononuclear cells of CLL patients, we planned to use this test as a 
clinical laboratory service. However, clinical samples are different from those used in the 
development of this test. They include fresh blood and formalin fixed paraffin embedded 
(FFPE) tissues. The aim of this chapter was to examine whether this test is suitable for these 
clinical samples, and establish a format for result reporting.  
 
5.2. Materials and methods 
5.2.1. Clinical samples 
A blood sample from a newly diagnosed CLL patient and a formalin fixed paraffin embedded 
(FFPE) tissue sample from a patient with a history of CLL and lacrimal sac involvement were 
collected from the out-patient clinic of Royal Liverpool University Hospital and used in this 
testing. The clinical information of these cases is summarised in Table 5.1. 
 
 
 
Chapter 5. Applying the ultra-deep NGS.. 
215 
 
Table 5.1. Overview of clinical information of the cases used in this chapter 
Cases Age Gender Diagnosis Binet stage Therapy prior to sampling 
1 50 Male CLL A None 
2 89 Male 
CLL with lacrimal sac 
involvement 
C 
Chlorambucil and 
bendamustine 
 
 
5.2.2. DNA extraction and NGS procedures 
The blood sample from the CLL patient was processed for mononuclear cell separation and 
the DNA was extracted as described in Sections 2.2.1 and 2.2.2, respectively. For the lacrimal 
sac sample, g. DNA from FFPE tissue sample was provided from the Pathology Laboratory of 
Royal Liverpool Hospital. After performing the quality control checks for each g. DNA sample 
as mentioned in Section 2.2.3, 225 ng and 675 ng of g. DNA from the respective newly 
diagnosed CLL and the CLL case with lacrimal sac involvement were used for target 
enrichment using HaloPlex probes. The DNA samples were successfully enriched using the 
same approaches stated in Section 2.2.8. Later, the enriched exon DNA of the 15 genes were 
sequenced on an Ion 318 chip as described in Sections 2.2.11, 2.2.12 and 2.2.13. Finally, the 
NGS data was processed as defined in Section 2.2.14. 
 
5.3. Results 
5.3.1. DNA quality and read length of the DNA libraries 
As shown in Table 5.2 and Figure 5.1, a sufficient amount of good quality of g. DNA was 
obtained from both the FFPE sample and the fresh peripheral blood mononuclear cells (PB 
MNCs). As expected, compared to the g. DNA from fresh PB MNCs and stored PB MNCs the 
integrity of the FFPE tissue g. DNA was low, with the range of sizes being 35 - 400 bp (also 
shown in Section 2.3.1.1), compared to 1000 - 10380 bp of fresh and stored MNCs. However, 
the optimised HaloPlex protocol enabled a successful enrichment of targets in both DNA 
samples within an acceptable size range: 150 - 450 bp for the FFPE and 150 - 550 bp for the 
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fresh PB MNCs DNAs, although the average size of the former was smaller than the latter 
(Figure 5.1). Of note, the starting amount of g.DNA from the FFPE tissue was 3 folds of that 
from the blood MNCs in order to obtain similar quantity of target DNA libraries for 
sequencing.    
 
Table 5.2. Quantities and qualities of g. DNA and DNA library size of each sample  
Samples 
g.DNA 
Source Quantity 
ng/µl 
Quality 
OD 280/260 
g. DNA size 
peak (bp) 
DNA library 
size range 
(bp) 
DNA 
library 
yield 
1 FFPE tissue 97.8 1.97 < 400 150-450 2.4 ng/ µl 
2 Fresh PB 
MNCs 
65.8 1.89 >1000 150-550 8.8 ng/ µl 
 
 
 
 
Figure 5.1. The g. DNA integrity and DNA library peak size of the 2 clinical samples 
Bioanalyser electophoreograms show size distribution (bp) of partially degraded g. DNA 
of a FFPE tissue (sample 1) and an intact g. DNA from the fresh blood MNCs (sample 2) 
and of the corresponding DNA libraries after enrichment with HaloPlex and XP bead 
purification 
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5.3.2. Sequencing quality 
Satisfactory chip loading density of 77% was achieved and the sequencing data was of good 
quality as determined by the number of bases with AQ 20 which was 537.5 Mbp compared 
to the respective average values of 71% and 663 Mbp for the CLL cohort (Chapter 2, Table 
2.8). However, as expected the average target DNA size (Figure 5.1), the average coverage 
depth and the target coverage (Table 5.3) for the blood sample was undoubtedly better than 
the FFPE sample, despite of the same amount of target DNA being sequenced.  
 
 
Table 5.3. Read length and quality of coverage for individual samples 
Coverage parameters Fresh PB MNCs sample FFPE tissue sample 
Mean read length 172 bp 144 bp 
Av. base coverage depth 5792 x 1110 x 
Av. uniformity of coverage 95.47 89.88 
Target base coverage at  
1 x 
20 x 
100 x 
 
99.93% 
99.76% 
99.16% 
 
99.75% 
98.24% 
95.7% 
 
 
  
5.3.3. Good test reliability as assessed by germline SNPs 
We used the number of SNPs identified in each sample library to estimate target coverage. It 
was 0.42 and 0.46 SNPs/Kbp for the lacrimal sac and the blood sample, respectively. As 
compared to mean number of SNPs identified in the CLL cohort (Mean ± SD: 0.41 ± 0.04) 
(Section 2.3.2.1) the results were very close. As expected, the allele frequencies of most 
SNPs identified were close to 50% or 100%, with those in the CLL sample being closer than in 
the lacrimal sac sample as shown in Figure 5.2. Moreover, even a SNP located in the GC- rich 
region of exon 4 of TP53 (17:7579472 G>C, p.P72R) was clearly detected in both samples, 
with a VAF of 95.3% and 98.8% for the lacrimal sac (FFPE tissue) sample and the CLL (fresh 
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blood mononuclear cell) sample, respectively. Inclusion of these controls minimised false 
negatives of the test for these cases.   
 
 
                A 
 
 
          B 
 
 
Figure 5.2. SNP allele frequency distribution of the clinical samples 
SNPs allele frequency distribution for the lacrimal sac sample (A) and the CLL sample 
(B) centred around 50% and 100% 
 
Chapter 5. Applying the ultra-deep NGS.. 
219 
 
5.3.4. Gene mutation status (somatic non-synonymous variants) identified  
In the total of 25 variants detected in the lacrimal sac sample, there were no somatic 
non-synonymous mutation, but 2 synonymous mutations with VAF of 10% and 11% in LRP1B 
(2:141259394 A>G) and SAMHD1 (20:35579942 G>C) were identified, respectively. While, in 
the CLL case, a single nucleotide insertion was identified in exon 10 of ATM (11: 108121602-
3 insertion A, VAF: 12.5%, target base coverage depth: 1998 x, the variant allele coverage: 
250 x, strand bias: 0.77 and AQ: 194.6) that resulted in truncation of the protein as recorded 
in the report below (Figure 5.3). 
         
5.3.5. Format of the clinical report produced 
In the result report, we firstly showed quality of the test, including the average coverage 
depth, uniformity and limit of detection (LOD). The LOD was calculated based on a minimum 
of 20 mutant alleles detected for each mutation in a sample. For somatic non-synonymous 
mutations detected, the exact nucleotide and amino acid sequence changes were reported 
along with the location at corresponding chromosome and the VAF. Owing to nature of this 
NGS method, an absolute (100%) uniformity could not be reached. Thus, not all the target 
regions were evenly sequenced. Accordingly, some mutations with very low VAF might not 
be detectable. We therefore reported the average limit and the lowest limit of detection, as 
well as the average and lowest coverage depths for all target genes with and without 
mutations detected, and made a disclaimer to avoid any misunderstanding of negative 
results (Figure 5.3). 
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Report: CLL-NGS2015-001                  
     The Royal Liverpool and NHS  
Broadgreen University Hospitals NHS trust 
Lymphoid R&D Biomarker Laboratory 
Royal Liverpool University Hospital 
Prescot Street, Liverpool L7 8XP 
Tel: 01517064326 
 
Mutation test of a CLL gene panel 
 
 
 
Materials and method: 
DNA extracted from blood mononuclear cells was used for enrichment of target exons using HaloPlex probes designed for 15 genes 
recurrently mutated in CLL. The resulting DNA was amplified by PCR and then purified with XP beads followed by sequencing on an Ion Chip 
318 using the Ion Torrent PGM platform. The sequence data were processed and analysed using the Ion Reporter (V4.2) software package 
with the human genome sequence Hg19 being the reference. Known SNPs and synonymous mutations were filtered out in the analysis. 
Overall sequencing quality is summarized below: 
Average depth of base coverage Uniformity of base coverage Average limit of detection 
5792x 95.47 0.3% mutant alleles 
 
Results: 
The non-synonymous somatic genomic alteration detected are presented in the table overleaf. 
Conclusion 
A single nucleotide insertion in ATM resulting in protein truncation was detected in 1.5% of alleles in this sample 
There are no detectable sequence alterations in the other 14 genes. However, mutations affecting a small proportion of alleles cannot be 
excluded due to low coverage depth in some target regions. 
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Genes Target 
exons 
Av. 
Coverage 
Av. 
depth 
Mutation 
detected 
Details of the mutation identified 
Location c.DNA variant Variant 
Protein 
Mutant/total 
alleles 
TP53 2-11 100x100.00
% 
4874x No 11:10611602 c.1410-1411insA p.N471Kfsx16 250/1998 
12.5% 
ATM 2-63 100x99,16
% 
5756x Yes     
SF3B1 7-19 100x100.00
% 
4984x N0     
PCLO 2-24 20x99.77% 
100x98.48
% 
5882x No     
BIRC3 2-9 100x99.37
% 
6465x No     
NOTCH1 34 20x99.87% 
100x94.60
% 
1674x No     
MYD88 2-5 100x100.00
% 
7163x No     
LRP1B 34-86 100x100.00
% 
6304x No     
SAMHD1 1-16 100x100.00
% 
5065x No     
XPO1 11-16 100x100.00
% 
4550x No     
FBXW7 6-12 100x100.00
% 
6147x No     
CHD2 12-36 100x100.00
% 
6929x No     
HIST1H1E 1 100x100.00
% 
5054x No     
ZFPM2 8 100x100.00
% 
6581x No     
POT1 5-19 20x100.00
% 
100x98.00
% 
6130x No     
 
Figure 5.3. An example report of NGS gene panel test for CLL recurrent mutations 
in blood MNCs of a newly diagnosed CLL case 
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5.4. Discussion 
Gathering information based on gene mutations that are expected to confer resistance to a 
target therapeutic agent will be important for imminent deployment of effective 
combination therapies. Given that more genetic determinants in CLL that drive disease 
progression and resistance have been discovered, there exists a need to adopt a targeted 
NGS approach that can affordably, quickly and reliably sequence multiple genes from 
individual patient samples. This is because routine use of whole genome or whole exome 
sequencing is likely to be a few years away due to lower sensitivity and vast amount of data 
produced which is difficult to be managed with the available platforms and bioinformatics 
infrastructure in clinical laboratories. Moreover, in the WGS and WES techniques a large 
number of mutations can be incidentally found without recognising their significance which 
poses a great reporting challenge for the laboratories [304]. Therefore, we sought to 
implement the developed targeted NGS approach to forge the way for entering mainstream 
diagnostic use. As, there were no formal standards for the minimum depth of targeted 
sequencing we determined the sensitivity (limit of detection) based on the average coverage 
depth. However, the obtained depth of coverage is not always identical in all targeted 
regions for NGS, suggesting that some of small-size mutations with a shallow coverage may 
not be detectable. Therefore, target regions with minimal coverage were defined to avoid 
false negative results in the clinical report. 
As discussed earlier, FFPE samples are invaluable both in research and clinical context. DNA 
library construction for NGS tends to be challenging for such samples as it has been reported 
that only 30% of such specimens could achieve successful enrichment [305, 306]. Here, our 
sample processing protocols have allowed us to robustly enrich g. DNA extracted from a 
FFPE sample which clearly showed degradation. We used an additional quality control step 
(FFPE DNA integrity analysis described in Section 2.3.1.1) by amplifying different fragment 
sizes of GAPDH before sample enrichment with HaloPlex and this provided hints that DNA 
fragments up to 300 bp can be successfully amplified (Figure 2.2.C). Moreover, we used 
greater amounts of g. DNA for the FFPE sample which was 3 folds higher than the amount 
used for the CLL sample. Though the amount of DNA library recovered was sufficient for 
sequencing, the yield of DNA library for the FFPE sample library was lower than that of the 
CLL sample. It is important to mention that, due to the natural flow of haematological 
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malignancies, the tumour specimen tends to be homogenous and thus all the subclones are 
equally represented [242, 307]. In contrast, a solid tumours’ tissue section, including the 
FFPE tissue sample used in this chapter may not be representative (commonly contaminated 
by the surrounding normal tissue) to the whole tumour or subclones [242] and therefore 
additional steps are needed to evaluate and quantify histology of the specimen to establish 
percentage of tumour cells in the specimen based on staining in addition to examining the 
effect of storage time on the NGS results.  
Despite that, due to the capacity of the enrichment probes in capturing short DNA 
fragments, this approach seems to be ideal for enrichment of FFPE derived DNA which 
frequently appear in degraded forms. However, the ideal number of cells or tissue sections 
for sufficient DNA extraction needs to be evaluated. Moreover, experiments for improving 
the quality of extracted DNA from FFPE tissue need to be conducted to improve the quality 
of the subsequent NGS results. 
All in all, our results are promising and suggest that the developed NGS technique can be 
used to study FFPE specimens and both fresh and stored (frozen) blood specimens. 
Moreover, the developed reporting process was suitable for clinical application as the 
communicated information has recently been published in guidelines for NGS reporting in 
clinical settings [257, 308]. 
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Chapter 6. General discussion 
The ultimate aim of this study was to develop predictive genomic biomarkers for CLL 
progression and response to treatment. The objectives were firstly, to establish a gene 
mutation profile of samples taken at advanced stages of the disease and secondly, to study 
clonal evolution dynamics in order to understand inter-clonal relations and association 
between target gene mutations and clinical outcome.  
Achievement of this goal required successful development and implementation of a highly 
sensitive method to monitor recurrent gene mutations in this disease. Among different NGS 
approaches, HaloPlex target gene enrichment and sequencing on Ion Torrent PGM were 
chosen for this project owing to their advantages described in the General Introduction. As 
both techniques were new, optimisation step by step from probe design to final reporting 
was essential. The work presented in chapter 2, regarding the development of the method 
included a series of assessments of the technique. A customised HaloPlex probe set for a 
panel of 15 genes reported to be recurrently mutated in CLL was designed. Together with 
carefully adjusted other conditions, this allowed good cost efficiency and a high test 
sensitivity. Thus, the cost of consumables for each test was only £265, and the average 
detection limit was as low as 1% VAF, if 4 DNA libraries were sequenced on each chip with an 
expected coverage depth 1846 x of 135.42 Kbp of sequenceable region.  
In our study, the average target coverage depth (2252 x) obtained was actually bigger than 
expected for the sequenceable regions, this was because the expected coverage depth was 
calculated assuming an even distribution of coverage across the target sequences and their 
adjacent off-target regions. However, the coverage for target regions was always much 
bigger than that for the off-target, due to the probe design.   
On the other hand, even in these target regions, the coverage was not absolutely even. This 
is an issue for NGS, which has been also reported by others [309], and was particularly 
important when certain regions with low coverage depth and no mutation detected. In this 
respect, false negative results might be reported. We were therefore very cautious in the 
report by including the average coverage depth of each target gene to avoid a 
misinterpretation of negativity to be wild type. This is still an issue for future discussion in 
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the clinical application of this test. Another finding in the initial phase of our study was the 
missing target regions with GC-rich sequences, including the 75 bp in exon 4 of TP53. Though 
small, these missing regions were not negligible and therefore were covered by a boost of 
probe overlay in our subsequent HaloPlex probe design which resulted in dramatic increase 
of the coverage depth of this GC rich target region. Thus, this strategy is useful for any other 
GC rich targets with low amplicons to augment the coverage depth (Figure 2.5).  
Considering the wet lab procedures, good quality DNA is essential for NGS. Moreover, 
successful library amplification and purification are key steps of HaloPlex target enrichment. 
Initially, we used the manufacture’s protocol, as shown in Figure 2.3, for the DNA digestion 
step; the fragments were larger than expected. Therefore, a longer DNA incubation time 
with the enzymes was necessary for appropriate DNA digestion. Furthermore, no DNA 
library was initially recovered following the manufacturer’s instructions. In our experiments, 
elongating the duration of XP bead-library incubation could overcome the problem and 
sufficient amounts of DNA libraries were obtained (Figure 2.7). In addition, sufficient purity 
was achieved using double purification by XP-beads (Figure 2.8) which later maximised the 
chip capacity usage for deeper sequencing. We also reduced the amounts of probes without 
any effect on DNA library amplification. This strategy improved the efficiency of purification 
and saved as much as 16% in the amount of the probes used (Section 2.3.1.5). 
Data analysis is as equally important for this NGS test. We used the manufacturer-
recommended analysis pipeline in the analytical process. However, the defaulted high and 
low stringency settings of the TVC plugin initially used were not designed for the purpose of 
this test for these recurrent mutations in CLL. Based on known VAF% of 5 different 
mutations scattered in TP53, we were able to test reliability of these defaulted settings. As 
shown in Table 2.11, false negative and false positive variant calls were found. Our optimised 
variant calling plugin with parameter settings that had yet acceptable confidence scores 
improved both sensitivity and precision of the test to 100%. In subsequent As-PCR 
experiments using serial diluted DNA, we confirmed the fidelity of these mutations identified 
by the PGM and verified the high sensitivity of the NGS test we developed (Section 2.3.3). 
Besides, we tested the reproducibility of the test by duplicate sequencing runs of multiple 
CLL samples. As expected, a high agreement between the tests for both the variant 
detection and VAF% in all samples were achieved (Figure 2.13). More convincingly, the 
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alternative validation of ATM mutational status in 7 samples by the University of 
Birmingham and the high agreement of the sequencing results of 5 CLL samples screened by 
ERIC for TP53 mutational status (multicentre double blinded study) confirmed the reliability 
of our NGS test (Section 2.3.3.4). The conclusions that can be drawn from Chapter 2 are that 
all the optimised steps including the data analysis generated robust results. Thus, this test 
can efficaciously be implemented to achieve other immediate (Chapter 3, 4 and 5) and 
future aims of this study.   
With the reliable NGS test established, we next implemented this approach in Chapter 3 to 
study the mutation profiles in 32 CLL patients with progressive and/or chemo-resistant 
disease along with another patient with an indolent disease. We further documented the 
high quality of data using SNP pattern as a genomic imprint [250] and Ti/Tv ratio to the 
expected levels reported by others [254]. These guaranteed the reliability of the data we had 
prior to downstream analysis. Although it was easy to distinguish non-synonymous from 
synonymous mutations, we were careful in identifying somatic alterations as there were no 
germline DNA controls. We determined somatic alterations by comparing the variants to 
records in dbSNP (for germline variants) and COSMIC (for somatic variants) databases. We 
also used the VAF of 2-40% or 60-90%, and the changeable VAF when serial samples were 
sequenced as additional criteria for somatic mutations if they were not previously reported.   
Of note, the gene panel was selected at the beginning of this study and therefore did not 
include recurrent mutated genes identified afterwards [278, 280]. Our results might not 
reflect the whole picture of the mutation profiles in this cohort of CLL. Nevertheless, we 
identified 79 somatic non-synonymous mutations in 28 cases. We could validate 89.87% of 
all these identified variants by various methods including Sanger sequencing, repeated NGS, 
As-PCR and the subsequent longitudinal study. Therefore, by alternative methods including 
Sanger sequencing and As-PCR, 16 point mutations and 10 indels with VAF ranging between 
5.0% to 98% in genes recurrently mutated in our cohort, including TP53, ATM, SF3B1, PCLO 
and NOTCH1 were verified (Figure 3.8).  
Although we have not targeted the non-coding region of NOTCH1 [278] and other genes that 
have only recently been identified in CLL including FAT1 [279], NFKBIE [310], BTK [29] and 
RPS15 [280], in this chapter we could identify mutations in 12 of the 15 selected genes in the 
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28 patients at the latest stages of the disease (Table 3.6). In total, 28%, 31%, 34% and 25% of 
cases harboured mutations in TP53, ATM, SF3B1 and PCLO, respectively. They were much 
higher than the frequency reported in other studies [95, 135, 186, 281]. This might reflect a 
difference of patient components in our cohort, as all were at advanced disease stages. We 
found a dispersal distribution of mutations in TP53 including a mutation in exon 11, and a 
mutation outside the Heat repeat of SF3B1 (exon 11) which are often not included in most of 
studies [158, 311]. This suggested that mutations outside hot regions exist in CLL and their 
biological and clinical impact should be studied further. Moreover, in ATM which is a large 
target gene, we found a widespread distribution of identified mutations in this cohort. In 
general, 37.97% of the mutations in all genes were between 2% and 20% VAF. Although 
those mutations are difficult to be detected with other methodologies, including 
conventional Sanger sequencing, it is difficult to ensure that mutations below 5% VAF are 
true mutations because of the absence of bio-informatic support in this study as well as lack 
of a reliable methodology to validate these mutations.  
We showed the heterogeneous subclonal composition between the cases. Not surprisingly, 
all the TP53 mutated cases and 80% of the ATM mutated cases had at least another gene 
mutation. We assumed that, in any patient, mutations with a higher VAF might have 
occurred earlier than mutations with a lower VAF or might have had more rapid clonal 
evolution and worse prognosis. Based on the VAF, we explored the dominance of these 
mutations. We revealed that ATM and TP53 mutations were dominant in 73.7% of the cases 
(Section 3.3.9), compared to 37.8% of other gene mutations, this was significantly different 
(P = 0.011). We also showed a borderline association of gene mutations and chemotherapy 
(Section 3.3.8), an increased number of mutation events or mutated genes were 
documented in cases who received chemotherapy prior to sampling with p values close to 
0.05. A larger number of samples are required to draw definitive conclusion about the 
existing relationships. Furthermore, we revealed a significant association between the 
number of chemotherapy cycles and multiplicity of gene mutations (P = 0.036). Considering 
the study of copy number changes in the 13 CLL cases, we identified the recurrent changes 
for CLL, including 11q-, 13q-, 17p- and chromosome 12+ and other alterations affected 
chromosome 2, 4, 6, 7, 8, 9, 10 and 20 (Table 3.8). Our analysis of genes involved in these 
chromosomal aberrations revealed an enrichment of some important CLL and cancer genes 
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which functioned in DNA damage/repair, cellular proliferation and apoptosis pathways. We 
reported the involvement of chromosome 17p, 11q and 2q in patients with TP53, ATM, 
BIRC3 and SF3B1 mutations. We also identified the copy neutral loss of heterozygosity 
affected 9q in a case who harboured two truncating NOTCH1 mutations. Moreover, we 
showed a statistically significant association of TP53 and ATM mutations with increased 
number of mutation and CNA events (P = 0.026).   
Conclusions that can be drawn from this chapter include that the dispersal distribution of 
mutations in important genes and the identification of a high proportion of mutations with 
low VAF, further stress the need of a high throughput and more sensitive methods for both 
research and clinical use. In addition, the high incidence of TP53 and ATM mutations and 
their dominance over the other mutations suggests that a defective DNA damage response 
pathway plays an important role in both the acquisition of additional mutations and in the 
development of an aggressive disease phenotype. Moreover, the association of 
chemotherapy and number of gene mutations suggests the possible role of treatment in the 
induction or selection of mutations.  
Paired serial samples were used for the study of subclonal evolution in Chapter 4. We firstly 
performed strict quality control checks to exclude any samples lacking matched SNP 
fingerprint (Section 4.3.1). This guaranteed the reliability of our analysis. Thus, 33 tumour 
samples from 23 CLL cases with a perfect SNP match were analysed. In the analysis of 
nucleotide changes in the context of tri-nucleotides, firstly, we showed the predominance of 
C:G>T:A changes as also found by others [288, 290]. We identified an increase in C>T 
changes after therapy in 14 CLL cases (Figure 4.1). By examining the mutation signature at 
earliest stages and at latest stages for the 21 serial samples with single nucleotide 
substitutions, we were able to divide all of these mutations in to AID-, ageing- and other 
factors-related mutations. Examination of the occurrence of each mutation type in patients 
who had available IGHV mutation data revealed that UM-IGHV cases had higher incidence of 
ageing associated mutations. This was consistent with findings by others [290] and 
suggested a proliferation history in UM-IGHV CLL.  
Exploring the role of each signature in clonal evolution, we statistically confirmed the role of 
AID in ongoing mutations in its off-target genes, because AID-related mutations were highly 
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associated with the subclonal evolution. This was a good evidence supported a notion made 
by Kasar et al based on a single time point WGS study that AID contributes to ongoing 
mutations in genes other than IGV in CLL [290]. However, AID seemed to not be the only 
driving force in such CLL clonal evolution as we found other factors that were also related 
with this process according to our study. Although further studies are required for 
understanding what exactly those factors are, APOBEC3 may be one of them. As suggested 
by others, distinguishing APOBEC3 signature requires sequencing of c.DNA to identify 
transcription bias characteristic of this enzyme produced by transcription-coupled DNA 
repair [312].  
Considering the clonal evolution in general, we found that 92.5% of the mutations detected 
at the latest time points were also identified at the earliest time points, indicating a 
dominance of the linear evolution over the branch evolution. Of the 65 mutations identified 
at the earliest time points in the 23 CLL cases, 60% of them underwent clonal evolution, 18% 
were stable and 22% underwent clonal devolution. This phenomenon has also been found 
by others [128]. In our cohort, only 5 (7.69%) mutations with VAF ranged 1% - 4% identified 
at early stages became undetectable at the latest time points. This was more likely due to 
the VAF reduction of those non-dominant subclones below the limit of detection of this test, 
with increase of the dominant subclones during disease progression. Moreover, convergent 
evolution and clonal dominance of deleterious mutations occurred in 2 patients with ATM 
and TP53 mutations, respectively. Further analysis revealed the prioritisation of deleterious 
mutations in convergent clonal evolutions in each of the cases. However, in this study we 
could not calculate the size of the mutant clones as performed by others [198,302]. This was 
due to incomplete information about leukocytes and lymphocyte counts. Therefore, 
“devolution” was the relative reduction of VAF, not necessarily meaning shrinkage of the 
subclonal size.  
Moreover, in the longitudinal CNA study, we reported the increase in the number of regions 
affected by the CNA as well as expanding in size of previously affected regions. There was an 
overt chromothripsis-like event (defined by ≥ 5 changes in copy number state affecting a 
single chromosome in a single event) that affected chromosome 6 of CLL-7 (Table 4.7). 
However, definitive identification of this event needs to rule-out gradual accumulation of 
the copy number changes. In this CLL patient, the number of the bands affected by the CNA 
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in both samples studied fulfilled this criterion, although we identified the addition of another 
band in the latest sample, yet a gradual accumulation of all the affected bands in the earlier 
sample studied need to be excluded. Therefore, additional earlier time points were required 
to rule out the possibility of chromothripsis by finding that the memory genetic lesion 
existed with the same composition. Moreover, for a conclusive identification of 
chromothripsis we also need to have information about the occurrence of the CNA changes 
on the same homolog. This can only be obtained through long read paired end WGS [313]. 
Chromothripsis is a rare incident in the development and progression of CLL. If it occurs, it is 
a massive genetic change in a single catastrophic event rather than the commonly believed 
gradual accumulation of genetic lesions in tumour progression [314].   
Considering the clinical impact of mutations, clonal and subclonal TP53 mutations tend to 
have similar clinical consequences [138]. Whether this is true for other recurrently mutated 
genes deemed to be potential drivers (NOTCH1, SF3B1, BIRC3 and more recently, SAMHD1) 
has not been well-established and still remained controversial [315]. To clarify this matter, 
as in our cohort, based on the observation that various gene mutations within the same 
tumour sample showed a different speed of evolution, we calculated the subclonal VAF 
doubling time for each target gene mutation regardless of their co-associated mutations. 
Our results showed that the above potential driver mutations had shorter VAF doubling time 
compared to other targeted genes (Figure 4.4). In agreement with the classification of these 
driver mutations under high risk category [316], our results confirmed their association with 
rapid clonal evolution as compared to ATM which has been put under intermediate risk 
category. This observation further supports the notion that these high-risk gene mutations 
are associated with unfavourable CLL outcome [317].  
In the analysis for clinical impact of the genes mutation on TFS and OS, we revealed that 
patients possessing at least a target gene mutation had a shorter TFS (calculated from the 
time of sampling time to the 1st treatment) compared to patients with no mutations. 
Moreover, within the mutated group, patients who harboured at least a driver gene 
mutation (including TP53, SF3B1, NOTCH1, BIRC3 and SAMHD1) with a certain subclonal size 
as previously set [293] were significantly associated with a shorter TFS (Figure 4.6).   
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Henceforth, given the relatively small number of cases in the studied cohort in general and 
among them small number of cases harbouring different gene mutations and the variability 
in the VAF at presentation, most of our findings are preliminary. It would be worth 
performing larger-scale (increase the number of patients) ultra-deep NGS studies in the 
future in order to analyse clonal/subclonal mutations with an effective bio-informatics 
support to draw solid conclusions regarding the relative impact of each type of mutation as 
solitary abnormality or in conjunction with the presence of other genetic events. 
Taken together, the results in Chapter 4 revealed the importance of AID in CLL evolution; 
therefore it might be a candidate gene for future studies on CLL biology and treatment. 
Moreover, the linearity of clonal evolution predominantly presented in our cohort suggested 
the requirement for this highly sensitive NGS test to detect the small mutant subclones at as 
early as possible, so that the genetic composition at the latest stages can be predictable 
from the early stages. However, the roles of deleterious mutations in convergent evolution 
suggest that not all the mutations within the same target gene have the same biological and 
clinical impacts. Therefore, how the subsequently dominant convergent mutations can be 
predicted at an early stage in CLL requires further study, likely in a cooperation of multiple 
centres.    
In our study of clinical implementation of this test (Chapter 5), we clearly showed the effect 
of degraded DNA extracted from formalin fixed-paraffin embedded tissue on quality of NGS 
(Figure 5.1). Despite of that, the results generated by us were promising and HaloPlex might 
be suitable for target gene enrichment of FFPE samples. However optimisation for DNA 
extraction from FFPE to improve quality of the resulting DNA is a key step for success in this 
NGS test. Moreover, for the DNA sample extracted from fresh mononuclear cell, a superior 
performance of HaloPlex and Ion Torrent NGS has been shown as we demonstrated the high 
quality of data and the extra-ordinary high coverage depth for that sample (Table 5.3). 
Nevertheless, to our concern, the uniformity of coverage should be always checked and 
regions with low coverage should be reported along with the limit of detection as we did in 
our result reporting (Figure 5.3) in order to avoid misunderstanding negative results.  
In conclusion, we have developed a sensitive and reliable in-house-NGS method to screen 
recurrent mutations in CLL. Moreover, the most frequently mutated genes included SF3B1, 
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ATM, TP53 and PCLO. Moreover, ATM-p53 pathway was the most common mutated 
pathway at late stages of disease. The association of this pathway with clonal evolution 
emphasises its importance in CLL progression. However, SF3B1, NOTCH1, SAMHD1, CHD2, 
PCLO and LRP1B can also be the dominant mutated gene. Importantly, due to a linear 
evolution pattern, most of the dominant mutations at late stages were detectable at early 
stages prior to treatment, and the therapeutic intervention contributed to the clonal 
selection. Therefore, it is important to detect these mutations as early as possible to help 
guide clinician’s treatment choice for individual patients. Therefore, a highly sensitive ultra-
deep sequencing as well as bio-informatics support are required to meet this clinical 
demand. In our study, the documented convergent clonal evolution has suggested that 
deleterious mutations are predominant in this phenomenon, but further studies are 
required to validate this. Moreover, the relationship between driver mutations and 
subclonal evolution need confirmation by further research work. For the study of clinical 
impact, we can no longer merely consider the presence or absence of mutations, it will be 
vital to know what proportion of cells harbour a mutation and what the functional 
consequence of mutation is. This will influence clinical decision making such as predicting 
outcome and choosing the right therapy. This information might also be important to 
optimize the dose of therapy. Along these lines, it might be imperative to address the issue 
of subclonal mutations in extended cohorts of homogeneously treated patients particularly 
in this new era of targeted therapy such as using inhibitors of BCR signalling and the newly 
developed pathway specific small molecules inhibitors. Therefore, target genes that have 
been recently identified in CLL, for example, RPS15 [280], BTK and PLCG [318], may need to 
be included in the gene panel in future. 
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7.1. HaloPlex probe design information  
Table 7.1. Chromosomal coordinates used to design HaloPlex probes for this study 
 
Genomic coordinate Gene Name Exon No. Ensembl Exon  ID
chr11:102195193-102196093 BIRC3 2 ENSE00001256551 
chr11:102196197-102196296 BIRC3 3 ENSE00002474565  
chr11:102198783-102198861 BIRC3 4 ENSE00000745287 
chr11:102199628-102199676 BIRC3 5 ENSE00000795265
chr11:102201730-102201972 BIRC3 6 ENSE00000795266
chr11:102206697-102206951 BIRC3 7 ENSE00000745300
chr11:102207491-102207532  BIRC3 8 ENSE00002467460 
chr11:102207640-102207880  BIRC3 9 ENSE00002162318
chr11:108098322-108098423  ATM 2 ENSE00003535574
chr11:108098503-108098615  ATM 3 ENSE00003590622
chr11:108099905-108100050  ATM 4 ENSE00003614955
chr11:108106397-108106561  ATM 5 ENSE00001667088  
chr11:108114680-108114845  ATM 6 ENSE00001670710
chr11:108115515-108115753  ATM 7 ENSE00001739598
chr11:108117691-108117854  ATM 8 ENSE00001617295
chr11:108119660-108119829  ATM 9 ENSE00001652815
chr11:108121428-108121799  ATM 10 ENSE00001658306 
chr11:108122564-108122758  ATM 11 ENSE00001638731
chr11:108123544-108123639 ATM 12 ENSE00001655406
chr11:108124541-108124766  ATM 13 ENSE00001592116
chr11:108126942-108127067  ATM 14 ENSE00001774900
chr11:108128208-108128333  ATM 15 ENSE00001723835
chr11:108129713-108129802  ATM 16 ENSE00001769509 
chr11:108137898-108138069  ATM 17 ENSE00001719378
chr11:108139137-108139336 ATM 18 ENSE00003595770
chr11:108141791-108141873  ATM 19 ENSE00001591923
chr11:108141978-108142133  ATM 20 ENSE00001764296
chr11:108143259-108143334  ATM 21 ENSE00003491738
chr11:108143449-108143579 ATM 22 ENSE00003484127  
chr11:108150218-108150335  ATM 23 ENSE00003605753
chr11:108151722-108151895  ATM 24 ENSE00001618543
chr11:108153437-108153606  ATM 25 ENSE00001761338
chr11:108154954-108155200  ATM 26 ENSE00001649610
chr11:108158327-108158442  ATM 27 ENSE00001728966
chr11:108159704-108159830  ATM 28 ENSE00003469194
chr11:108160329-108160528  ATM 29 ENSE00003581035
chr11:108163346-108163520  ATM 30 ENSE00003598677
chr11:108164040-108164204  ATM 31 ENSE00003529497 
chr11:108165654-108165786  ATM 32 ENSE00003559264 
chr11:108168014-108168109  ATM 33 ENSE00003480406
chr11:108170441-108170612  ATM 34 ENSE00003565584
chr11:108172375-108172516  ATM 35 ENSE00003590115
chr11:108173580-108173756  ATM 36 ENSE00003508061
chr11:108175402-108175579  ATM 37 ENSE00003472092
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Table 7.1. (continued) 
 
 
Genomic coordinate Gene Name Exon No. Ensembl Exon  ID
chr11:108178624-108178711  ATM 38 ENSE00003472517
chr11:108180887-108181042  ATM 39 ENSE00003591034
chr11:108183138-108183225  ATM 40 ENSE00003458427
chr11:108186550-108186638  ATM 41 ENSE00003614552 
chr11:108186738-108186840  ATM 42 ENSE00003552391
chr11:108188100-108188248  ATM 43 ENSE00003522577
chr11:108190681-108190785  ATM 44 ENSE00003688819
chr11:108192028-108192147 ATM 45 ENSE00003648389 
chr11:108196037-108196271  ATM 46 ENSE00003542516  
chr11:108196785-108196952  ATM 47 ENSE00003580001 
chr11:108198372-108198485 ATM 48 ENSE00003479049 
chr11:108199748-108199965 ATM 49 ENSE00003599084
chr11:108200941-108201148  ATM 50 ENSE00003659411
chr11:108202171-108202284  ATM 51 ENSE00003596787
chr11:108202606-108202764  ATM 52 ENSE00003571052
chr11:108203489-108203627  ATM 53 ENSE00003483502
chr11:108204613-108204695  ATM 54 ENSE00003573212
chr11:108205696-108205836  ATM 55 ENSE00003560896
chr11:108206572-108206688  ATM 56 ENSE00003666486
chr11:108213949-108214098  ATM 57 ENSE00003611442
chr11:108216470-108216635  ATM 58 ENSE00003671649
chr11:108218006-108218092  ATM 59 ENSE00003588344
chr11:108224493-108224607  ATM 60 ENSE00003609743
chr11:108225538-108225601  ATM 61 ENSE00003638878
chr11:108235809-108235945  ATM 62 ENSE00003502604
chr11:108236052-108236236  ATM 63 ENSE00001331356
chr15:93489268-93489446 CHD2 12 ENSE00003593607
chr15:93492182-93492306 CHD2 13 ENSE00001255168
chr15:93496587-93496803 CHD2 14 ENSE00003481778
chr15:93498653-93498742 CHD2 15 ENSE00003587849
chr15:93499689-93499879 CHD2 16 ENSE00003503986
chr15:93510555-93510743 CHD2 17 ENSE00001255136 
chr15:93514995-93515157 CHD2 18 ENSE00001255131
chr15:93515495-93515647 CHD2 19 ENSE00003659253
chr15:93518109-93518180 CHD2 20 ENSE00003535318
chr15:93521464-93521613 CHD2 21 ENSE00002434605
chr15:93522365-93522513 CHD2 22 ENSE00001097892
chr15:93524045-93524141 CHD2 23 ENSE00001097780
chr15:93524595-93524687 CHD2 24 ENSE00001097863
chr15:93527560-93527730 CHD2 25 ENSE00001097839
chr15:93528728-93528903 CHD2 26 ENSE00001097827
chr15:93534706-93534747 CHD2 27 ENSE00001097770
chr15:93536089-93536228 CHD2 28 ENSE00001097848
chr15:93540187-93540325 CHD2 29 ENSE00001097738
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Table 7.1. (continued) 
 
 
 
 
Genomic coordinate Gene Name Exon No. Ensembl Exon  ID
chr15:93540483-93540633 CHD2 30 ENSE00002469647
chr15:93541729-93541851 CHD2 31 ENSE00003503542  
chr15:93543742-93543870 CHD2 32 ENSE00003673545
chr15:93545407-93545547  CHD2 33 ENSE00003587375 
chr15:93547847-93547981  CHD2 34 ENSE00001314469
chr15:93552375-93552553  CHD2 35 ENSE00001097753
chr15:93555575-93555674  CHD2 36 ENSE00001179528
chr17:7572926-7573008  TP53 11 ENSE00003605891
chr17:7573927-7574033  TP53 10 ENSE00003545950
chr17:7576853-7576926  TP53 9 ENSE00003636029
chr17:7577019-7577155  TP53 8 ENSE00003586720
chr17:7577499-7577608  TP53 7 ENSE00003504863
chr17:7578177-7578289 TP53 6 ENSE00003462942 
chr17:7578371-7578554  TP53 5 ENSE00003518480
chr17:7579312-7579590  TP53 4 ENSE00003625790
chr17:7579700-7579721  TP53 3 ENSE00002419584
chr17:7579839-7579940  TP53 2 ENSE00002667911
chr20:35521334-35521469  SAMHD1 16 ENSE00000800455
chr20:35526225-35526362  SAMHD1 15 ENSE00000661812
chr20:35526843-35526947  SAMHD1 14 ENSE00000661813
chr20:35532560-35532652  SAMHD1 13 ENSE00003692177
chr20:35533767-35533906 SAMHD1 12 ENSE00000661815
chr20:35539621-35539736  SAMHD1 11 ENSE00001622813
chr20:35540864-35540955  SAMHD1 10 ENSE00001711142
chr20:35545125-35545233  SAMHD1 9 ENSE00001793017
chr20:35545352-35545452  SAMHD1 8 ENSE00001667406
chr20:35547776-35547922  SAMHD1 7 ENSE00001752622
chr20:35555585-35555655  SAMHD1 6 ENSE00003598833
chr20:35559163-35559278  SAMHD1 5 ENSE00003535434  
chr20:35563432-35563592  SAMHD1 4 ENSE00003546823
chr20:35569442-35569514  SAMHD1 3 ENSE00003462531
chr20:35575141-35575207  SAMHD1 2 ENSE00003619308
chr20:35579839-35580079  SAMHD1 1 ENSE00001898623
chr2:141027811-141027915  LRP1B 86 ENSE00001132056   
chr2:141031993-141032167  LRP1B 85 ENSE00001132065 
chr2:141055377-141055538 LRP1B 84 ENSE00001153896 
chr2:141072504-141072668  LRP1B 83 ENSE00001182326
chr2:141079532-141079657  LRP1B 82 ENSE00001153862  
chr2:141081462-141081635  LRP1B 81 ENSE00001131995
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Table 7.1. (continued) 
 
 
 
Genomic coordinate Gene Name Exon No. Ensembl Exon  ID
chr2:141083331-141083447  LRP1B 80 ENSE00001131999
chr2:141092022-141092128  LRP1B 79 ENSE00001132004
chr2:141093184-141093407 LRP1B 78 ENSE00001132013
chr2:141108366-141108607  LRP1B 77 ENSE00001132019
chr2:141110522-141110641  LRP1B 76 ENSE00001132026
chr2:141113911-141114045  LRP1B 75 ENSE00001132029 
chr2:141115548-141115685 LRP1B 74 ENSE00001132034
chr2:141116390-141116515  LRP1B 73 ENSE00001182394
chr2:141122230-141122352  LRP1B 72 ENSE00001182403
chr2:141128279-141128411  LRP1B 71 ENSE00001328871
chr2:141128748-141128854  LRP1B 70 ENSE00001182417
chr2:141130577-141130706  LRP1B 69 ENSE00001182423
chr2:141135749-141135855  LRP1B 68 ENSE00001182430
chr2:141143462-141143578  LRP1B 67 ENSE00001182437
chr2:141200073-141200192  LRP1B 66 ENSE00001153839
chr2:141201899-141202018  LRP1B 65 ENSE00001131958
chr2:141202132-141202248  LRP1B 64 ENSE00001131968
chr2:141208137-141208230  LRP1B 63 ENSE00001131978
chr2:141214024-141214172  LRP1B 62 ENSE00001131982
chr2:141215032-141215220  LRP1B 61 ENSE00001131988
chr2:141232707-141232906  LRP1B 60 ENSE00001153849
chr2:141242912-141243093  LRP1B 59 ENSE00001153824
chr2:141245186-141245308 LRP1B 58 ENSE00001131904
chr2:141250177-141250262  LRP1B 57 ENSE00001131912 
chr2:141253134-141253317  LRP1B 56 ENSE00001131919
chr2:141259256-141259443 LRP1B 55 ENSE00001131923
chr2:141260532-141260672  LRP1B 54 ENSE00001131930
chr2:141264365-141264487  LRP1B 53 ENSE00001131937
chr2:141267497-141267625  LRP1B 52 ENSE00001131947
chr2:141272222-141272341  LRP1B 51 ENSE00001153830
chr2:141274458-141274580  LRP1B 50 ENSE00001182504
chr2:141283413-141283562  LRP1B 49 ENSE00001182509
chr2:141283806-141283919 LRP1B 48 ENSE00001182513
chr2:141291590-141291709  LRP1B 47 ENSE00001153804
chr2:141294150-141294278  LRP1B 46 ENSE00001131890
chr2:141298542-141298667  LRP1B 45 ENSE00001131896
chr2:141299348-141299540  LRP1B 44 ENSE00001153813
chr2:141356200-141356404  LRP1B 43 ENSE00001182529
chr2:141359019-141359208  LRP1B 42 ENSE00001182536
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Table 7.1. (continued) 
 
 
 
Genomic coordinate Gene Name Exon No. Ensembl Exon  ID
chr2:141457819-141458190 LRP1B 41 ENSE00001316880
chr2:141459290-141459414 LRP1B 40 ENSE00001131885
chr2:141459710-141459861 LRP1B 39 ENSE00001182554 
chr2:141459996-141460122  LRP1B 38 ENSE00001182559
chr2:141473542-141473671  LRP1B 37 ENSE00001182564 
chr2:141474251-141474385  LRP1B 36 ENSE00001182569     
chr2:141526782-141526913  LRP1B 35 ENSE00001182573
chr2:141528450-141528575  LRP1B 34 ENSE00001182578
chr2:198264976-198265158  SF3B1 19 ENSE00000964872
chr2:198265439-198265660  SF3B1 18 ENSE00000964871
chr2:198266124-198266249  SF3B1 17 ENSE00000964870 
chr2:198266466-198266612  SF3B1 16 ENSE00000964869
chr2:198266709-198266854 SF3B1 15 ENSE00000964868
chr2:198267280-198267550 SF3B1 14 ENSE00000964867
chr2:198267673-198267759 SF3B1 13 ENSE00000964866 
chr2:198268309-198268488 SF3B1 12 ENSE00000964865
chr2:198269800-198269901  SF3B1 11 ENSE00000964864
chr2:198269999-198270196 SF3B1 10 ENSE00000964863
chr2:198272722-198272843 SF3B1 9 ENSE00000964862
chr2:198273093-198273305 SF3B1 8 ENSE00000964861
chr2:198274494-198274731  SF3B1 7 ENSE00000964860
chr2:61719170-61719333 XPO1 16 ENSE00003613775
chr2:61719460-61719616  XPO1 15 ENSE00003675145
chr2:61719702-61719883  XPO1 14 ENSE00003464720
chr2:61720050-61720188 XPO1 13 ENSE00003631255
chr2:61721029-61721226  XPO1 12 ENSE00000757711
chr2:61722590-61722748  XPO1 11 ENSE00003556668
chr3:38181355-38181489 MYD88 2 ENSE00003582265 
chr3:38181879-38182059  MYD88 3 ENSE00001744479
chr3:38182248-38182339 MYD88 4 ENSE00003552693
chr3:38182623-38182783  MYD88 5 ENSE00003619131
chr4:153244031-153244301  FBXW7 12 ENSE00001431204
chr4:153245336-153245546 FBXW7 11 ENSE00000821072
chr4:153247158-153247383 FBXW7 10 ENSE00000821073
chr4:153249360-153249541  FBXW7 9 ENSE00003478818
chr4:153250824-153250937  FBXW7 8 ENSE00003629197
chr4:153251884-153252020  FBXW7 7 ENSE00003495121
chr4:153253748-153253871  FBXW7 6 ENSE00000821077
chr4:153258954-153259088  FBXW7 5 ENSE00001002596
chr6:26156619-26157280 HIST1H1E 1 ENSE00001173828
chr7:124464008-124464128  POT1 19 ENSE00001863642
chr7:124465306-124465411  POT1 18 ENSE00002488410
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Table 7.1. (continued) 
 
Genomic coordinate Gene Name Exon No. Ensembl Exon  ID
chr7:124467268-124467359  POT1 17 ENSE00002495808
chr7:124469308-124469396  POT1 16 ENSE00002463467
chr7:124475333-124475468  POT1 15 ENSE00002489137
chr7:124481027-124481232  POT1 14 ENSE00002489750
chr7:124482861-124483017  POT1 13 ENSE00002511886
chr7:124486996-124487052 POT1 12 ENSE00002441395
chr7:124491926-124492005  POT1 11 ENSE00001136130
chr7:124493026-124493192  POT1 10 ENSE00001136133
chr7:124499011-124499166 POT1 9 ENSE00001136138
chr7:124503404-124503694  POT1 8 ENSE00003688811
chr7:124510965-124511095  POT1 7 ENSE00001785664
chr7:124532320-124532434  POT1 6 ENSE00003596271
chr7:124537219-124537266 POT1 5 ENSE00003488402
chr7:82389955-82390100 PCLO 24 ENSE00002431590
chr7:82390675-82390809 PCLO 23 ENSE00002462574
chr7:82430834-82430907  PCLO 22 ENSE00002457830
chr7:82435004-82435145 PCLO 21 ENSE00003509997 
chr7:82451811-82452005  PCLO 20 ENSE00002527473
chr7:82453552-82453732  PCLO 19 ENSE00003647047 
chr7:82455905-82455976  PCLO 18 ENSE00003644760 
chr7:82457189-82457282  PCLO 17 ENSE00003501634
chr7:82464983-82465009  PCLO 16 ENSE00002459797
chr7:82467534-82467658 PCLO 15 ENSE00003621206
chr7:82470775-82470825 PCLO 14 ENSE00003532351
chr7:82474587-82474801 PCLO 13 ENSE00003668844
chr7:82475883-82475950  PCLO 12 ENSE00003573676
chr7:82476455-82476563  PCLO 11 ENSE00003581347  
chr7:82508653-82508778  PCLO 10 ENSE00003503371
chr7:82531967-82532057  PCLO 9 ENSE00002490267
chr7:82538193-82538329  PCLO 8 ENSE00002529510  
chr7:82544002-82546189  PCLO 7 ENSE00002432640
chr7:82578792-82580806  PCLO 6 ENSE00002709222
chr7:82581172-82586251 PCLO 5 ENSE00001715762   
chr7:82595087-82595803  PCLO 4 ENSE00001646940
chr7:82763566-82764972  PCLO 3 ENSE00001774996
chr7:82784064-82785708  PCLO 2 ENSE00001622512   
chr8:106813275-106815770 ZFPM2 8 ENSE00002135760
chr9:139390510-139392010  NOTCH1 34 ENSE00001247584 
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7.2. Recipes of routinely used solutions 
 
Table 7.2.Contents of 50 mM NaOH solution 
Components  Amount 
Sodium hydroxide (NaOH) (40 
g/L) 
0.2 g 
De-ionised nuclease free water 100 ml 
 
 
Table 7.3. Components of 2 M Acetic acid  
Components  Amount 
Glacial acetic acid (60.05 g/L) 1.15 ml 
De-ionised nuclease free water 9.85 ml 
 
 
Table 7.4. Substances used to prepare 10 mM Tris-HCl buffer, pH 8.0 
Components  Amount 
Tris-acetate (121.14 g/L) 0.121 g 
De-ionised nuclease free water Up to 100 ml 
Hydrochloric acid (HCl) Adjusted to obtain pH of 8.0 
 
 
7.3. Routinely used protocols 
7.3.1. Preparation of template- positive Ion PGM Sphere Particles 
The Ion OneTouch TM Recovery Tube and Ion OneTouch TM 2 Amplification Plate (connected to 
the disposable tube and injector) are put in their designated places with the disposable 
tubing inserted along the instrument’s notches shaped. The injector is implanted straight in 
to the Ion OneTouchTM DL Injector Hub which is connected to the underlying recovery rotor. 
 
Ion OneTouchTM Oil and OneTouchTM Recovery Solution are added (half full) to the two 
provided reagent tubes. Then new Sipper Tubes are attached to the corresponding ports and 
the filled reagent tubes are screwed firmly into their corresponding places. After ensuring 
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that the Waste Container is empty, both room temperatures equilibrated Ion PGMTM 
Template OT2 200 Reagent Mix and Ion PGMTM Template OT2 200 PCR Reagent B is vortexed 
and spun briefly to proceed with amplification step. 
 
In the amplification step using a 1.5-ml Eppendorf LoBind tube, 25 µl of Nuclease Free 
Water, 500 µl of Ion PGMTM Template OT2 200 Reagent Mix, 300 µl of Ion PGMTM Template 
OT2 200 PCR Reagent B, 50 µl of briefly centrifuged and ice chilled PGMTM Template OT2 200 
Enzyme Mix and 25 µl of the diluted library are mixed by briefly vortexed and centrifuged to 
create the amplification solution. This is followed by adding 100 µl of Ion PGMTM Template 
OT2 200 Ion SphereTM Particles which is equilibrated to room temperature, vortexed, spun 
and mixed by pipetting up and down before its use. The total of 1000 µl amplification 
solution is vortexed for 5 sec before pipetting it to the sample port of the Ion PGMTM One 
Touch Plus Reaction Filter Assembly. Then 1500 µl of Reaction Oil is added through the same 
port. With the sample port of the assembly oriented to the right hand direction, the above 
Reaction Filter Assembly is carefully inverted to face down the three ports on the surface of 
the assembly. Then the three ports are inserted to the specified holes on the Ion OneTouch 
Instrument and the assembly is firmly seated. On the home screen the option Run is pressed. 
In the drop-down menu, the used template kit is selected among the list of predefined 
template kit lists and the run is started. 
 
After completion of the amplification reaction on the Ion Sphere Particles, using the on 
screen prompts, final spin is performed. The ISP is collected from each recovery tube by 
removal of 50 µl of the supernatant from the surface and the opposite side of the ISP pellet 
using a pipette. This is followed by dispensing the ISP in the remaining solution by pipetting 
up and down. The product of up to 100 µl is transferred in to a new 1.5 ml Epppendorf 
LoBind tube, 1 ml of Ion OneTouchTM Wash Solution is added afterwards. The ISPs either 
ware stored at 4 oC for 1-2 days or used immediately. In any occasion, the Eppendorf tube 
containing ISP in the Wash solution is centrifuged at 15,500 rpm for 2.5 minutes, all the 
supernatant is removed except for 100 µl at the bottom of the tube which is used to re-
suspend the ISPs using a pipette. 
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Ion OneTouch™ ES instrument is used to isolate the template enriched ISP from non-
templated ISPs. This instrument uses automated magnetic bead technology for this purpose. 
Initially, fresh Melt-Off Solution is prepared by combining 280 µl TweenR Solution and 40 µl 
of 1 M NaOH. Then, 13 μl of vortexed Dynabeads MyOne™ Streptavidin C1 magnetic beads is 
put in a 1.5-ml LoBind Eppendorf Tube which is transferred to a magnetic rack until a clear 
supernatant is formed; subsequently the supernatant is discarded using a pipette. The bead 
is resuspended in 130 μl of MyOne™ Beads Wash Solution by vortexing and brief 
centrifugation. An 8-well strip from the Ion OneTouch™ kit is obtained, and placed in right 
side of Ion OneTouch™ ES instrument slot with left side orientation of the square-shaped tab 
of the strip. Following this, the 100 μl template enriched ISP sample is added to Well 1, while 
the 130 μl resuspended MyOne™ Beads to Well 2. Each of Well 3, 4, and 5 is loaded with 300 
μl of Ion OneTouch™ Wash Solution. Wells 6 and 8 are left empty and Well 7 loaded with 
300 μl of fresh Melt-Off Solution. 
The Ion OneTouch™ ES instrument is prepared by placing a new tip on the Tip Arm and a 
fresh 0.2-ml PCR tube with its cap open in the base of the Tip Loader before initialising the 
run. 
Following completion of this step, the Template-Positive Ion Sphere™ Particles accumulated 
in the 0.2 ml-PCR tube is mixed with 5 μl of Control Ion Sphere Particle and 100 μl of 
Annealing Buffer and is spun at 15,500 × g for 2 minutes. The supernatant is carefully 
removed except 15 μl is left in the tube. After adding 12 μl of Sequencing Primer, the 
mixture is pipetted up and down multiple times to disrupt the ISP pellet. To anneal the 
primers, the tube is put in a thermal cycler programmed with a heated lid and 95 oC for 2 
minutes followed by 37 oC for 2 minutes.  
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7.3.2. Creating a planned run for Ion PGM system 
Information about application of the PGM runs can be pre-saved for sequencing under the 
same conditions. It includes type of template (DNA or RNA), name of kit, and number of 
flows, barcodes and reference files. It can be done following the two steps below. 
1. Log into the Torrent Browser to access the server connected to the PGM system. 
2. Select Plan tab, then Templates and select the application type and then press Plan 
Run which can be reviewed using the Review tab or edited using Plan New Run tab 
 
7.3.3. Cleaning of Ion PGM system 
7.3.3.1. Cleaning the PGM machine with 18 MΩ water 
Cleaning the system is necessary when the system is in daily use after every 2 runs or if > 10 
hours but less than 48 hours have elapsed between the last cleaning/ initialisation and the 
start of a run. Before cleaning set up, the old sipper tubes and an old chip should be left in 
place. The 2 empty cleaning bottles provided are rinsed with 100 ml of fresh 18 MΩ water 
twice. 
The sipper tube in W1 is rinsed with the same type of water put in a squirt bottle. 
The cleaning bottles are placed in W2 and W3 positions and a collection tray below the 
sipper tubes in the dNTP positions. The tab Clean with 18 MΩ water is pressed to begin the 
cleaning process. After completion of the process, all the bottles and sipper tubes from W1, 
W2 and W3 positions are removed while the collection tray and the reagent sipper tubes are 
left in place. 
 
7.3.3.2. Cleaning the PGM machine with Chlorite 
This cleaning is performed once per week, unless the instrument has not been used since the 
last cleaning with Chlorite and whenever the machine is left with reagents for more than 48 
hr. 
1. Evacuate any remaining solution from each cleaning bottle and rinse twice with fresh 
18 MΩ water. 
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2. In a large clean glass bottle dissolve PGM (Chlorite) Cleaning Tablet in 1 L of 18 MΩ 
water. Then add 1 mL of freshly prepared 1 M NaOH (prepared by dilution with 18 
MΩ water) and filter the solution using 0.22-0.45 µm filter which should be used 
within 2 hours, 250 ml of this solution is then added to a 250 ml cleaning bottle. 
3. The outside of sipper tube in W1 position is rinsed with 18 MΩ water. The other 
cleaning bottles are placed in W2 and W3 positions with a collection tray underneath 
the sipper tubes in the dNTP positions. 
4. Press the Clean with Chlorite on the touch screen and press next to start cleaning. 
5. After completion of the process, remove all the bottles and sipper tubes from W1, 
W2 and W3 positions while leave the collection tray and the reagent sipper tubes in 
place. 
 
7.3.4. Sequencing on the Ion Torrent PGM 
Cleaning of the Ion Torrent PGM machine (Life Technologies, UK) is performed with either 18 
MΩ water alone or with Chlorite followed by 18 MΩ water washing.   
Before initialising the Ion PGM system, The Wash 2 Bottle is filled with 18 MΩ water up to 
the upper marked Mold line, followed by pouring the entire content of Ion PGM™ 
Sequencing 200 v2 W2 and adding 70 μl of freshly prepared 100 mM NaOH solution. The 
bottle is then capped and the mixture is mixed by inverting the bottle several times. 350 μl 
of freshly prepared 100 mM NaOH is added to the Wash 1 Bottle and 50 ml Ion PGM™ 
Sequencing 200 v2 1 x W3 Solution is poured into Wash 3 Bottle. Following the onscreen 
instructions, the machine is initialised. After thawing each dNTP stock solution on ice, 
vortexing and brief spinning is performed. Carefully with changing gloves for handling each 
dNTP container, 20 μl of each dNTP stock solution is pipetted into its respective Reagent 
Bottle. The old dNTP sipper tubes are carefully replaced by new sipper tubes and the dNTP 
reagent bottles are firmly tightened to their corresponding places to complete the 
initialisation. 
Chip Checking is performed to ensure that the machine can recognise and read it by 
scanning the new chip barcode and placing the chip on to the chip ground plate with bare 
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hands to avoid damage by electrostatic discharge. When this step is completed, the old chip 
is inserted to completely evacuate the waste bottle according to the touch screen 
instructions. To bind Sequencing Polymerase to the template positive-ISPs annealed to 
sequencing primer, 3 μl of Ion PGM™ Sequencing 200 v2 Polymerase is added to the 27 μl 
previously prepared template enriched- ISP sample and mixed by pipetting up and down. 
This mixture is left at room temperature for 5 minutes. 
Ion 318™ Chip v2 (Life Technologies, UK) that passed the chip checking step, is taken out and 
tilted to 45 degree angle to bring down the loading port to lower most position. Withdrawal 
of any liquid in the chip is performed by a pipette through the circular loading port. For 
complete removal of any residual liquid, the chip is centrifuged upside down for 5 seconds 
using an adapter bucket. With the chip placed in a dry clean adapter bucket, the entire 
sample (~30 μl of template enrich ISPs) is loaded slowly with a firmly inserted pipette tip 
through the loading port to avoid introducing air bubble. The chip is transferred to the 
MiniFuge and centrifugation is performed for 30 seconds with the chip tab pointing toward 
the centre of the MiniFuge. Then, with a pipette set to 30 μl, the sample inside the chip is 
pipetted in and out slowly while the chip is tilted to 45 degrees with the loading port in 
lower most position. 
Following this, the chip is centrifuged for another 30 seconds with the chip tab pointing 
away from the centre of the MiniFuge. Any residual sample is slowly removed from the 
loading port by a pipette with the chip at a 45-degree angle. After completion of the chip 
loading, the sequencing by 500 flow cycle run is performed following the displayed onscreen 
prompts.  
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7.3.5. Summary of somatic non-synonymous variants identified in serial NGS study 
of 23 CLL cases 
 
Table 7.5. Detailed information of somatic non-synonymous variants identified in 
longitudinal study 
 
 
Gene (sub-clone) Chr. Location (Hg19) Ref Var Aminoacid change TP1 TP2 TP3 TP4
LRP1B 2:141259338 C T p.R2923K 0 6
SF3B1 (A) 2:198266834 T C p.K700E 1 6
SF3B1 (B) 2:198267360 T A p.K666M 4 14
PCLO 7:82581658 G T P.P2871T 0 6
TP53 (A) 17:7577079 C A p.E278X 3 10
TP53 (B) 17:7577118 C G p.V274L 2 4
TP53 (C) 17:7576891 T A p.K319X 7 25
TP53 (D) 17:7577580 T C p.Y234C 1 3
 XPO1 2:61719472 C T p.E571K 29.8 25.3
LRP1B 2:141457824 A G p.V2265A 3.9 0
PCLO 7:82581607 C T p.V2888I 49.3 48.6
TP53 17:7577551 C T p.G244S 14.9 38.9
SF3B1 2:198267699 G A p.R594X 5 0 4
TP53 17:7577568 C T p.C238Y 1 1.63 42.6
SF3B1 2:198267385 A G p.W685R 49.4 49.8
BIRC3 11:102207709 A  - p.V565fs 1.3 12.7
TP53 17:7577100  T C p.R280G 74.3 74.1
SF3B1 2:198267491 C A p.E622D 40.4 47.4
PCLO (A) 7:82784834-35 - Ins30N p.Q374_Q375Ins10 24.6 23.5
PCLO (B) 7:82784832 C G p.Q375H 36.5 36
TP53 17:7577538 C T P.R248Q 64.8 83.6
SF3B1 2:198266834 T C p.K700E 44.6 52.8
TP53 17:7578394 T C p.H179R 4.4 95.6
TP53 17:7578457 C A p.R158L 3.5 1
FBXW7 4:153247330 C G p.G491A 0 0 9.9
TP53 (A) 17:7578525 G C p.C135W 35.6 62 31.2
TP53 (B) 17:7578211 C A p.R213L 13.7 14 54.3
SF3B1 2:198268383 G A p.R549C 3.5 8.4 2
PCLO 7:82508679 G A p.A4543V 14.6 8 3.6
TP53 (A) 17:7572969-76 8N  - p.HPP380X 41.2 2.7 36.8
TP53 (B) 17:7576854 T C p.Q331R 48.9 44.8 44
TP53 (C) 17:7578413 C A p.V173L 2 2.1 11
TP53 (D) 17:7577121 G C p.R273G 1 3.7 0
Variant information
Cases
VAF% at follow-up time points 
CLL-4
CLL-7
CLL-8
CLL-5
CLL-6
CLL-1
CLL-2
CLL-3
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Table 7.5. (continued) 
 
 
Gene (sub-clone) Chr. Location (Hg19) Ref Var Aminoacid change TP1 TP2 TP3 TP4
LRP1B 2:141032152 T A p.Y4328F 0 3.9  
SF3B1 2:198269834 A T p.L502X 2 5.5
NOTCH1 (A) 9:139390945 G A p.Q2416X 3.5 20.7
NOTCH1  (B) 9:139390649-50 CT - p.F2482Ffs*2 4 11.3
ATM (A) 11:108106443 T A p.D126E 53.7 50.9
ATM (B) 11:108175530-31 - T p.H1876fs 7.5 4.5
ATM  (A) 11:108121763 G A p.W524X 37.2 40.2
ATM (B) 11:108213973 G A p.G2765S 38.2 37.5
LRP1B 2:141359103 C T p.R2302Q 3.2 0 0
SF3B1 2:198266834 T C p.K700E 10 20.8 29.9
ATM 11:108186598 T C p.Y2019H 97.6 96.5 98.4
 XPO1 2:61719472 C T p.E571K 36 30 24
ATM 11:108236179 G C p.A3039P 11 0 10
PCLO (A) 7:82784834-35 -  Ins30N p.Q374_Q375Ins10 42 41.4
PCLO (B) 7:82784832 C G p.Q375H 38.6 37.2
ATM 11:108236179 G C p.A3039P 0 6.6
SAMHD1 (A) 20:35526885-86  -  A p.K523X 16 24.4
SAMHD1 (B) 20:35580045 A T p.M1K 58 71.9
ATM (A) 11:108143528 T G p.L1078R 14.7 18.1
 ATM (B) 11:108168106-07  - C p.L1668fs 14.4 12.7
ATM (C) 11:108236179 G C p.A3039P 0 5.6
NOTCH1 9:139390649-50 CT - p.F2482Ffs*2 10 8.6
SF3B1 2:198269834 A T p.L502X 8 6.6 2 2
ATM (A) 11:108186599 A G p.Y2019C 41 46.8 50.8 48.1
 ATM (B) 11:108216582-86 5N - p.W2845fs 46 47.5 47.9 48.3
CLL-18 ATM 11:108198445-54 10N - p.E2351fs 31 50.5
FBXW7 4:153249384 C A p.R465L 5.3 4.4
CHD2 (A) 15:93499738 A T p.H620L 21.3 27.6
CHD2 (B) 15:93499735  C G p.A619G 21.3 29.5
SAMHD1 20:35545207 T - p.N327fs 7 21.2
SF3B1 (A) 2:198267699 G A p.R594X 0 5.4
SF3B1 (B) 2:198267370 T C p.T663A 54.9 80.2
CLL-21 SF3B1 2:198266611 C T p.G742D 22.1 28.6 40.6
LRP1B 2:141032021 T A p.N4372Y 41.7 48.6 49
ATM 11:108098521 A T p.K31X 4.1 0 0
MYD88 3:38182032 C G p.S219C 4 0
 SAMHD1 20:35526319 C T p.R551Q 49.1 49.4
CLL-25 PCLO 7:82784834-35 - Ins30N p.Q374_Q375Ins10 41.3 38.2
HIST1H1E 6:26156965 C T p.A116V 39 47.7 47.5
PCLO 7:82390770 T C p.K5016R 44 38.3 59.2
Cases
Variant information VAF% at follow-up time points 
CLL-14
CLL-17
CLL-26
CLL-19
CLL-22
CLL-23
CLL-20
CLL-15
CLL-10
CLL-11
CLL-12
CLL-13
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7.3.6. Supplementary data of CNA test using CytoSNP 850K array  
Table 7.6. A summary of CNA detected with the SNP array in the 14 CLL samples 
studied 
 
CLL Samples Type Start Cyto End Cyto Chr Start End Size (bp) Comments 
LOSS 4q21.1 4q21.3 4 76,692,898 87,004,521 10,311,624
LOSS 13q14.2 13q14.3 13 48,766,751 51,825,548 3,058,798
LOSS 13q14.2 13q14.3 13 50,637,548 51,496,077 858,530 Biallelic
LOSS 17p13.3 17p11.2 17 12,344 21,810,779 21,798,436
LOSS 18q22.1 18q23 18 65,709,017 77,982,456 12,273,440
LOSS 4p16.3 4p15.1 4 49,450 32,515,265 32,465,816
LOSS 4q34.2 4q35.2 4 177,100,644 190,915,650 13,815,006
GAIN 7p22.3 7q36.3 7 44,935 159,126,310 159,081,376 Trisomy 7
GAIN 8q21.3 8q24.3 8 93,187,902 146,293,414 53,105,512
LOSS 11q22.1 11q24.1 11 100,729,841 122,526,501 21,796,660
LOSS 13q14.2 13q22.2 13 48,184,645 76,104,956 27,920,312
LOH 17p13.3 17p13.1 17 12,344 9,163,144 9,150,800 Mosaic LOH 17p
LOH 18q11.2 18q23 18 22,177,459 77,893,683 55,716,225 Mosaic LOH 18q
LOSS 2p25.3 2p16.1 2 14,238 58,795,436 58,781,199
LOSS 2p13.2 2p11.2 2 73,361,948 83,633,730 10,271,783
LOSS 6p25.2 6p24.3 6 3,077,141 9,275,594 6,198,454
LOSS 6p22.3 6p22.3 6 16,998,804 19,017,212 2,018,409
LOSS 6p21.33 6p21.2 6 30,770,000 38,728,142 7,958,143
LOSS 6p21.1 6p11.2 6 45,345,899 58,630,693 13,284,795
LOSS 6q11.1 6q12 6 61,891,118 67,977,326 6,086,209
LOSS 6q13 6q15 6 74,166,098 88,152,535 13,986,438
LOSS 7q21.11 7q21.12 7 79,585,451 87,226,690 7,641,240
LOSS 7q31.1 7q36.3 7 112,071,795 159,126,310 47,054,516
LOSS 8p23.3 8p12 8 164,984 35,042,190 34,877,207
LOSS 10q24.1 10q26.3 10 99,267,639 135,477,883 36,210,245
GAIN 11q22.3 11q25 11 107,617,257 134,934,063 27,316,807
LOSS 17p13.3 17p11.2 17 12,344 20,117,151 20,104,807
GAIN 19p13.3 19p13.11 19 5,830,302 18,342,477 12,512,176
LOSS 19p13.11 19p11 19 18,347,539 24,487,350 6,139,812
LOSS 2p25.3 2p21 2 14,238 46,082,995 46,068,757
LOSS 2p16.3 2p16.1 2 48,771,605 59,409,979 10,638,375
LOSS 2p13.1 2p11.2 2 73,556,155 84,249,446 10,693,292
LOSS 6p25.2 6p24.3 6 3,205,325 9,745,037 6,539,713
LOSS 6p21.33 6p21.2 6 30,724,430 38,723,575 7,999,146
LOSS 6p21.1 6q12 6 44,568,740 66,916,257 22,347,518
LOSS 6q13 6q15 6 74,217,278 88,021,118 13,803,841
LOSS 7q21.11 7q21.12 7 80,512,536 86,608,786 6,096,251
LOSS 7q31.1 7q32.1 7 112,044,527 127,479,262 15,434,736
LOSS 7q32.3 7q36.3 7 131,304,940 159,126,310 27,821,370
LOSS 8p23.3 8p11.23 8 164,984 36,646,217 36,481,234
LOSS 17p13.3 17p11.2 17 12,344 21,246,375 21,234,032
CLL-4
CLL-3
CLL-1
CLL-7 Latest
CLL-7 Earlier
Chapter 7. Appendices 
248 
 
Table 7.6. (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLL Samples Type Start Cyto End Cyto Chr Start End Size (bp) Comments 
LOH 9q21.11 9q34.3 9 68838522 141066491 72227969 Mosaic LOH 9q
GAIN 12p13.33 12q24.33 12 191,619 133,777,645 133,586,027 Trisomy 12
LOSS 8p23.3 8p12 8 164,984 32,141,515 31,976,532
GAIN 8q21.11 8q24.3 8 77,059,481 146,293,414 69,233,934
LOSS 13q14.11 13q14.11 13 40,825,707 41,797,397 971,691
LOSS 13q14.2 13q14.3 13 50,390,096 51,825,548 1,435,453  Biallelic
LOSS 11q21 11q23.3 11 94,388,085 115,638,755 21,250,671
LOSS 13q14.2 13q14.3 13 50,214,959 51,462,799 1,247,841
GAIN 6p25.3 6p25.1 6 165,632 4,349,814 4,184,183
LOSS 6q14.1 6q27 6 83,704,533 170,919,470 87,214,938
LOSS 13q14.2 13q14.3 13 48,684,856 51,723,601 3,038,746 Deleted 13q14
LOSS 18p11.32 18p11.21 18 13,034 14,753,891 14,740,858
CLL-19 GAIN 12p13.33 12q24.33 12 191,619 133,777,645 133,586,026
LOH 2q14.3 2q37.3 2 129,819,469 243,048,760 113,229,291 Mosaic LOH 2q
LOSS 6q14.1 6q21 6 79,911,290 106,815,036 26,903,747
GAIN 12p13.33 12q24.33 12 191,619 133,777,645 133,586,027 Trisomy 12
LOH 20q11.21 20q13.33 20 30686423 62912463 32226040 20q Complete LOH
CLL-21 NA NA NA NA Na NA NA No CNA >5Mb detected
CLL-23 LOSS 12p13.2 12p13.1 12 10,925,439 14,337,924 3,412,485
LOSS 7q33 7q34 7 134,746,551 140,012,638 5,266,088
LOH 11q13.2 11q25 11 65,962,002 134,934,063 68,972,061 Mosaic LOH 11q
GAIN 12p13.33 12q24.33 12 191,619 133,777,645 133,586,027 Trisomy 12
CLL-10
CLL-11
CLL-12
CLL-17
CLL-20
CLL-26
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